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Abstract(!
Type 1 diabetes (T1DM) is managed by exogenous insulin administration, either by 
multiple daily injections (MDI) of insulin or via continuous subcutaneous insulin 
infusion (CSII). Despite intensive insulin therapy and structured education a 
significant proportion of people with T1DM are unable to achieve optimal glucose 
control without the risking recurrent hypoglycaemia. Longstanding hyperglycaemia 
can lead to microvascular and macrovascular complications, whereas hypoglycaemia 
can lead to seizures, arrhythmias and ‘dead in bed’ syndrome.  
 
A closed-loop insulin delivery system, consisting of a glucose sensor measuring 
interstitial glucose, a control algorithm and an insulin pump for subcutaneous insulin 
delivery, has the potential to improve glucose control, reduce hypoglycaemia, reduce 
long-term diabetes associated complications and improve overall quality of life. A 
novel closed-loop system has been developed by the Imperial College Diabetes 
Technology Team. The Bio-inspired Artificial Pancreas (BiAP), uses a control 
algorithm based on mathematical model of pancreatic beta-cell physiology 
implemented in a microchip integrated in small low-powered handheld device.   
 
This thesis outlines the ‘first in human’ clinical evaluation of the Bio-inspired 
Artificial Pancreas in adults with T1DM. The safety and efficacy of the system has 
been evaluated incrementally, initially fasting over 6 hours, followed by 13-hour 
overnight and post-meal study and finally in a 24-hour randomised controlled trial 
which included assessment of the algorithm without meal announcement. The 
feasibility of the BiAP system with glucagon was evaluated in a 6-hour fasting study. 
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A separate sub-study evaluating whether glycaemic variability impacts quality of life 
in adults with type 1 diabetes on either MDI or CSII was also conducted. 
 
The results of the studies demonstrated that the Imperial College closed-loop insulin 
delivery system is safe and achieved a significant reduction in hypoglycaemia when 
compared to standard therapy (insulin pump), particularly overnight. Glycaemic 
variability was shown to have no significant impact on overall or subscale quality of 
life in adults with type 1 diabetes, irrespective of whether they are on MDI or CSII. 
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1 Chapter 1: Introduction 
!
1.1 Type 1 diabetes mellitus !
Type 1 diabetes mellitus (T1DM) affects an estimated 300 000 people in the United 
Kingdom (1, 2). The condition is caused by a T-cell mediated autoimmune 
destruction of the pancreatic β-cells within the islets of Langerhans resulting in an 
inability of the pancreas to produce insulin in response to a glucose stimulus. The role 
of insulin is multi-fold and includes promoting glucose uptake in muscle and adipose 
tissue cells via the Glut-4 transporter followed by glycolysis for immediate energy. 
Glucose glucose uptake in the liver occurs via the Glut-2 transporter for storage in the 
form of glycogen (glycogenesis). Insulin also inhibits hepatic gluconeogenesis and 
plays a central role in growth and development through its anabolic actions. In a 
person with a fully functioning pancreas gland, insulin production is primarily 
regulated by glucose concentrations in the blood and by glucagon, a hormone 
produced by the α-cells in the pancreas. At diagnosis, people with T1DM often 
present with hyperglycaemia and osmotic symptoms such as polydipsia, polyuria, 
weight loss and blurred vision. If left untreated, the body eventually switches to 
utilising fat as an energy source leading to diabetic ketoacidosis, which can be life-
threatening if not treated promptly. The mortality risk among people with T1DM is 
131% greater than the general population and the age-specific mortality risk for 
females aged 15-34years is 6.6 times higher than their peers without diabetes (2). 
Diabetes is directly associated with the development of long-term microvascular 
complications (retinopathy, nephropathy and neuropathy) and macrovascular 
complications (cardiovascular disease, cerebrovascular accidents and peripheral 
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vascular disease). Additionally it has been shown that diabetes is associated with  
reduced quality of life (3) and the condition carries an increased risk of developing 
depression (4). The importance of glycaemic variability as a contributory factor for 
developing diabetes-related complications is controversial (5). Quality of life (QoL) 
and glycaemic variability in T1DM is discussed in more detail in Chapter 6.  
No cure has been discovered for T1DM. However, with the increased understanding 
of the pathogenesis of the disease, as well as the identification of predisposing genetic 
and environmental factors, there exist several potential theoretical targets for disease 
process modification. One of the major limitations in conducting studies targeting a 
cure is that majority of patients with T1DM already have significant β-cell destruction 
at diagnosis. Hence, aiming for maintenance or improvement of remaining functional 
β-cell mass is a more realistic goal. There is significant evidence suggesting that 
intensifying glycaemic control early after diagnosis plays a major role in preserving 
β-cell function (6, 7). The majority of people with T1DM use either multiple daily 
injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII) via a 
pump, to mimic physiological insulin secretion in response to glucose levels.  
The National Institute of Clinical Excellence (NICE) recommends that structured 
education should be offered to all adults diagnosed with T1DM with the aim of 
supporting self-management of the condition. In the early 1980s a 5-day structured 
education programme for T1DM based on a set of principles targeting intensive self-
management was developed in Germany (8). One and a half decades later, the 
German programme was translated and adapted for use in the UK as the Dose 
Adjustment for Normal Eating (DAFNE) course. A UK based multi-centered 
randomised controlled trial demonstrated reduced HbA1c and improved quality of life 
12 months after completion of DAFNE (9): follow-up at 4 years showed that the 
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psychosocial benefit was sustained (10). Other evidence-based structured education 
courses for T1DM delivered in the UK include the Bournemouth Type 1 Intensive 
Education (BERTIE) and X-PERT(11). 
Interventions to support optimal glucose self-management include regular monitoring 
of capillary blood glucose using finger-prick testing and adjusting insulin meal bolus 
doses according to carbohydrate content. Insulin bolus calculations at meal times 
provide flexibility, but require knowledge of individualised insulin to carbohydrate 
ratios (ICR (the amount of carbohydrate in grams covered by 1 unit of insulin)) and 
the insulin sensitivity factor (ISF (the reduction in blood glucose achieved with 1 unit 
of insulin)). The complexity of calculating meal boluses, which involves a 
combination of arithmetic division, addition and subtraction, can be a challenge, 
particularly for people with reduced numeracy skills (12). Standard bolus calculators 
have been incorporated into most commercially available insulin pumps (13) and have 
been shown to be of benefit when compared to mental arithmetic (14, 15). More 
recently bolus calculators have been integrated into some glucose meters (e.g. Accu-
Chek Aviva Expert and FreeStyle InsuLinx) for MDI users. Structured education also 
covers how to deal with insulin dose adjustment when faced with additional 
challenges such as exercise, alcohol consumption, illness and travel. However, despite 
structured education and clinical support, there are multiple reasons why existing 
insulin regimens do not achieve optimal glycaemic control, including insulin 
resistance, non-compliance with multiple insulin injections, needle-phobia, fear of 
hypoglycaemia and the time commitment required to manage the condition (16, 17).  
It is well established that intensive treatment of T1DM reduces the risk of 
microvascular complications including retinopathy, nephropathy and neuropathy (18) 
and macrovascular complications such as cerebrovascular accidents and 
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cardiovascular disease (19). However, intensive insulin therapy is associated with an 
increased risk of hypoglycaemia (20) and over time can lead to hypoglycaemia 
unawareness. The mechanism behind hypoglycaemia unawareness is not fully 
understood, but is thought to be mediated by a reduced sympathoadrenal response 
(autonomic failure) to hypoglycaemia. There are two important components to this 
mechanism: 1. reduced sympathetic neural response and 2. reduced adrenaline 
response.  The hypoglycaemia unawareness is due to the lack of symptoms that would 
normally be associated with these components, were adequate function preserved 
when blood glucose falls (21).  
Achieving optimal glycaemic control, without recurrent hypoglycaemia, remains a 
challenge for many people with T1DM. It is reported that only 27% of people with 
T1DM achieve an HbA1c target of <58mmol/mol (7.5%) with the existing treatment 
regimens available (2).  
 
1.2 State of the art diabetes technology and importance of closed-loop insulin 
delivery systems 
Diabetes technology has increasingly become an important component of T1DM 
management with the use of CSII (pump therapy) currently being supported by a 
NICE technology appraisal (1) and the added benefits of subcutaneous (SC) 
continuous glucose monitoring (CGM) suggested by an emerging evidence base (22, 
23). The combination of a sensor and CSII in sensor-augmented pump therapy with a 
low-glucose suspend feature has been reported to improve HbA1c and reduce 
hypoglycaemia (24, 25). The next step in diabetes technology is the artificial 
pancreas, comprising a subcutaneous glucose sensor, control algorithm to calculate 
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insulin infusion from dynamic glucose changes, and an insulin pump. Figure 1 gives 
an overview of a generic closed-loop insulin system. 
 
 
Figure 1. Overview of a closed-loop insulin delivery system. The glucose sensor measures interstitial 
glucose and transmits a glucose value to the control algorithm every 5 minutes. The controller then 
calculates and informs the pump how much insulin to deliver subcutaneously.  
 
 The closed-loop system has the potential to further reduce hypo- and hyperglycaemic 
excursions and consequently glycaemic variability. The development of a user-
friendly artificial pancreas for day-to-day use would be a major step towards 
eliminating the need for frequent insulin injections and finger-prick blood glucose 
monitoring which could assist with compliance with therapy and improve overall 
quality of life. Since the first ‘artificial pancreas’ was developed back in the 1970s 
(26), the mode of glucose measurement and insulin delivery has included the 
intravenous route, the intra-peritoneal route and the subcutaneous route, of which the 
latter has been considered the most practical and user-friendly approach for 
ambulatory use. The technology has progressed since the first artificial pancreas was 
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developed, but 30 years later a commercially available device that is fully automatic, 
is still not available. The reasons for delay are that each of the three components of 
the closed-loop insulin delivery system has its own limitations. The next three 
sections aim to give an overview of each of these components, the glucose sensor, the 
control algorithm and the insulin pump, and in addition, will cover their strengths and 
limitations before summarising the literature on the clinical closed-loop studies 
completed to date.  
 
1.3 Glucose sensor 
For a safe and effective closed-loop delivery system a reliable CGM system is 
required. All commercially available glucose sensors use enzyme electrodes. The 
enzyme glucose oxidase produces hydrogen peroxide, which is directly proportional 
to the concentration of glucose. This reaction results in the movement of electrons, 
which can be measured as a current by the electrode. The current is then transmitted 
to a recorder and converted to a corresponding glucose concentration (Fig 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Enzyme electrode technology 
GOx = glucose oxidase 
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The various types of glucose sensing modality for CGM include invasive sensors (SC, 
microdialysis and implantable intravenous), minimally invasive sensors (microneedle) 
and non-invasive sensors (optical and transdermal) (27). From the user’s point of 
view a non-invasive sensor would be ideal. However these are currently not widely 
available due to sensor inaccuracies. From the accuracy perspective, an intravenous 
glucose sensor is optimal, but due to its invasiveness, is not acceptable for the user. 
The SC sensor balances accuracy and user acceptability, and is the only commercially 
available option for home-based CGM monitoring at present. However, the current 
available SC CGM systems do not meet optimal criteria for reliability and accuracy.  
The main problem is that SC CGM sensors measure interstitial glucose and there is a 
delay in transport of glucose from the blood to subcutaneous tissue, causing a time-
lag resulting in discrepancy between blood glucose and interstitial glucose at any one 
point in time (28, 29). This lag becomes more evident when the blood glucose 
concentration is rapidly changing (30). Also, the sensor processing time is an 
additional cause for time-lag (31). Electrochemical noise and motion artefacts are 
other potential causes of sensor inaccuracy. However, filtering algorithms are 
incorporated within sensor technologies to reduce these potential artefactual “spikes’ 
in glucose levels (32). 
Once a SC glucose sensor is inserted into the interstitium it has a lifespan of up to 
seven days before it needs to be replaced with a fresh sensor. To assess the accuracy 
of a CGM sensor one can compare paired values of sensor glucose values and 
venous/capillary blood glucose values and calculate the mean absolute relative 
difference (MARD). The continuous glucose-error grid analysis (CG-EGA) provides 
a method for assessing the sensor’s ability to capture the direction and rate of glucose 
fluctuations, as well as the precision of point samples of sensor glucose values (33).  
! 24!
There are a number of different CGM devices available for patient use, some of which 
provide retrospective glucose analysis and others real-time glucose values. With real-
time CGM, the user can view readings on a monitor enabling the individual to 
immediately adjust therapy. In a diabetes outpatient clinic setting, retrospective 
analysis of CGM data can be helpful in recognising patterns in daily glucose 
variations in those in whom there are concerns regarding glycaemic control despite 
compliance with insulin, or in individuals with a low HbA1c indicating possible 
hypoglycaemic unawareness (34). 
For the day-to-day self-management of T1DM, real-time CGM used either with MDI 
or CSII has the potential to improve glycaemic control and reduce the incidence of 
hypoglycaemia (35). At present, real-time CGM is not routinely offered to people 
with T1DM in the UK. Although later generation real-time CGM devices may not 
provide measurements that are as accurate as capillary blood glucometers, 
retrospective data analysis demonstrates that their accuracy (36) and functionality are 
improved and that user-acceptability is enhanced, compared to first generation CGM 
devices. One explanation for this could be the utilisation of more advanced calibration 
algorithms (37, 38). 
The latest commercially available SC CGM systems are listed in Table 1. The MARD 
quoted for a specific sensor varies from one clinical trial to another and it is therefore 
difficult to determine if sensor superiority exists. However, recent head-to-head 
clinical trials have shown greater accuracy with the Dexcom G4 sensor when 
compared to the Enlite sensor (39, 40). 
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CGM system Sensor Transmitter Sensor 
life 
Compatible 
monitor 
Glucose 
suspend 
feature 
Minimum 
calibrations 
Guardian REAL-
Time system 
Enlite Sensor MiniLink 
transmitter  
 
Guardian 2 Link 
transmitter 
6 days Guardian Real-time 
monitor 
No 12 hourly 
§MiniMed 640G 
system with 
Smartguard, 
Medtronic 
Enlite Sensor Guardian 2 Link 
transmitter 
6 days MiniMed 640G 
insulin pump 
Yes 12 hourly 
§MiniMed Paradigm 
Veo™ system, 
Medtronic 
Enlite Sensor MiniLink  
transmitter  
 
6 days MiniMed Paradigm 
Veo insulin pump 
Yes 12 hourly 
 
 
*iPro2 Professional 
CGM, Medtronic 
Enlite Sensor iPro2 recorder  
6 days 
No monitor 
(blinded) 
No 12 hourly 
(retrospective
ly) 
Dexcom G4 
PLATINUM System 
Dexcom G4 
Platinum  
sensor 
Dexcom G4 
transmitter 
7 days Dexcom G4 
PLATINUM 
Receiver 
No 12 hourly 
§Animas Vibe™ 
System 
 
Dexcom G4 
Platinum  
sensor 
Dexcom G4 
transmitter 
7 days Animas Vibe Insulin 
pump 
Yes 12 hourly 
¶Freestyle Libre 
Flash Glucose 
Monitoring system 
Freestyle Libre 
sensor 
  
Freestyle Libre  
recorder 
14 
days 
Freestyle Libre 
reader 
No 0 (Factory 
calibration) 
Freestyle Navigator 
II 
Freestyle 
Navigator II 
sensor 
Freestyle 
Navigator II 
transmitter 
7 days Freestyle Navigator 
II monitor 
No 12 hourly  
 
Table 1. Overview of  commercially available subcutaneous CGM systems as of mid 2015 
*Retrospective blinded CGM system 
§ Sensor-augmented pump 
¶Intermittent glucose monitoring (preceding 8 hours of data displayed at reading) 
 
The clinical studies looking at the efficacy and long-term outcomes following CGM 
use have demonstrated mixed results. However, an overall benefit has been suggested, 
particularly in those with poor glycaemic control at baseline (41). The Juvenile 
Diabetes Research Foundation Continuous Glucose Monitoring Study Group 
conducted a multi-centre randomised clinical study evaluating CGM safety and 
efficacy in 322 adults and children over a 6-month period. In the oldest age group 
(≥25 years), there was a significant improvement in HbA1c (Mean difference in 
change = -0.53%, -0.71 -0.35, p<0.001) when compared to the control group who 
performed home glucose testing. In the lower age groups (8-14 years and 14-25 years) 
there was no benefit in overall glycaemic control associated with CGM use. However, 
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a sub-analysis demonstrated a benefit across all age groups when the sensor was used 
≥6 days/week. The CGM use averaged ≥ 6 days/week for 83% of participants aged ≥ 
25 years, 30% of those aged 15-24 years and 50% of those aged 8-14 years (22). 
Following on from this trial, the same group showed that CGM is of benefit, in terms 
of sustaining HbA1c and reduction in hypoglycaemia, even in patients with optimal 
glycaemic control (HbA1c<7%) (23).  
The STAR 3 study (24), a large multi-centred randomised controlled trial that 
included 485 subjects with T1DM, compared the efficacy of sensor-augmented pump 
therapy with that of MDI therapy over a 1 year period. The Medtronic MiniMed 
Paradigm REAL-time System was used in the pump therapy group.  The mean 
HbA1c at baseline (8.3%) decreased to 7.5% in the sensor-augmented pump therapy 
group as compared with 8.1% in the MDI group (p < 0.001). One must keep in mind 
that the improvements seen could be attributed to pump therapy being more 
efficacious than MDI, as seen in the CSII literature (42), rather than CGM alone. 
Using a pump-only population, as the control group would have allowed a more 
appropriate and accurate comparison of the benefit of CGM against self-monitoring of 
blood glucose. In addition, the study would have included motivated individuals as 
CGM requires significant input from the subject. Therefore, these positive results may 
not be replicable in a less motivated cohort with T1DM.  The SWITCH study group 
evaluated the efficacy of adding CGM to CSII in 153 participants and showed a 
reduction in HbA1c with CGM (8.04% vs. 8.47%, p<0.01) and less time spent in 
hypoglycaemia (19 vs. 31 min/day, p$=$0.009) (35). This latter finding is important as 
severe or prolonged hypoglycaemia is a major concern and can result in seizures (43), 
cardiac arrhythmias and “dead-in-bed” syndrome (44). Algorithms capable of 
predicting impending hypoglycaemia, based on the rate of decline of glucose 
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concentrations, can be incorporated into real-time CGM devices. These predictive 
algorithms combined with sound alarms and vibration at times of impending 
hypoglycaemia is a function which may be life-saving for people with T1DM who 
have reduced hypoglycaemia awareness, especially at night when these people are 
unlikely to check their own blood glucose. However, it has been shown that a 
proportion of people, in particular children, do not respond to every alarm triggered 
by nocturnal hypoglycaemia (44), making its use somewhat counterproductive. An 
attempt to overcome this barrier involves the introduction of a low glucose suspend 
mechanism (LGS). LGS is a function whereby insulin pump delivery is temporarily 
suspended either when the glucose is below a pre-defined threshold or, if 
hypoglycaemia is predicted. Sensor-augmented pump therapy with LGS will be 
discussed in more detail under section 1.5 (CSII, Insulin pump). Another approach is 
one that combines five different hypoglycaemia prediction algorithms, where at least 
two out of the five algorithms have to be positive in order for the pump to temporarily 
suspend insulin delivery. This approach has been clinically assessed and preliminary 
data has yielded encouraging results (45, 46).  
Glucose sensor requirements for the closed-loop system include a reliable non-
invasive or minimally invasive sensor with a long life span, an incorporated ability to 
minimise the time lag experienced with the current sensors, and efficient and accurate 
communication with the insulin pump via the control algorithm software. The 
emergence of minimally invasive micro-needle based sensors and the potential for 
integrating these into the closed-loop system is on the horizon. These sensors are 
made up of multiple microscopic needles coated by a membrane containing glucose 
oxidase. The micro-needles pierce the outermost layer of the skin only, but cover a 
larger surface area that could potentially increase accuracy (47).  
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The main barriers to CGM use at present relate to financial and technical issues. CGM 
is currently not routinely offered under the National Health Service and therefore 
people with diabetes have to self-fund. Technical issues such as sensor failure, 
restricted life span and inaccuracy limit acceptability. However, despite these barriers 
it has been shown that many people with T1DM consider CGM a valuable addition to 
their diabetes management (48). 
 
1.4 Control algorithm  
The configuration of a suitable algorithm to mimic physiological glycaemic control is 
not an easy task (49). Over the years, three main control algorithms (proportional-
integral-derivative, model predictive control and MD-logic) have been used in clinical 
closed-loop studies as outlined in section 1.6 below. The Imperial College Diabetes 
Team has developed a bio-inspired algorithm. This PhD thesis predominantly 
describes the first human clinical trials evaluating the algorithm in adults with T1DM.  
 
With most control algorithms there exists an advantageous flexibility either in 
integrating modifications such as meal announcements thus allowing the algorithms 
to work more aggressively in the temporary post-prandial state or by priming with a 
pre-meal bolus, with both options aimed at reducing post-prandial hyperglycaemia. 
Additionally, most of the algorithms can be fine-tuned using the participant’s pre-
existing clinical information such as body mass index (BMI), ICR, ISF and total daily 
insulin dose. Taking into account one or more of these features when initialising the 
algorithm enables the closed-loop system to be optimised for each individual user. 
Safety measures to prevent hypoglycaemia include reducing or suspending insulin 
delivery when there is a significant decrease in glucose concentration (50). The 
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insulin-on-board (the amount of insulin remaining from the previous delivery) is 
taken into account when the next insulin dose is recommended to prevent over-
insulinisation (51) Incorporation of glucagon (a counter regulatory hormone) delivery 
at times of impending low glucose concentration is a safety feature itself and more 
physiological (52). 
 
1.4.1 Proportional-integral-derivative (PID) !
The PID algorithm has been used in many systems that utilise control-engineering 
technology (such aeroplanes, satellites, motor vehicles). The first and second phase of 
insulin secretion by the beta-cell in response to a glucose stimulus has been well-
described by hyperglycaemic clamp studies (53). It was discovered that the first and 
second phase of insulin secretion could be simulated using a PID algorithm (54).  
Steil and colleagues developed a PID algorithm (54) for use in a closed-loop system 
which they referred to as a ‘physiologic insulin delivery’ and which later also 
included terms to emulate a cephalic-phase insulin response (pre-meal bolus) (55) and 
insulin-on-board (51).  The PID algorithm adjusts insulin delivery by a three-way 
approach (Fig 3). The proportional component considers the deviations from target 
glucose level, the integral component takes into account the area under the curve 
between the measured and target glucose level and finally the derivative component 
incorporates the rate of change in the measured glucose level, thus enabling the PID 
algorithm to mimic beta-cell physiology (Figure 3) (54).  
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Figure 3. Response of the β-cell (closed circles) to a step change in glucose (a) together with PID 
model response. Proportional (b) integral (c) and derivative (d) components making up the total PID 
response (e) (54). 
 
The PID algorithm is considered to be a reactive controller as it responds to changes 
in glucose concentrations after they have occurred. Consequently, one of the 
challenges the PID algorithm is faced with is the risk of proposing insulin infusion 
rates that are too high post-prandially, thus increasing the risk of delayed post-
prandial hypoglycaemia. However, the inclusion of an insulin feedback term aims to 
overcome this. 
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1.4.2 Model predictive control (MPC) !
To overcome the reactive nature of the PID control a more proactive approach, the 
model predictive control (MPC), has been utilised in closed-loop systems and was 
first optimised in the clinical trial setting by Hovorka’s group (56). In the context of a 
closed-loop insulin delivery system, the MPC algorithm calculates the insulin infusion 
rate by minimising the difference between the predicted glucose and the target 
glucose over a 2-4 hour period and repeats this process at pre-determined time 
intervals. An in-silico trial in 2007 showed that the MPC achieved better glycaemic 
regulation compared to the PID control (57). In contrast to the PID controller, the 
MPC controller is proactive in that it predicts expected glucose levels based on the 
effect of the insulin delivered. It is important to note that MPC relies on a model and 
if this model is not optimal, the predictions are unsatisfactory and the benefits of MPC 
are lost. Arguments for whether PID or MPC is the better controller have been put 
forward (58, 59), but the issue remains inconclusive as no large head-to-head trial 
comparing PID and MPC has been done.  
 
1.4.3 Fuzzy logic (MD-logic) !
Fuzzy logic incorporates a simple, rule-based ‘IF’ X(input) and Y ‘THEN’ Z(output) 
and methods of “fuzzification” and “defuzzification” to evaluate the fuzzy rule output 
in solving a control problem (60). An MD-logic algorithm, which uses the principles 
of fuzzy logic to mimic how a diabetologist would make a treatment decision, has 
been developed for closed-loop insulin delivery (61). The MD-logic controller relies 
on qualitative and quantitative parameters derived from the subject’s management 
records including physical characteristics (age, weight, height), insulin delivery 
regimen (total daily dose insulin, total basal insulin dose), and insulin 
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pharmacodynamic parameters (ISF, ICR, IOB). Other useful information that can be 
extracted from clinic records and incorporated into the controller includes 
subcutaneous continuous glucose monitoring data, capillary blood glucose 
measurements, insulin treatment, and recorded activity.  
 
1.4.4 Bio-inspired glucose algorithm !
The ideal artificial pancreas is one that replicates the physiology of the biological 
endocrine pancreas and more specifically the function of the insulin secreting beta 
cells. Several recent mathematical models describing beta cell insulin release from 
glucose concentrations have been reported (62-64), enabling the implementation of 
beta-cell physiology in a closed-loop insulin delivery system. 
The Bio–inspired Artificial Pancreas (65) is one such system and uses a novel control 
algorithm based on the mathematical model of the beta-cell physiology proposed by 
Pedersen et al (62). The appeal of this approach is that the algorithm is based on the β-
cell physiology in its aim to replicate the functionality of the pancreas, in contrast to 
the PID and MPC algorithms that try to implement control-engineering solutions to 
biology. The mathematical model of the beta-cell physiology developed by Pedersen 
et al. incorporates equations that account for the various steps involved in glucose-
stimulated insulin release at the molecular level. This step-wise process includes the 
mobilisation of secretory granules from a reserve pool to the periphery of the cell, 
where they then attach to the plasma membrane (docking). The granules then mature 
further (priming), before entering the 'readily releasable pool' (RRP). Calcium influx 
triggers membrane fusion and subsequent insulin release. The possibility of so-called 
“kiss-and-run” exocytosis is also included, where the fusion pore reseals before the 
granule cargo is released. Additionally, the algorithm accounts for the glucose-
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dependent increases in the number of cells showing a calcium signal thus 
distinguishing between readily releasable granules in silent and active cells: the RRP 
is heterogeneous in the sense that only granules residing in cells with a threshold for 
calcium activity below the ambient glucose concentration are allowed to fuse. A 
schematic diagram of the beta-cell model is given in Figure 4.  
 
 
Figure 4. Schematic representation of the mechanistic model of insulin secretion from pancreatic beta-
cells. The readily releasable pool (RRP) has been divided into readily releasable granules located in 
silent cells with no calcium influx, exocytosis, or release (circles) and readily releasable granules 
located in triggered cells (dots) (62) 
 
The core component of the bio-inspired glucose controller used in the BiAP is the 
mathematical model of the beta-cell physiology described above. In addition, it 
incorporates an insulin feedback term to avoid insulin stacking by compensating for 
delays associated with subcutaneous insulin delivery. The insulin feedback 
component uses a model of insulin pharmacokinetics to estimate plasma insulin 
concentration (66). To attenuate the delays associated with subcutaneous glucose 
sensing, glucose measurements are forecast 15 minutes ahead using a linear 
regression of the last 6 glucose values (i.e. the preceding 30 minutes). This linear 
regression is reset when the glucose sensor is recalibrated.  Using linear extrapolation 
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of glucose values for glucose prediction is limited by the fact that glucose fluctuations 
are generally nonlinear in time. A personalised tuneable gain is employed to 
overcome the intra- and inter-subject variability in insulin sensitivity. The basal 
insulin term of the employed beta-cell model is set to 70% of the subject’s basal 
insulin infusion profile. The states of the ordinary differential equations (ODE) 
comprising the beta-cell model are initialized based on the initial glucose 
measurement. These values are selected from a pre-calculated look-up table storing 
the ODE states values corresponding to different glucose concentrations. To tackle 
the perturbation introduced by meals, a meal announcement strategy is used which 
delivers a meal bolus determined by a standard bolus calculator. 
To minimise hypoglycaemia, a LGS algorithm is incorporated into the controller. A 
schematic representation of the bio-inspired control algorithm is illustrated in Figure 
5.  
 
 
Figure 5: Block diagram of the bio-inspired controller. 
Subcutaneous sensor (s.c sensor), tuning gain (K), low glucose suspend (L.G.S.) 
 
The details of the bio-inspired algorithm have been published by Herrero et al. and 
have showed promising results when tested in silico with 97.8 (±4.0) % of time spent 
in target range and 0.22 (±1.36) % in hypoglycaemia (65). The main objective of this 
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thesis is to provide the first-in-human evaluation of this algorithm, which has been 
implemented on a single miniature 5mm by 5mm silicon microchip within a portable 
handheld device. Further specifications and details of the changes to the algorithm for 
each phase of the study as well as the details for the other components of the BiAP 
system are given in the Methods sections in the relevant chapters (Chapters 2, 3, 4 and 
5).  
 
1.5 Continuous subcutaneous insulin infusion (insulin pump) 
Worldwide the majority of people with T1DM are still on MDI of insulin. An 
approach to achieving better glycaemic control came in the form of an insulin pump 
providing a continuous subcutaneous infusion of insulin. Some of the first clinical 
trials evaluating CSII were conducted in the late 1970s and showed that it was 
possible to improve the mean glucose concentration compared to subjects on MDI 
insulin (67, 68). In the UK, it took almost a quarter of a century from these initial 
trials, before CSII became widely accepted and started to be used in clinical practice 
(69). The uptake of insulin pump therapy varies from country to country. In the UK 
its use is guided by specific indications outlined in the NICE guidelines (NICE 2008). 
A common indication for a person with T1DM to start pump therapy is significant 
hypoglycaemia on MDI. The latest ‘smarter’ insulin pumps on the market have added 
features such as bolus calculators that simplify the task of delivering appropriate 
insulin boluses and are integrated with blood glucose meters as well as CGM devices 
with customized hypo-and hyperglycaemia alarms. Sensor-augmented pump (SAP) 
therapy with a low glucose suspend feature is at present the closest thing available to 
an artificial pancreas in clinical practice. A clinical trial testing the Paradigm Veo 
insulin pump with the LGS feature, in 31 adult subjects with T1DM over a three-week 
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period, showed reduced duration of nocturnal hypoglycaemia (<2.2mmol/L) in those 
with the highest incidence of hypoglycaemia at baseline (70). The largest trial to date 
demonstrating the benefit of LGS was conducted by the ASPIRE In-Home Study 
Group in which 247 participants were randomised to SAP with LGS or SAP alone for 
3 months with significant reductions in nocturnal hypoglycaemia being demonstrated 
(25). In a more recent study, 45 participants randomised to either SAP with predictive 
LGS or without predictive LGS for 3 weeks before crossing over showed a reduction 
in hypoglycaemia (% of nights with >1 episode of glucose <3.3mmol/L) from 33 to 
21%, p<0.001(71)  
Despite the improved rapid-acting insulin analogues, the delay in insulin absorption 
via SC route and the variability in insulin pharmacokinetics and pharmacodynamics 
between subjects is a major challenge for the control algorithm in a closed-loop 
system, particularly during the post-prandial period. The coefficient of variability for 
a particular subject is estimated at 15-25%, whilst between subjects it is about 10% 
higher (72). This variability is likely to be due to changes in blood flow and insulin 
sensitivity.  
The intraperitoneal (IP) route of insulin delivery has more theoretical advantages 
compared to the SC route as insulin absorption and action is quicker (73). Insulin 
delivered via the IP route results in hepatic gluconeogenesis being more rapidly 
switched off, which is of major benefit in reducing post-prandial hyperglycaemia 
(74). Additionally, less insulin remains in the peripheral system as it passes the 
hepatic circulation first when administered intraperitoneally, resulting in a reduced 
risk of hypoglycaemia (75, 76).  Overall, insulin delivery via the IP route creates a 
more physiological insulin delivery profile. The future ambulatory closed-loop system 
incorporating an implantable insulin pump could potentially result in better quality of 
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life for the subject compared to being connected to an external pump delivering 
insulin subcutaneously. The IP route of insulin delivery is not the most popular option 
at present due to its potential disadvantages and complications, which include the 
invasive nature of pump insertion, the need for the device to be regularly replaced and 
the potential for pump failure, infection risk, blockage of catheters and in some 
individuals the increased risk of insulin antibodies production with time (77, 78). 
Pump failure is a recognised safety concern with all the existing pumps currently in 
use and if unrecognised for a prolonged time period, can lead to diabetic ketoacidosis 
(79). The current insulin pumps available have systems incorporated within the device 
to detect certain faults, such as an obstruction in the infusion set, which then alerts the 
user by alarming and displaying an error message. However, the pumps are currently 
unable to detect other types of fault such as a disconnection or a leak in the infusion 
set. This is a potential pitfall in closed-loop insulin delivery systems where the 
algorithm takes into account the delivered insulin dose in its calculations. More 
advanced fault detection systems are being developed and could be an effective tool 
for detecting disconnection faults in both sensor augmented pump therapy and closed-
loop systems (80). 
Although insulin is the primary hormone used in the closed-loop system the addition 
of glucagon in a bi-hormonal configuration may have additional benefits and in 
mimicking a more physiological state. Other potential hormonal outputs in a closed-
loop system include amylin and glucagon-like peptide (GLP-1).  
 
1.5.1 Insulin  !
After the discovery of insulin in 1922, diabetes was no longer equated to mortality, 
and although life expectancy was still reduced due to potential complications, it was 
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recognised that survival was possible by replacing the deficient hormone. Insulin 
preparations have improved since the first animal insulin preparation was made 
available. Over the years several pharmaceutical companies have focused their efforts 
towards producing insulin therapies that allow us to mimic normal physiological 
insulin secretion profiles in patients with diabetes. Closed-loop insulin delivery 
requires a rapid-acting insulin and for a long time short-acting soluble human insulin 
was the only preparation available for post-prandial control of glucose.  
Newer rapid-acting insulin analogues such as insulin aspart and lispro are mostly used 
nowadays and these preparations have shown improved pharmacokinetic and 
pharmacodynamic profiles compared to human soluble insulin (81, 82). 
Insulin aspart is produced by recombinant technology that replaces proline with 
aspartic acid at position 28 on the B chain of insulin. This allows the hexamer 
molecule to rapidly dissociate into monomers and dimers when injected SC.  When 
insulin aspart is injected SC the onset of action occurs within 10-20 minutes, the 
maximum effect is achieved within 1-3 hours, and the duration of action lasts 3-5 
hours. Insulin aspart reaches its peak concentration at 40 minutes post SC injection 
and baseline concentration by 4-6 hours. Aspart and lispro have been demonstrated to 
be equally effective for post-prandial glycaemic control (83). The rate of absorption 
of SC injected insulin varies with site of injection, injection volume and concentration 
and is affected by local degradation and tissue blood flow (84). Ultra-fast acting 
insulin formulations are under development and may have the potential to overcome 
the delay in absorption associated with subcutaneous delivery of existing insulin 
analogues(85). 
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1.5.2 Glucagon !
Glucagon is a hormone secreted by the alpha-cells in the pancreas and plays a vital 
role in regulating blood glucose levels. It is secreted straight into the portal vein and 
its main physiological effect is therefore breakdown of glycogen in the liver, in 
response to hypoglycaemia. Hypoglycaemia in T1DM is a result of an imbalance 
between the glucose concentration in the blood, the exogenous insulin dose taken and 
a lack of counter regulatory hormone production. In addition to destruction of 
pancreatic β-cells in T1DM there is some evidence that the α-cells also lose their 
secretory function with time. As mentioned before, recurrent hypoglycaemia in 
patients with T1DM is a major contribution to the challenge of achieving optimal 
glycaemic control and can over time result in hypoglycaemia unawareness.  
Using glucagon in addition to insulin in a closed-loop system is theoretically more 
physiological and has the potential to prevent impending hypoglycaemia. However, in 
the event of repeated glucagon delivery during closed-loop control, the glucagon 
could become less effective due to the depletion of liver glycogen stores. Nausea and 
vomiting are potential associated side-effects, but they do not appear to occur 
significantly during bi-hormonal closed-loop studies where only micro boluses of 
glucagon are delivered (86-88). One of the main factors limiting the utility of 
glucagon in a bi-hormonal closed-loop artificial pancreas is the lack of sufficient data 
to support the stability, efficacy and safety of glucagon preparations, at various 
temperatures, over time in a portable pump cartridge. Currently available preparations 
of glucagon, for use in emergency situations, come in a crystallised form and have to 
be dissolved in aqueous solution immediately prior to using. There is a concern that 
glucagon in a solution has a tendency to form amyloid fibrils with aging (89). 
Amyloid fibrils have in turn been linked to the development of degenerative diseases 
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such as Alzheimer’s disease. One study by El-Khatib et al. tested the in vivo potency 
and time course of activity of subcutaneously administered glucagon in type 1 
diabetic swine models (90). This showed that there was no diminution in effect of 
glucagon stored in solution, at room and body temperature, over a 7 day time period. 
Following this, the same group conducted a feasibility study of bihormonal closed-
loop blood glucose control, using dual subcutaneous insulin and glucagon in 
ambulatory diabetic swine with promising results that opened the door for testing 
these systems in humans (91). 
It has been shown that when the pH of the glucagon buffer during aging is kept at 
alkaline levels, amyloid formation and cytotoxicity are much lower than at an acidic 
pH (92). The glucagon needed for pump use should ideally be chemically and 
physiologically stable in a solution at body temperature of 37°C, over a 5-7 day time 
period. There is an on-going research attempt to formulate this optimal and stabilised 
glucagon formulation. One such promising glucagon analogue is the Biodel glucagon, 
which remained stable beyond 7 days at 37°C (93).There is yet no stable glucagon 
formulation available for long-term use in an artificial pancreas, but on-going 
research efforts appear promising (94, 95). 
 
1.5.3 Islet cell amyloid polypeptide  !
In addition to insulin the pancreatic β-cells produce islet cell amyloid polypeptide 
(IAPP), otherwise known as amylin. IAPP is stored within the insulin granules and is 
secreted simultaneously with insulin in response to a glucose stimulus. Receptors for 
IAPP are located in the hindbrain and its effects are mediated through the central 
nervous system (96). The main effects of IAPP include delayed gastric emptying and 
inhibition of glucagon secretion, and therefore in principle IAPP has the potential to 
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reduce the post-prandial hyperglycaemia often seen in subjects with T1DM, 
irrespective of whether they are on MDI, pump therapy or on closed-loop insulin 
delivery in clinical trials. It is well known that the current fast-acting insulin 
analogues given subcutaneously as pre-meal boluses do not act rapidly enough to 
prevent the post-prandial peak often seen at 60-90 minutes after a meal. Pramlintide, a 
synthetic analogue of amylin, was given FDA-approval in 2005 to be used as adjunct 
therapy with insulin in T1DM. The use of Pramlintide as an insulin adjunct has been 
shown to reduce post-prandial blood glucose excursions compared to insulin alone 
(97, 98). 
 
1.5.4 Glucagon-like peptide 1 !
Glucagon-like peptide 1 (GLP-1) is a gut hormone produced by intestinal L-cells. The 
main actions of GLP-1 include an increase in insulin secretion in response to a 
glucose load in the intestinal tract, an increase in insulin sensitivity, inhibition of beta-
cell apoptosis, enhancement of beta-cell regeneration, inhibition of glucagon release 
and induced satiety (99). Treatment with injectable GLP-1 analogues, such as 
Exenatide and Liraglutide have been shown to improve glycaemic control in T2DM 
(100) and there is some evidence to suggest its benefit in T1DM (101, 102). NICE 
recommends GLP-1 analogues as a 3rd line agent in obese (BMI >30) people with 
T2DM who do not achieve glycaemic target with oral medication. There has been 
increased interest in using GLP-1 analogues in T1DM (103) and larger randomised 
controlled trials are underway (104). 
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1.6 Review of closed-loop studies to date 
The initial clinical trials assessing the various forms of closed-loop insulin delivery 
systems were carried out from 1974 (26, 105-107). These early trials mainly looked at 
closed-loop using an intravenous (IV) method of sensing glucose and IV insulin 
delivery. After the initial clinical trials in the 1970s, there were minimal advances in 
the field for approximately 20 years. Only since the development of commercially 
available SC CGM devices towards the end of the 1990s, and the accepted use of 
insulin pumps, have we witnessed exciting progress in the development of SC-SC 
closed-loop insulin delivery systems.  A major breakthrough was also the acceptance 
of the UVa-Padova T1DM simulator for the testing of control algorithms. The 
simulator is a computer model of the human metabolic system based on the glucose-
insulin dynamics in human subjects and contains an in silico population of 300 
subjects with parameters derived from triple tracer metabolic studies that reflect the 
human metabolism found with T1DM. As a result in silico trials of closed-loop 
algorithms became a substitute to animal trials, saving time and money, thus allowing 
more rapid progression from the development of technology to clinical trials (108).  A 
literature search of published clinical AP trials was performed using PubMed and an 
online database (www.thedoylegroup.org/APdatabase). Since 2004 over 70 clinical 
trials assessing various artificial pancreas systems, starting from short fasting studies 
to fully automatic home studies, have been completed all over the world. These trials 
have been summarised in Table 2 of which a few selected initial inpatient studies 
using different approaches have been discussed in more detail below. Due to 
differences in clinical protocols and primary outcomes measured it is very challenging 
to compare the clinical results and hence close to impossible to determine whether 
one AP system is superior to another.  
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The first SC-SC automated closed-loop insulin delivery system was evaluated in 10 
subjects with T1DM using a PID algorithm and showed that glucose stayed within 
target 75% of the time compared to 63% in open-loop, with the incidence of 
hypoglycaemia being similar in both groups (109). It was recognised that postprandial 
glucose values were frequently above target and later studies demonstrated that 
delivering priming boluses of insulin 15 minutes prior to meals improved postprandial 
glycaemic excursions (55). Further insight into the role of insulin feedback 
incorporated into a PID algorithm was assessed by Steil et al. and showed some 
improvement compared to previous studies. However, hypoglycaemia persisted (51).  
 
An alternative closed-loop insulin delivery system designed to overcome the 
challenges associated with the pharmacokinetics of insulin delivered in the interstitial 
space and the subcutaneous sensors, as well as the constraints of wearing an external 
device, was attempted by Renard and team with an implantable system based on IP 
insulin delivery and a venous glucose sensor (110). The concept was optimistic, and 
although the results were similar to the SC-SC closed-loop trials conducted at the 
same time, the disadvantages associated with the IV sensors, such as significant time-
lag, level of invasiveness and the need for annual replacements, prevented its use in 
subsequent trials. However, a few years later the same study group conducted another 
semi closed-loop trial (pre-meal boluses of insulin given) using a simpler system with 
a SC sensor, IP insulin delivery and a PID algorithm which showed that a higher 
percentage of time was spent in target (4.4-6.6mmol/L) during closed-loop vs.. open-
loop (39.1% vs.. 27.7%, p=0.05): 76.5% of the time blood glucose was between 4.4-
10mmol/L in closed-loop vs.. 63.7% in open-loop (IP insulin) (111). 
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Hovorka’s group from Cambridge, UK, demonstrated that overnight, their MPC 
driven closed-loop system in children and adolescents, caused a reduction in the risk 
of nocturnal hypoglycaemia following both various types of evening meals (rapidly 
and slowly absorbed meals) and exercise. This study included three randomised 
crossover (closed-loop vs. open-loop (standard CSII)) studies in 17 patients and 
primary outcomes were time spent in target glucose range (3.9-8.0mmol/L) and time 
spent in hypoglycaemia (<3.9mmol/L). Although the primary outcomes did not differ 
significantly between treatment groups, the overall pooled data showed that 60% of 
time was spent within target in the closed-loop group vs. 40% in the open-loop group 
and a reduced time in hypoglycaemia in the former was also observed (2.1% vs. 
4.1%, p=0.03) (112). Another crossover overnight study completed by the same 
group, but this time in 24 adults, showed the closed-loop increased the overall time 
plasma glucose was in target by a median of 22% (P<0.001) and reduced the time 
spent below target by 3% overnight (p<0.04) (113).  
 
The first multinational closed-loop study using an MPC algorithm, evaluated the 
closed-loop system overnight and post breakfast for a total of 14.5 hours in 20 
subjects. A significant reduction in the incidence of nocturnal hypoglycaemia was 
achieved with closed-loop (from 1.15 episodes/subject to 0.25 episodes/subject). 
Although the average glucose concentration did not differ between the groups, the 
time spent in target increased from 64% to 78% with closed-loop control overnight. 
However, there were no significant differences between the groups post-breakfast 
(114). The iAP (International Artificial Pancreas) study group assessed MPC closed-
loop system using two different strategies referred to as standard control to range 
(sCTR) and enhanced control to range (eCTR) (115). The main aim of sCTR was to 
! 45!
achieve a reduction in severe glucose excursions and aim for near normoglycaemia 
(defined as 3.9-10 mmol/L), wheras eCTR was designed to achieve optimal glucose 
control (defined as 4.4-7.8mmol/L). sCTR significantly increased time in target (3.9-
10mmol/L) from 61.5 (±5.2)% in open-loop to 74.4 (±3.9) % in closed-loop (p=0.01). 
Time in target using eCTR versus open-loop was 90.1(±3.4)% versus 76.8 (±5.05)% 
respectively (p=0.05). There was no significant difference in frequency of 
hypoglycaemia with eCTR compared to sCTR.  
 
Pregnancy is associated with increased hypoglycaemia unawareness compared to the 
non-pregnant state (116). Closed-loop control with MPC has been assessed in well-
controlled pregnant women and has shown a similar time spent in target-glucose 
range compared with standard CSII. However, less time was spent in hypoglycaemia 
(<2.5mmol/L) with closed-loop (0.0% vs. 0.3%, p<0.05) (117). Closed-loop was also 
shown to be safe during early and late stage gestation (118).  
 
The fuzzy-logic algorithm has mainly been adopted by the team conducting the 
DREAM (Diabetes WiREless Artificial Pancreas ConsortiuM) study, a crossover 
multicentre trial in Germany, Israel and Slovenia designed to assess the safety and 
efficacy of an MD-Logic Artificial Pancreas system (119-122).  
 
The first clinical human study assessing a bihormonal (using insulin and glucagon) 
closed-loop system was conducted by El-Khatib et al. where closed-loop was assessed 
over 27 hours in 11 participants. Out of the 11 subjects, 6 subjects had no episodes of 
hypoglycaemia requiring treatment: the mean blood glucose concentration achieved 
was 7.8mmol/L. The remaining 5 subjects did develop hypoglycaemia requiring 
! 46!
treatment; however, it was later shown that they had slower lispro absorption kinetics 
compared to the 6 subjects that did not experience significant hypoglycaemia. 
Following adjustment to the algorithm´s pharmacokinetic parameters, a repeat 
experiment was done with 9 subjects, and this time there were no episodes of 
hypoglycaemia requiring treatment and the mean blood glucose concentration was 
9.1mmol/L (123). Shortly following this, another bihormonal closed-loop study in 13 
participants by Castle et al demonstrated a reduction in time spent in the 
hypoglycaemic range (CL 15 ± 6 vs.. OL 40± 10 min/day, p=0.04)(86).  A head to 
head study comparing bi-hormonal CL vs. insulin only CL in 30 participants showed 
no significant difference (significance level set to p<0.01) in percentage time in target 
(4-10mmol/L) (74 vs. 77%, p=0.34) or percentage time in hypoglycaemia 
(<4mmol/L) (1.5 vs. 3.1%, p=0.02)(87). 
 
Breton et al showed that informing the closed-loop algorithm of the heart rate, as a 
measure of activity, could be beneficial in terms of reducing the risk of hypoglycemia 
both during and after exercise, although no difference in time in target was 
demonstrated when compared to not informing the controller of the heart rate (124). 
 
The initial results of the 6-hour and 13-hour overnight and post-prandial study 
evaluating the Bio-inspired Artificial Pancreas were published last year by the author 
of this thesis (125) (outlined in detail in Chapter 2 and 3), but no other published AP 
trials have used a bio-inspired control algorithm based on a mathematical model of 
beta-cell physiology.  
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Over the last two years several outpatient studies assessing closed-loop control 
overnight have been published, which have encouragingly demonstrated trends 
towards reduced hypoglycaemia and increased time in glucose target range (122, 126-
128). More recently, results from randomised controlled crossover trials where 
participants have used 24-hours/day closed-loop control in an outpatient setting have 
become available (129-133). Proving that using an artificial pancreas is safe in free-
living conditions brings the AP one step closer to becoming available to patients.  The 
outcomes from outpatient/home studies can be found in Table 2. 
 
! !
48!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
 
n 
M
ea
n 
(S
D
) A
ge
  
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
on
te
nt
 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
M
ea
n 
(S
D
) %
 
T
im
e 
in
 ta
rg
et
 
 
M
ea
n 
(S
D
) 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
* 
 
L
y 
et
 a
l 
 
20
15
 
 
(1
30
) 
N
=2
0 
 O
P 
(o
ut
pa
tie
nt
) 
 R
C
T 
of
 H
yb
rid
 
C
lo
se
d 
Lo
op
 
(H
C
L)
 v
s. 
SA
P 
 
 In
su
lin
 
PI
D
 IF
B
 
 M
ed
tro
ni
c 
4S
 se
ns
or
 
12
.6
%
 
 M
ed
tro
ni
c 
M
in
iM
ed
 
53
0G
 
C
L:
 1
0 
 SA
P:
 1
0 
18
.6
 (3
.7
) 
 (A
ge
 ra
ng
e 
15
.2
-
31
.4
) 
 9.
1 
(4
.7
) 
8.
6 
(1
.5
) 
 70
 (1
6)
 
A
pp
ro
x.
 6
 
da
ys
 
3.
9-
10
 
N
ot
 re
st
ric
te
d 
     
Fu
ll 
bo
lu
s 
N
ot
 re
st
ric
te
d 
H
C
L 
69
.9
%
 v
s. 
O
L 
73
.1
%
 (p
=0
.5
80
) 
 O
ve
rn
ig
ht
 (2
3:
00
-
07
:0
0)
: 
H
C
L 
79
.9
(4
.0
) v
s 
O
L 
68
.2
(6
.1
), 
p=
0.
11
. 
H
C
L 
2.
1(
0.
4)
 v
s. 
O
L 
2.
4(
0.
6)
, 
p=
0.
65
6 
 H
C
L 
1.
7 
(0
.9
) v
s. 
O
L 
4.
2(
1.
3)
, p
= 
0.
13
6 
H
ai
da
r 
et
 a
l 
 
20
15
 
 
(8
7)
 
N
=3
0 
 IP
 (i
np
at
ie
nt
) 
 R
C
T 
C
lo
se
d 
Lo
op
 
(C
L)
 v
s. 
B
i-
ho
rm
on
al
 C
L 
(B
H
C
L)
 v
s. 
O
pe
n 
Lo
op
 (O
L)
 
de
si
gn
ed
 to
 a
ss
es
s 
ef
fic
ac
y 
gl
uc
ag
on
 
  In
su
lin
 A
sp
ar
t 
G
lu
ca
ge
n 
(N
ov
o)
 
M
PC
 
G
lu
ca
go
n:
 h
eu
ris
tic
 
lo
gi
ca
l r
ul
es
 
 M
ed
tro
ni
c 
So
fS
en
so
r 
16
.7
-1
7.
3%
 
 M
in
iM
ed
 P
ar
ad
ig
m
 
V
eo
 
  
A
ge
>1
8:
 
20
  
 A
ge
>1
8:
 
10
  
33
 (1
8)
 
  16
 (1
1)
 
7.
7 
(1
.0
) 
60
.3
 (1
0.
5)
 
24
 
 08
:0
0h
-
08
:0
0h
 
4-
10
 
4  08
:0
0h
: 5
9g
 
 12
:0
0h
: 7
0g
 
 17
:0
0h
: 9
5g
 
 21
:0
0h
: 2
0g
 
70
-1
00
%
 
ca
lc
ul
at
ed
 
ba
se
d 
on
 C
H
O
 
an
d 
fu
zz
y 
lo
gi
c 6
0m
in
  
Tr
ea
dm
ill
 
 60
%
  
V
O
2 m
ax
 
C
L 
74
%
 (1
5)
 v
s. 
B
H
C
L 
77
%
 (1
4)
, 
p=
0.
34
 v
s. 
O
L 
61
%
 
(2
0)
.  
 O
ve
rn
ig
ht
 
(2
3:
00
h-
08
:0
0h
): 
C
L 
86
(1
5)
 v
s. 
B
H
C
L 
84
(2
0)
 v
s. 
O
L 
59
 (3
7)
 
 C
L 
an
d 
B
H
C
L 
vs
 
O
L,
 p
<0
.0
01
. 
C
L 
vs
 B
H
C
L 
(N
S)
 
ov
er
al
l +
ov
er
ni
gh
t 
 
C
L 
3·
1%
 (0
·6
 to
 
8·
7)
 v
s. 
B
H
C
L 
1·
5%
 (0
·0
 to
 3
·5
), 
p=
0.
02
 v
s. 
O
L 
13
·3
%
 (2
·8
 to
 2
0·
9)
 
  C
L 
0·
0%
 (0
·0
 to
 
3·
1)
 v
s. 
B
H
C
L 
0·
0%
 (0
·0
 to
 
0·
0)
 v
s. 
 
O
L 
0·
0%
 (0
·0
 to
 
21
·8
) 
C
L&
B
H
C
L 
vs
 O
L 
(<
0.
00
1)
  
C
L 
vs
 B
H
C
L 
(p
=0
.0
18
) o
ve
ra
ll 
D
el
 F
av
er
o 
 
et
 a
l  
20
15
 
 
(1
34
) 
N
=1
3 
 O
P 
 R
C
T 
C
L 
vs
. O
L 
 
 In
su
lin
 
    
M
PC
 
 D
ex
co
m
 G
4 
Pl
at
in
um
 
 R
oc
he
 A
cc
uc
he
k 
Sp
iri
t C
om
bo
 
13
 
45
 (1
4)
 
  19
(1
6)
 
7.
4 
(0
.9
) 
12
 
 19
:0
0h
-
07
:0
0h
 
3.
9-
10
 
1  19
:0
0h
: 
V
ar
ia
bl
e 
(g
) 
10
0%
 
N
/A
 
C
L 
83
.6
 (1
4.
0)
 v
s. 
O
L 
62
.4
(2
9.
0)
%
, 
p=
0.
04
. 
C
L 
1.
96
 (4
.5
6)
 v
s. 
O
L 
12
.7
6 
(1
5.
84
), 
p=
0.
03
. 
! !
49!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
B
ro
w
n 
et
 a
l 
20
15
 
 
(1
35
) 
N
=1
0 
 O
P 
 
 C
L 
vs
. O
L 
w
ith
 
ai
m
 a
se
ss
es
si
ng
 
ef
fic
ac
y 
of
 n
ew
 
co
nt
ro
l a
lg
or
ith
m
.  
 In
su
lin
 
O
th
er
 
 D
ex
co
m
 G
4 
Pl
at
in
um
 
10
.2
%
 
 R
oc
he
 A
cc
uc
he
k 
Sp
iri
t C
om
bo
 
  
10
 
46
.4
 (8
.5
) 
7.
03
 (1
.0
5)
 
40
 
 (5
 x
 8
h 
se
ss
io
ns
: 
23
:0
0h
-
07
:0
0h
) 
3.
9-
10
 
  
N
/A
 
N
/A
 
N
/A
 
 
C
L 
85
.4
 (7
1.
6–
10
0)
 
vs
. O
L 
59
.1
 (3
0.
2–
10
0)
, p
<0
.0
01
. 
  
C
L 
0.
55
 (0
–0
) v
s. 
O
L 
1.
56
 (0
–0
), 
p=
ns
. 
B
re
to
n 
et
 a
l 
 
20
14
 
 
(1
24
) 
N
=1
0 
 IP
 
 Es
ta
bl
is
h 
fe
as
ib
ili
ty
 o
f a
 
co
nt
ro
l-t
o-
ra
ng
e 
(C
TR
) c
lo
se
d-
lo
op
 
sy
st
em
 in
fo
rm
ed
 
by
 h
ea
rt 
ra
te
 (H
R
). 
 In
su
lin
 L
is
pr
o 
C
on
tro
l-t
o-
ra
ng
e 
(d
ef
in
iti
on
 n
ot
 
sp
ec
ifi
ed
) 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 In
su
le
t  
O
m
ni
Po
d 
 
10
 
38
 (3
.3
) 
 23
.6
 (4
.4
) 
6.
9(
0.
2)
 
24
 
 09
:0
0h
-
09
:0
0h
 
3.
9-
10
 
3  11
:0
0h
: 4
6g
 
 19
:0
0h
: 4
2g
 
 08
:0
0h
: 2
0g
 
10
0%
 
 
30
m
in
 
Er
go
m
et
er
 
bi
ke
 
 Pe
rc
ei
ve
d 
ex
er
tio
n 
of
 9
-
10
 o
n 
th
e 
B
or
g 
sc
al
e 
C
L+
H
R
 8
1 
(3
.9
) 
vs
. C
L 
75
 (4
.3
), 
p=
0.
2.
 
N
ot
 a
na
ly
se
d 
T
ur
ks
oy
 e
t a
l 
 
20
14
 
 
(1
36
) 
N
=2
0 
IP
 
 C
L 
vs
. O
L.
  
H
yp
og
ly
ca
em
ia
 
al
ar
m
 tr
ig
ge
re
d 
by
 
ph
ys
io
lo
gi
ca
l 
pa
ra
m
et
er
s 
in
te
gr
at
ed
 in
to
 C
L 
sy
st
em
.  
 In
su
lin
 
   
M
PC
 
 M
ed
tro
ni
c 
G
ua
rd
ia
n 
R
ea
l-T
im
e 
 Su
bj
ec
t's
 o
w
n 
C
L:
 9
 
 O
L:
11
 
18
.3
 
 10
 
7.
5 
32
 
 (0
8:
00
h-
16
:0
0h
) 
3.
9-
10
 
5 
(+
sn
ac
ks
) a
t 
fo
llo
w
in
g 
tim
e 
po
in
ts
: 
08
:1
5h
 
11
:3
0h
 
18
:0
0h
 
08
:1
5h
 
11
:4
5h
 
 V
ar
ia
bl
e 
C
H
O
 
co
nt
en
t (
g)
 
N
on
e 
 
O
ne
 se
ss
io
n 
of
 
20
 
m
in
ut
es
/d
ay
  
 85
%
 o
f 
pr
ed
ic
te
d 
H
R
 
C
L 
58
 v
s O
L 
54
 
 (S
D
 n
ot
 g
iv
en
) 
C
L 
1.
0 
vs
 8
7 
! !
50!
 
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
C
ap
el
 e
t a
l 
 
20
14
 
 
(1
37
) 
N
=1
0 
IP
 
 R
C
T 
C
L 
vs
. O
L 
to
 
as
se
ss
 th
e 
ef
fic
ac
y 
of
 C
L 
sy
st
em
 
co
m
pr
is
in
g 
a 
pr
ed
ic
tiv
e 
ru
le
-
ba
se
d 
al
go
rit
hm
 
(p
R
B
A
). 
 In
su
lin
 A
sp
ar
t 
pR
B
A
  
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
R
ea
l-T
im
e 
12
.6
%
 
 A
ni
m
as
 2
02
0 
10
 
46
.7
(1
0.
8)
 
 18
.0
 –
 5
.7
 
7.
1 
(0
.8
) 
 55
 (8
.7
) 
8  00
:0
0h
-
08
:0
0h
 
3.
9–
8 
1 (N
B
 n
ot
 
in
cl
ud
ed
 in
 
re
su
lt 
pe
rio
d)
 
 08
:0
0h
: 4
1g
 
 
50
%
 
N
/A
 
C
L 
95
.8
(7
3–
10
0)
 
vs
. O
L 
66
.6
(8
.3
–
75
), 
p<
0.
05
. 
C
L 
0.
0(
0.
0–
0.
0)
 v
s 
O
L 
4.
2 
(0
–2
1)
, 
p<
0.
05
. 
Ja
co
bs
 e
t a
l 
 
20
14
 
 
(1
38
) 
N
=1
3 
IP
 
 Ev
al
ua
te
 e
ff
ic
ac
y 
B
H
C
L 
us
in
g 
di
ff
er
en
t s
en
so
rs
. 
N
o 
op
en
-lo
op
 a
rm
.  
 In
su
lin
 A
sp
ar
t 
G
lu
ca
ge
n(
N
ov
o)
 
PD
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
(n
=8
) 
D
ex
co
m
 G
4 
Pl
at
in
um
 
(n
=5
) 
C
la
rk
e 
er
ro
r g
rid
 
gi
ve
n-
no
 M
A
R
D
 
  In
su
le
t O
m
ni
po
d 
13
 
39
.5
 (1
0.
9)
 
 22
.5
 (1
2.
4)
 
7.
7 
(0
.6
) 
28
 
3.
9-
10
 
4  B
 7
3g
 
L 
72
g 
D
 9
3g
 
B
 6
3g
 
 M
ea
l t
im
es
 n
ot
 
pr
ov
id
ed
 
60
%
 
N
/A
 
C
L 
72
.5
 (1
1.
8)
 
 N
B
 C
al
cu
la
te
d 
fr
om
 ra
w
 d
at
a 
 
 
C
L 
0.
8 
(1
.4
) 
 N
B
 C
al
cu
la
te
d 
fr
om
 
ra
w
 d
at
a 
 
 
E
l K
ha
tib
  
et
 a
l  
20
14
 
 
(1
39
) 
N
=2
4 
IP
 
R
C
T 
3r
d  g
en
er
at
io
n 
B
H
C
L 
A
M
B
 v
s. 
C
L 
N
M
B
 in
 a
du
lts
 
an
d 
ad
ol
es
ce
nt
s. 
 
 In
su
lin
 L
is
pr
o 
G
lu
ca
go
n 
(E
li 
Li
lly
) 
   
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
12
.3
%
 
 In
su
le
t O
m
ni
Po
d 
12
  
(>
18
 y
rs
) 
 12
 (<
18
 
yr
s)
 
A
du
lts
: 
45
(1
4)
 
 27
(1
5)
 
  A
do
le
sc
en
ts
: 
15
(2
) 
 7(
4)
 
  
A
du
lts
: 
7.
3(
0.
9)
 
    A
do
le
sc
en
ts
 
7.
9 
(0
.4
) 
48
 
 18
:0
0-
18
:0
0 
(D
ay
 
3)
 
  
3.
9-
10
 
6  18
:0
0h
 
07
:3
0h
 
12
:3
0h
 
18
:0
0h
 
07
:3
0h
 
12
:3
0h
 
 M
ea
n 
C
H
O
 (g
) 
=9
8 
(1
7)
 
   
Pa
rti
al
 b
ol
us
: 
au
to
m
at
ic
al
ly
 
ad
ap
tiv
e 
m
ea
l-
pr
im
in
g 
bo
lu
s, 
st
ar
tin
g 
at
 0
.0
5 
U
/k
g 
St
at
io
na
ry
 
bi
ke
 
Ta
rg
et
 h
ea
rt 
ra
te
 o
f 1
20
-
14
0 
bp
m
 u
nt
il 
40
00
 
he
ar
tb
ea
ts
 
re
ac
he
d 
A
du
lts
: 
C
L 
A
M
B
 8
0(
6)
 v
s. 
C
L 
N
M
B
 7
0(
9)
, 
p=
0.
04
. 
  A
do
le
sc
en
ts
: 
C
L 
A
M
B
 6
8(
8)
 v
s 
C
L 
N
M
B
 6
0(
4)
, 
p=
0.
05
. 
 
A
du
lts
: 
C
L 
A
M
B
 5
.1
 (6
.7
) 
vs
. C
L 
N
M
B
 3
.6
 
(4
.5
), 
p=
0.
67
. 
 A
do
le
sc
en
ts
: 
C
L 
A
M
B
 0
.3
 (0
.5
) 
vs
 C
L 
N
M
B
 
0.
4(
0.
7)
, p
=0
.7
8.
 
 
! !
51!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
H
ar
ve
y 
et
 a
l 
20
14
 
 
(1
40
) 
  
N
=2
0 
 IP
 
 Te
st
 sa
fe
ty
 a
nd
 
ef
fic
ac
y 
of
 A
P 
us
in
g 
zo
ne
-m
od
el
 
pr
ed
ic
tiv
e 
co
nt
ro
l 
(z
on
e-
M
PC
) w
ith
 
in
te
gr
at
ed
 h
ea
lth
 
m
on
ito
rin
g 
sy
st
em
 
(H
M
S)
.  
 In
su
lin
 
Zo
ne
- M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
C
la
rk
e 
er
ro
r g
rid
 9
8%
 
in
 z
on
e 
A
+B
 
 A
ni
m
as
 O
ne
To
uc
h 
Pi
ng
 
12
 
49
.4
 (1
0.
4)
 
 32
.7
 (1
6)
 
7.
3 
(1
.2
) 
24
 
 17
:0
0h
-
17
:0
0h
(n
ex
t 
da
y)
 
3.
9-
10
 
2  M
ea
ls
 
un
an
no
un
ce
d 
 19
:0
0h
: 5
0g
 
07
:0
0h
: 4
0g
 
N
on
e 
  
30
m
in
 
 St
at
io
na
ry
 
bi
ke
 
 50
%
 o
f 
pr
ed
ic
te
d 
he
ar
t 
ra
te
 re
se
rv
e 
C
L 
80
 
C
L 
1.
2 
(1
.7
) 
Fi
na
n 
et
 a
l 
 
20
14
 
 
(1
41
) 
  
N
=1
3 
 IP
 
 C
L 
in
co
rp
or
at
in
g 
th
e 
H
yp
og
ly
ca
em
ia
-
H
yp
er
gl
yc
ae
m
ia
 
M
in
im
is
er
 sy
st
em
 
(H
H
M
) 
 In
su
lin
: A
sp
ar
t; 
Li
sp
ro
; A
pi
dr
a 
M
PC
 
(Z
on
e 
M
od
el
 
Pr
ed
ic
tiv
e 
C
on
tro
lle
r 
w
ith
 S
af
et
y 
Su
pe
rv
is
io
n 
M
od
ul
e)
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 A
ni
m
as
 O
ne
To
uc
h 
Pi
ng
 
13
 
42
.4
 (1
2.
7)
 
 27
.2
(1
3.
3)
 
7.
4 
(0
.8
) 
20
 
 00
:0
0-
 
20
:0
0h
(n
ex
t 
da
y 
3.
9-
10
 
2  07
:0
0h
: 1
g/
kg
 
 13
:0
0h
: 1
g/
kg
 
10
0%
 
In
 5
 su
bj
ec
ts
: 
B
F 
bo
lu
s 
un
de
re
st
im
at
ed
 
by
 3
0%
 a
nd
 
lu
nc
h 
bo
lu
s 
ov
er
es
tim
at
ed
 
by
 3
0%
  
N
/A
 
C
L 
69
.6
 (2
4.
7)
 
 O
ve
rn
ig
ht
  
(0
0:
00
-0
7:
00
h)
: 
C
L 
81
.8
 (3
5.
6)
  
C
L 
0.
2(
0.
5)
 
 O
ve
rn
ig
ht
 (0
0:
00
-
07
:0
0h
): 
C
L 
0.
3 
(0
.9
) 
L
ee
la
ra
th
na
 
et
 a
l  
20
14
 
 
(1
29
) 
  
N
=1
7 
 O
P 
 C
L 
vs
. O
L 
in
 fr
ee
-
liv
in
g 
co
nd
iti
on
s. 
 
 In
su
lin
 A
sp
ar
t 
   
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 D
an
a 
R
 D
ia
be
ca
re
 
17
 
34
 (9
) 
 19
 (9
) 
7.
6 
(0
.8
) 
16
8 
 D
ay
 2
-8
 
(D
ay
 1
 a
s 
IP
) 
3.
9-
10
 
N
o 
re
st
ric
tio
ns
 
on
 m
ea
ls
 
10
0%
 
D
ai
ly
 
ac
tiv
iti
es
 
 M
ild
 e
xe
rc
is
e 
C
L 
75
 (6
1-
79
) v
s. 
O
L 
62
 (5
3-
70
), 
 
p=
0.
00
5.
 
C
L 
3.
7 
(2
.2
-7
.9
) v
s. 
O
L 
5.
0 
(2
.3
-8
.5
), 
p=
0.
33
9.
 
! !
52!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
L
ee
la
ra
th
na
 
et
 a
l  
20
14
 
 
(1
42
) 
N
=8
 
 IP
 
 A
ss
es
s t
he
 
re
lia
bi
lit
y 
of
 a
 
no
ve
l a
ut
om
at
ed
 
cl
os
ed
-lo
op
 
gl
uc
os
e 
co
nt
ro
l 
sy
st
em
 d
ev
el
op
ed
 
w
ith
in
 th
e 
A
P@
ho
m
e 
 
 In
su
lin
 A
sp
ar
t 
M
PC
 
 D
ex
co
m
 G
4 
Pl
at
in
um
 
8.
3%
 
C
la
rk
e 
er
ro
r g
rid
 8
7%
 
zo
ne
A
 
 R
oc
he
 A
cc
uc
he
k 
Sp
iri
t C
om
bo
 
8   
40
.5
(1
4.
3)
 
 28
.2
 (1
4.
1)
 
  
8.
2 
(0
.8
) 
12
 
 19
:0
0h
-
07
:0
0h
 
3.
9-
10
 
1  19
:0
0h
: 8
0g
 
10
0%
 
de
liv
er
ed
 1
0 
m
in
 b
ef
or
e 
m
ea
l 
N
/A
 
C
L 
84
.4
 (6
3.
3-
10
0)
 
 O
ve
rn
ig
ht
 2
2:
00
-
07
:0
0 
(ta
rg
et
 3
.9
 to
 
8.
0 
m
m
ol
/l)
: 
C
L 
 
75
.4
 (3
7.
5-
92
.9
) 
C
L 
0.
0 
(0
.0
-1
.4
) 
  O
ve
rn
ig
ht
 2
2:
00
-
07
:0
0:
 
C
L 
0.
0 
(0
.0
-0
0)
 
V
an
 B
on
 
et
 a
l  
20
14
 
 
(1
31
) 
N
=1
1 
 O
P 
 Fe
as
ib
ili
ty
 
as
se
ss
m
en
t o
f C
L 
vs
. O
L 
us
in
g 
po
rta
bl
e 
B
H
C
L 
sy
st
em
 a
t h
om
e 
 In
su
lin
 A
sp
ar
t 
G
lu
ca
ge
n 
(N
ov
o)
 
PD
 
 M
ed
tro
ni
c 
So
fS
en
so
r; 
M
ed
tro
ni
c 
En
lit
e 
18
.6
%
 
(o
ve
ra
ll)
 
 D
is
et
ro
ni
c 
D
-T
ro
n+
 
11
 
52
.1
 (2
5–
66
) 
 35
.3
 (1
2–
53
) 
7.
6 
(6
.2
–9
.5
) 4
8  A
na
ly
si
s 
di
vi
de
d 
in
to
 
da
y 
1 
an
d 
da
y 
2 
3.
9-
10
 
V
ar
ia
bl
e 
N
o 
m
ea
l 
an
no
un
ce
m
en
t 
D
ai
ly
 ro
ut
in
e 
of
 su
bj
ec
ts
 
D
ay
 1
 
C
L1
 7
9.
2(
16
.9
) v
s. 
O
L1
 6
7.
2 
(3
8.
5)
, p
 
= 
0.
19
. 
 D
ay
2 
C
L2
 7
6.
5 
(2
3.
9)
 v
s. 
O
L2
 6
6.
0 
(2
9.
8)
, 
p=
 0
.1
6.
 
 C
L1
 2
.1
(7
.6
) v
s. 
O
L1
 0
.7
 (8
.7
), 
 
p=
 0
.5
9.
 
  C
L2
 2
.8
 (9
.8
) v
s. 
O
L2
 0
.0
 (1
1.
1)
,  
p=
 0
.0
2.
 
E
lle
ri
 e
t a
l 
 
20
14
 
 
(1
43
) 
  
N
=1
1 
 IP
 
 C
L 
w
ith
 d
ilu
te
 
in
su
lin
 (C
L-
D
il)
 
vs
. s
ta
nd
ar
d 
in
su
lin
 
(C
L-
St
d)
 in
 y
ou
ng
 
ch
ild
re
n 
 
 In
su
lin
 A
sp
ar
t 
 
M
PC
 
 D
ex
co
m
 G
4 
11
.6
%
 
 A
ni
m
as
 2
02
0 
11
 
5.
07
 (1
.1
2)
 
 2.
2 
(1
.0
) 
 
11
 
3.
9-
10
 
1 
(n
ot
 in
cl
ud
ed
 
in
 re
su
lt 
pe
rio
d)
 
 17
:0
0h
: 4
4g
 
 O
pt
io
na
l 
be
dt
im
e 
sn
ac
k 
(n
o 
bo
lu
s)
 
10
0%
 
N
/A
 
C
L-
D
il 
98
 (7
9-
10
0)
 
vs
 C
L-
St
d 
85
 (7
2-
97
), 
p=
0.
33
. 
C
L-
D
il 
0.
0 
(0
.0
-1
.4
) 
vs
 C
L-
St
d 
1.
4 
(0
.0
-
11
.6
), 
p=
0.
16
. 
! !
53!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
R
ed
dy
 e
t a
l 
 
20
14
 
 
(1
25
) 
N
=1
7 
IP
 
 A
ss
es
s p
ro
of
 o
f 
co
nc
ep
t a
nd
 sa
fe
ty
 
of
 a
 n
ov
el
 b
io
-
in
sp
ire
d 
ar
tif
ic
ia
l 
pa
nc
re
as
 (B
iA
P)
 
 In
su
lin
 A
sp
ar
t 
B
io
-in
sp
ire
d 
(B
iA
P)
 
 En
lit
e 
M
ed
tro
ni
c 
11
.8
%
 
 R
oc
he
 A
cc
uc
he
k 
Sp
iri
t C
om
bo
 
17
 
44
 (1
0)
 
 22
 (1
2)
 
7.
4 
(0
.7
) 
11
 
 00
:0
0h
-
11
:0
0h
 
3.
9-
10
 
1  06
:0
0h
: 4
0g
 
Pa
rti
al
 7
0%
 
N
/A
 
C
L 
67
.6
 (5
9.
5–
70
.3
) 
 O
ve
rn
ig
ht
 0
0:
00
h-
06
:0
0:
 
10
0 
(8
1.
3–
10
0)
 
C
L 
0.
0 
(0
.0
–0
.0
) 
    C
L 
0.
0 
(0
.0
–0
.0
) 
D
el
 F
av
er
o 
et
 
al
  
20
14
 
 
(1
44
) 
N
=6
 
O
P 
 C
L 
vs
. O
L 
w
ith
 
ai
m
 to
 d
et
er
m
in
e 
ab
ili
ty
 o
f w
ea
ra
bl
e 
A
P 
to
 c
on
tro
l 
po
st
pr
an
di
al
 
gl
uc
os
e.
 
 In
su
lin
 
M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 In
su
le
t O
m
ni
Po
d 
6 
R
an
ge
 2
1–
44
 
 D
M
 d
ur
at
io
n 
no
t 
av
ai
la
bl
e 
N
ot
 
av
ai
la
bl
e 
28
 to
ta
l 
O
L 
18
:0
0h
-
08
:0
0h
 
(p
rio
r t
o 
C
L 
st
ar
t) 
 C
L 
08
:0
0h
- 
12
:0
0h
 
(D
ay
 3
) 
3.
9-
10
 
4 N
o 
de
sc
rip
tio
n 
of
 m
ea
ls
 
10
0%
 
de
liv
er
ed
 
15
m
in
 b
ef
or
e 
m
ea
l 
N
/A
 
C
L 
86
.6
6 
vs
 O
L 
82
.0
5 
 O
ve
rn
ig
ht
 
C
L 
89
.4
0 
vs
. O
L 
84
.9
7 
 
C
L 
1.
15
 v
s O
L 
8.
56
 
T
ha
bi
t e
t a
l 
 
20
14
 
 
(1
26
) 
N
=2
4 
 O
P 
 C
L 
vs
. O
L 
to
 
im
pr
ov
e 
gl
uc
os
e 
co
nt
ro
l. 
 In
su
lin
 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 D
an
a 
R
 D
ia
be
ca
re
 
24
 
43
 (1
2)
 
  29
 (1
1)
 
8.
1 
(0
.8
) 
65
 (5
) 
O
ve
rn
ig
ht
 
fo
r 4
 w
ee
ks
 
(7
hr
s p
er
 
ni
gh
t) 
3.
9-
10
 
0 
10
0%
 b
ol
us
 fo
r 
O
L 
0 
C
L 
73
·2
%
 (9
·0
) v
s  
O
L 
61
·2
%
 (1
3·
7)
 
(p
=0
.0
00
4)
  
C
L 
1·
8%
 (0
·6
 to
 
3·
6)
 v
s. 
O
L 
2·
1%
 
(0
·7
 to
 3
·9
) 
(p
=0
.2
8)
 
C
am
er
on
 
et
 a
l  
20
14
 
 
(1
45
) 
N
=1
0 
IP
 
Te
st
 C
L 
(m
ea
ls
 
un
an
no
un
ce
d)
 in
 2
 
se
pa
ra
te
 c
oh
or
ts
 
(C
H
). 
 In
su
lin
 L
is
pr
o 
M
PC
 
 A
bb
ot
t N
av
ig
at
or
 
16
.4
%
 
 In
su
le
t O
m
ni
po
d 
C
H
1:
 4
 
 C
H
2:
 6
 
C
oh
or
t 1
: 3
2 
  C
oh
or
t 2
: 2
6 
 D
M
 d
ur
at
io
n 
no
t 
av
ai
la
bl
e 
C
oh
or
t 1
: 
7.
4 
 C
oh
or
t 2
: 
7.
2 
32
 
3.
9-
10
 
5 
at
 fo
llo
w
in
g 
tim
es
: 0
9:
00
, 
13
:0
0,
 1
7:
30
, 
09
:0
0 
an
d 
13
:0
0h
.  
 
O
pt
io
na
l 
sn
ac
k:
 2
0:
00
h 
0.
8-
1.
2 
g/
kg
 
N
o 
m
ea
l 
an
no
un
ce
m
en
t 
20
m
in
 
W
al
ki
ng
 
Lo
w
 in
te
ns
ity
 
C
oh
or
t 1
: 
53
%
 
 C
oh
or
t 2
: 
60
%
 
 
C
oh
or
t 1
: 0
.8
%
 
 C
oh
or
t 2
: 0
.7
%
 
 R
es
ul
ts
 q
uo
te
d 
pe
r 
24
 h
ou
rs
 (%
 n
ot
 
gi
ve
n 
fo
r o
ve
ra
ll 
st
ud
y 
pe
rio
d)
. 
! !
54!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
N
im
ri
 e
t a
l 
 
20
14
 
 
(1
28
) 
 
N
=2
4 
 O
P 
 C
L 
vs
. O
L 
in
 
ac
hi
ev
in
g 
ta
rg
et
 
gl
uc
os
e 
ov
er
ni
gh
t 
at
 h
om
e.
 
 In
su
lin
 
 
M
D
-lo
gi
c 
 M
ed
tro
ni
c 
En
lit
e 
15
.8
%
 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
24
 
A
ge
 ra
ng
e 
12
-4
3 
7.
5 
(0
.8
) 
 
O
ve
rn
ig
ht
 
fo
r 6
 w
ee
ks
 
 (2
3:
00
h-
07
:0
0h
) 
3.
9-
10
 
0 
10
0%
 b
ol
us
 
du
rin
g 
th
e 
da
y 
N
o 
re
st
ric
tio
ns
 
du
rin
g 
th
e 
da
y 
C
L 
72
.8
7 
(6
7.
83
-
79
.9
4)
 v
s. 
O
L 
58
.7
2 
(5
1.
28
- 
67
.6
0)
, p
=0
.0
01
. 
C
L 
2.
53
 (1
.3
3-
3.
78
) 
vs
. O
L 
5.
16
 (2
.0
3-
 
7.
32
), 
p=
0.
02
. 
C
ha
se
 e
t a
l 
 
20
14
 
 
(1
46
) 
N
=5
3 
 IP
 
 To
 a
ss
es
s a
bi
lit
y 
of
 
C
L 
to
 c
on
tro
l 
po
st
pr
an
di
al
 
gl
uc
os
e 
us
in
g 
fo
ur
 
se
pa
ra
te
 m
ea
l 
bo
lu
s i
ns
ul
in
 
de
liv
er
y 
st
ra
te
gi
es
 
(S
tu
di
es
 1
-4
: S
1-
4)
  
 In
su
lin
  
 
M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
13
%
 
 In
su
le
t O
m
ni
po
d 
  
S1
: n
=5
1 
 S2
: 
n=
 4
0 
 S3
: 
n=
40
 
 S4
: 
n=
46
 
28
 
7.
9 
4 
ho
ur
s  
(p
os
t-
pr
an
di
al
) 
  09
:0
0h
-
13
:0
0h
 
or
  
07
:0
0h
-
11
:0
0h
 
 
1 
pe
r s
tu
dy
 
 St
ud
y 
1:
 
09
:0
0h
 
 St
ud
y 
2 
07
:0
0h
 
 St
ud
y 
3 
09
:0
0h
 
 St
ud
y 
4 
07
:0
0h
 
 1g
/k
g 
St
ud
y 
1:
 
St
an
da
rd
 B
ol
us
 
+ 
M
ea
l 
 St
ud
y 
2:
 
St
an
da
rd
 B
ol
us
 
15
 m
in
 p
re
-
m
ea
l 
 St
ud
y 
3:
 
30
%
 O
ve
r 
B
ol
us
 
 St
ud
y 
4 
O
m
itt
ed
 B
ol
us
 N
/A
 
St
ud
y 
1:
 
27
 (9
-6
4)
 
 St
ud
y 
2:
 
27
 (1
0-
55
) 
 St
ud
y 
3:
 
55
 (3
0-
85
) 
 St
ud
y 
4:
 
18
 (9
-2
7)
 
St
ud
y 
1:
 
0.
0 
(0
.0
-0
.0
) 
 St
ud
y 
2:
 
0.
0 
(0
.0
-0
.0
) 
 St
ud
y 
3:
 
0.
0 
(0
.0
-0
.0
) 
 St
ud
y 
4:
 
0.
0 
(0
.0
-0
.0
) 
 
T
ur
ks
oy
 
et
 a
l  
20
14
 
 
(1
47
) 
  
N
=3
 
 IP
 
 A
ss
es
s e
ff
ic
ac
y 
of
 
C
L 
w
ith
 a
da
pt
ed
 
al
go
rit
hm
   
 In
su
lin
 
   
M
PC
  
 M
ed
tro
ni
c 
G
ua
rd
ia
n 
R
ea
l-T
im
e 
 Su
bj
ec
t’s
 o
w
n 
pu
m
p 
3 
N
ot
 a
va
ila
bl
e 
N
ot
 
av
ai
la
bl
e 
32
 
3.
9-
10
 
5 + 
pr
e-
be
d 
sn
ac
k 
an
d 
ad
di
tio
na
l 
sn
ac
ks
 o
n 
re
qu
es
t 
N
on
e 
20
m
in
 
Tr
ea
dm
ill
 
85
%
 o
f a
ge
-
pr
ed
ic
te
d 
H
R
 
 Se
ns
ew
ea
r 
ar
m
ba
nd
 
50
.2
%
 
 N
o 
SD
 
0.
0%
 
 N
o 
SD
 
! !
55!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
R
us
se
ll 
et
 a
l 
 
20
14
 
 
(1
32
) 
N
=5
2 
O
P 
 C
L 
vs
. O
L 
in
 
un
re
st
ric
te
d 
liv
in
g 
co
nd
iti
on
s i
n 
tw
o 
co
ho
rts
 o
f a
du
lts
 
(C
H
1)
 a
nd
 
ad
ol
es
ce
nt
s (
C
H
2)
 
 In
su
lin
 L
is
pr
o 
G
lu
ca
go
n(
El
i 
Li
lly
) 
M
PC
 (i
ns
ui
n)
 
PD
 (g
lu
ca
go
n)
 
 D
ex
co
m
 G
4 
Pl
at
in
um
 
 Ta
nd
em
 t:
sl
im
 
C
H
1:
 2
0 
 C
H
2:
32
 
A
du
lts
: 
40
(1
6)
 
 24
(1
1)
 
 A
do
le
sc
en
ts
: 
16
(3
) 
 9(
5)
 
A
du
lts
: 
7.
1 
(0
.8
) 
 A
do
le
sc
en
ts
 
8.
2(
1.
0)
 
96
 (4
 d
ay
s)
 
    18
:0
0h
-
18
:0
0h
 
3.
9-
10
 
U
nr
es
tri
ct
ed
 
Pa
rti
al
 B
ol
us
: 
ad
ap
te
d,
 
st
ar
tin
g 
at
 
0.
05
U
/k
g 
bo
dy
 
w
ei
gh
t 
 
U
nr
es
tri
ct
ed
 
A
du
lts
 
C
L 
79
.5
 (8
.3
) v
s. 
O
L 
58
.8
 (1
4.
6)
, 
p<
0.
00
1.
 
A
do
le
sc
en
ts
 
C
L 
75
.9
 (7
.9
) v
s. 
O
L 
64
.5
 (1
4.
1)
, 
p<
0.
00
1.
 
O
ve
rn
ig
ht
: 
A
du
lts
 
C
L 
86
.5
 (1
0)
 v
s O
L 
55
.6
 (2
1.
5)
, 
p<
0.
00
1.
 
A
do
le
sc
en
ts
 
C
L 
 8
6.
9 
(8
.1
) v
s 
O
L 
66
.7
 (1
9.
9)
, 
p<
0.
00
1.
 
A
du
lts
 
C
L 
4.
1 
(3
.5
) v
s. 
O
L 
7.
3 
(4
.7
), 
p=
0.
01
. 
A
do
le
sc
en
ts
 
C
L 
3.
1 
(2
.7
) v
s. 
O
L 
4.
9 
(5
.1
), 
p=
0.
05
. 
O
ve
rn
ig
ht
: 
A
du
lts
 
C
L1
.8
 (2
) v
s. 
O
L 
6.
2(
6.
7)
, p
=0
.0
1.
 
 A
do
le
sc
en
ts
 
C
L 
2.
6(
2.
5)
 v
s. 
O
L 
4.
0 
(5
.3
), 
p=
0.
16
. 
 
H
ov
or
ka
  
et
 a
l  
20
14
 
 
(1
27
) 
N
=1
6 
O
P 
 C
L 
vs
. O
L 
in
 
ad
ol
es
ce
nt
s i
n 
fr
ee
-li
vi
ng
 
co
nd
iti
on
s  
 In
su
lin
 A
sp
ar
t 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 D
an
a 
R
 D
ia
be
ca
re
 
16
 
15
.6
 (2
.1
) 
 7.
2 
(4
.3
) 
8.
0 
(0
.9
) 
63
.9
 (9
.3
) 
O
ve
rn
ig
ht
 
pe
rio
d 
fo
r 
3w
ee
ks
 
 23
:0
0-
07
:0
0 
3.
9-
10
 
0 
10
0%
 d
ur
in
g 
th
e 
da
y 
N
/A
 
C
L 
85
 (6
8-
94
) v
s 
O
L 
69
 (4
2-
87
), 
p<
0.
00
1.
 
C
L 
1.
4 
(0
.4
-5
.0
) v
s 
O
L 
0.
9 
(0
.0
-9
.7
), 
p=
0.
13
. 
L
y 
et
 a
l 
 
20
14
 
 
(1
48
) 
 
N
=2
0 
O
P 
 C
L 
vs
. O
L 
in
 
ch
ild
re
n 
an
d 
ad
ol
es
ce
nt
s d
ur
in
g 
th
e 
ov
er
ni
gh
t 
pe
rio
d 
at
 d
ia
be
te
s 
su
m
m
er
 c
am
p.
  
 In
su
lin
: S
ub
je
ct
’s
 
ow
n 
A
lg
or
ith
m
 n
ot
 d
ef
in
ed
 
 D
ex
co
m
 G
4 
Pl
at
in
um
 
17
.5
%
 
 Ta
nd
em
 t:
sl
im
 
20
 
  
15
(2
.1
) 
 7.
6(
4.
6)
 
8.
7(
0.
7)
 
72
(8
) 
8h
ou
rs
 x
 
5n
ig
ht
s 
 23
:0
0h
-
07
:0
0h
 
3.
9-
10
 
0 
10
0%
 d
ur
in
g 
th
e 
da
y 
N
/A
 
C
L 
92
 (6
9-
10
0)
 
80
(4
8-
95
), 
p 
= 
0.
02
2.
 
C
L 
< 
O
L,
 p
 =
 
0.
02
3.
 
 (V
al
ue
s %
 ti
m
e 
< 
3.
9m
m
ol
/l 
no
t 
gi
ve
n)
 
! !
56!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
H
ai
da
r 
et
 a
l 
 
20
14
 
 
(1
49
) 
N
=1
2 
IP
 
C
L 
w
ith
 fu
ll 
C
H
O
 
m
at
ch
ed
 b
ol
us
 v
s. 
C
L 
w
ith
 w
ei
gh
t-
de
pe
nd
en
t b
ol
us
.  
 In
su
lin
 A
sp
ar
t 
G
lu
ca
G
en
 
Fu
zz
y 
lo
gi
c 
 M
ed
tro
ni
c 
So
fS
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
12
 
  
37
.5
 (9
.4
) 
 D
M
 d
ur
at
io
n 
no
t 
av
ai
la
bl
e 
7.
9 
(1
.2
) 
5 
ho
ur
s 
 08
:0
0h
-
13
:0
0h
 
- 
1 08
:0
0h
: 7
5g
 
Fu
ll 
bo
lu
s  
 O
r 
 Pa
rti
al
 b
ol
us
: 
pr
im
in
g 
bo
lu
s 
of
 0
.0
47
 iU
/k
g 
of
 b
od
y 
w
ei
gh
t N
/A
 
In
cr
em
en
ta
l A
U
C
: 
Fu
ll 
bo
lu
s  
2.
1 
m
m
ol
/L
/h
 (0
.8
–4
.2
) 
vs
 p
ar
tia
l b
ol
us
  8
.3
 
m
m
ol
/L
/h
 (6
.5
–
11
.4
), 
p<
0.
00
1.
 
 %
 ti
m
e 
>1
0m
m
ol
/l 
Fu
ll 
bo
lu
s 2
4%
 
(6
%
–2
9%
) v
s. 
pa
rti
al
 b
ol
us
 2
4%
 
(6
%
–2
9%
), 
p<
0.
00
1.
 
- 
Q
ue
m
er
ai
s 
et
 a
l  
20
14
 
 
(1
50
) 
N
=1
2 
IP
 
C
L 
vs
. O
L 
to
 
de
te
rm
in
e 
ef
fic
ac
y 
of
 D
ia
be
lo
op
 
al
go
rit
hm
 (a
da
pt
ed
 
M
PC
)  
 In
su
lin
: S
ub
je
ct
’s
 
ow
n 
M
PC
 
 D
ex
co
m
 G
4 
 Su
bj
ec
t’s
 o
w
n 
pu
m
p 
  
12
 
35
.6
 (1
2.
7)
 
7.
3 
(0
.8
) 
5 
ho
ur
s 
 12
:0
0h
-
17
:0
0h
 
 (i.
e.
 p
os
t-
pr
an
di
al
 
st
at
e)
 
3.
9-
10
 
 
Pa
rti
al
 b
ol
us
: 
75
%
 o
r 5
0%
 
N
/A
 
Se
m
i C
L 
84
.5
 
(2
0.
8)
 v
s. 
O
L 
69
.2
 
(3
3.
9)
, p
=0
.1
1.
 
Se
m
i C
L 
0.
2 
(0
.8
) 
vs
. O
L4
.4
(8
.2
), 
p=
0.
18
. 
R
en
uk
un
tla
 
et
 a
l  
20
14
 
 
(1
51
) 
N
=1
0 
 
IP
 
 Te
st
 2
 g
lu
ca
go
n 
su
pp
re
ss
or
s i
n 
th
e 
C
L 
sy
st
em
 v
s. 
O
L 
(S
tu
di
es
 1
-3
: S
1-
3)
.  
 In
su
lin
 A
sp
ar
t (
I)
 
Pr
am
lin
tid
e 
(P
) 
Ex
en
at
id
e 
(E
) 
   
PI
D
 
 M
ed
tro
ni
c 
So
fs
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
M
M
T 
71
5 
S1
: 
O
L 
 
 S2
: 
C
L 
(I
+P
) 
 S3
: 
C
L 
(I
+E
) 
23
 (1
) 
 10
.6
(2
) 
7.
3 
(0
.3
) 
56
 (1
) 
11
 h
ou
rs
 
 11
:0
0h
-
22
:0
0h
 
4.
4-
10
 
3  07
:0
0h
: 5
0g
 
(C
L,
 b
ut
 n
ot
 
in
cl
ud
ed
 in
 
an
al
ys
is
) 
 12
:0
0h
: 6
0g
 
 17
:0
0h
: 6
0g
 
25
%
 o
f 
br
ea
kf
as
t 
bo
lu
s, 
no
ne
 fo
r 
lu
nc
h 
an
d 
di
nn
er
 
N
/A
 
O
L 
61
.5
 (2
) v
s. 
C
L 
(I
+P
) 6
2 
(4
), 
p=
 
0.
83
 v
s. 
C
L 
(I
+E
) 7
7 
(6
), 
p=
0.
03
. 
O
L 
10
 (4
) v
s. 
C
L 
(I
+P
) 9
 (2
), 
p 
= 
0.
9 
vs
. 
C
L 
(I
+E
) 7
 (2
), 
p=
0.
5.
 
! !
57!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
E
lle
ri
 e
t a
l 
 
20
14
 
 
(1
52
) 
N
=1
2 
IP
 
 C
L 
vs
. O
L 
in
 
ad
ol
es
ce
nt
s 
 In
su
lin
 A
sp
ar
t 
M
PC
 
 M
ed
tro
ni
c 
En
lit
e 
 A
ni
m
as
 2
02
0 
12
 
15
.9
 (1
.8
) 
 7.
8 
(3
.2
) 
9.
2 
(1
.2
) 
 77
 (2
7)
 
23
 
 19
:0
0-
18
:0
0 
(n
ex
t 
da
y)
 
3.
9-
10
 
3  19
:0
0:
 7
0g
 
 08
:0
0:
 5
0g
 
 12
:3
0:
 5
5g
 
D
in
ne
r: 
Pa
rti
al
 
50
%
 
 B
re
ak
fa
st
: 
10
0%
 
 Lu
nc
h:
 
no
ne
 
N
/A
 
C
L 
74
 (5
5-
86
) v
s. 
O
L 
62
 (4
9-
75
), 
 
p 
= 
0.
26
. 
C
L 
1(
0-
4)
 v
s. 
O
L 
5 
(1
-1
0)
, p
 =
 0
.2
4.
 
K
ov
at
ch
ev
 
et
 a
l  
20
14
 
 
(1
33
) 
N
=1
8 
O
P 
 C
L 
vs
. O
L 
in
 
re
du
ci
ng
 
hy
po
gl
yc
ae
m
ia
 
ris
k 
in
 su
pe
rv
is
ed
 
O
P 
se
tti
ng
 
 In
su
lin
-s
ub
je
ct
’s
 
ow
n 
M
PC
 
 D
ex
co
m
 G
4 
 Ta
nd
em
 t:
sl
im
 
18
 
46
 (1
0)
 
7.
4 
(0
.7
) 
40
 
 19
:0
0h
 –
 
09
:0
0h
 (d
ay
 
3)
 
3.
9-
10
 
N
o 
re
st
ric
tio
ns
 1
00
%
 b
ol
us
 
45
m
in
 
W
al
k 
Lo
w
 in
te
ns
ity
 
C
L 
 6
6.
1 
vs
. O
L 
 
70
.7
, p
 >
0.
1.
 
C
L 
0.
7 
vs
. O
L 
1.
25
, 
p>
0.
1.
 
T
ha
bi
t e
t a
l 
 
20
15
 
 
(1
53
) 
  
N
=4
0 
O
P 
 C
ro
ss
ov
er
 R
C
T 
C
L 
vs
. O
L 
(s
en
so
r 
au
gm
en
te
d 
pu
m
p 
th
er
ap
y)
 in
 fr
ee
-
liv
in
g 
co
nd
iti
on
s 
in
 a
du
lts
 a
nd
 
ad
ol
es
ce
nt
s. 
  In
su
lin
-s
ub
je
ct
s 
ow
n 
M
PC
 
 A
bb
ot
t F
re
es
ty
le
 
N
av
ig
at
or
 
 D
an
a 
R
 D
ia
be
ca
re
 
 
A
ge
 >
18
: 
24
 
 A
ge
 
<1
8:
 
16
 
 
A
du
lts
: 4
3 
(1
2)
 
 29
 (1
1)
 
 A
do
le
sc
en
ts
: 1
5.
6 
(3
.6
) 
 7.
2 
(4
.3
) 
A
du
lts
:  
8.
1 
(0
.8
) 
 A
do
le
sc
en
ts
: 
8.
0 
(0
.8
) 
8 
(x
 3
-4
 
w
ee
ks
) 
 00
:0
0-
08
:0
0 
 
3.
9-
10
 
V
ar
ia
bl
e 
10
0%
 
V
ar
ia
bl
e 
C
L 
77
.4
 (8
.6
) v
s. 
O
L 
 6
1.
8 
(1
3.
3)
, 
p<
0.
00
1.
 
C
L 
1.
9 
(0
.7
-3
.5
) v
s. 
O
L 
2.
9 
(1
.0
-6
.4
), 
p=
0.
01
4.
  
C
he
rn
av
vs
ky
 
et
 a
l  
20
14
 
 
(1
54
) 
N
=1
6 
IP
 
C
L 
vs
. O
L 
in
 
ad
ol
es
ce
nt
s  
 In
su
lin
 
A
lg
or
ith
m
 n
ot
 d
ef
in
ed
 
D
ex
C
om
 G
4 
Pl
at
in
um
 
10
.6
%
 
 Ta
nd
em
 t:
sl
im
 
16
 
15
.2
 (2
) 
 7 
(r
an
ge
 3
-1
4)
 
8.
2 
(r
an
ge
 
6.
9 
– 
9.
8)
 
8 
ho
ur
s 
3.
9-
10
 
2  09
:0
0:
 3
0g
 
 13
:0
0:
 8
0g
 
Pa
rti
al
: 7
5%
 
fo
r l
un
ch
 
N
/A
 
C
L 
 4
3.
4 
(6
.5
) v
s. 
O
L 
 1
8.
9 
(7
), 
p=
 
0.
02
. 
H
yp
o 
ev
en
ts
: 
C
L 
0.
06
 (0
.0
6)
 v
s. 
0.
13
 (0
.1
3)
, p
=0
.3
. 
! !
58!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
Fr
ec
km
an
n 
et
 a
l  
20
14
 
 
(1
55
) 
 
N
=1
2 
IP
 
 C
L 
w
ith
 m
ea
l 
an
no
un
ce
m
en
t v
s. 
O
L 
 In
su
lin
 
A
lg
or
ith
m
 n
ot
 d
ef
in
ed
 
 R
oc
he
 S
C
G
M
 
 D
is
et
ro
ni
c 
D
-T
ro
n 
12
 
40
 ±
 7
 
 22
 ±
 8
 
6.
9 
± 
0.
9 
32
 
 22
:0
0h
 (d
ay
 
2)
- 0
6:
00
h 
(d
ay
 3
) 
5 
 
Fu
ll 
bo
lu
s 
 
C
L 
57
.6
 (1
3.
5)
 v
s. 
O
L 
46
.1
(1
2.
7)
, 
p=
0.
03
. 
N
o 
di
ff
er
en
ce
 in
 
nu
m
be
r o
f s
ub
je
ct
s 
w
ho
 h
ad
 a
 
hy
po
gl
yc
ae
m
ic
 
ev
en
t (
<3
.9
m
m
ol
/L
) 
D
as
sa
u 
et
 a
l 
 
20
13
 
 
(1
56
) 
N
=1
7 
IP
 
 A
im
 to
 d
et
er
m
in
e 
C
L 
ef
fic
ac
y 
us
in
g 
co
m
m
er
ci
al
ly
 
av
ai
la
bl
e 
de
vi
ce
 
 In
su
lin
 a
sp
ar
t 
M
PC
 
 D
ex
co
m
 S
TS
 S
ev
en
; 
D
ex
co
m
 S
ev
en
 P
lu
s 
 In
su
le
t O
m
ni
po
d 
 
17
 
37
 (1
5)
 
 21
(1
3)
 
N
o 
H
bA
1c
 
6 
ho
ur
s 
 09
:0
0h
-
15
:0
0h
 
3.
9-
10
 
1  13
:0
0h
: 3
0g
 
N
o 
bo
lu
s 
N
/A
 
C
L 
70
 
C
L 
2.
1 
(6
.3
) 
E
lle
ri
 e
t a
l 
 
20
13
 
 
(1
57
) 
N
=1
2 
IP
 
 C
L 
vs
. O
L 
du
rin
g 
fo
llo
w
in
g 
m
ea
ls
 
an
d 
ex
er
ci
se
 
(m
ea
ls
 n
ot
 
an
no
un
ce
d)
 in
 
ad
ol
es
ce
nt
s. 
 In
su
lin
 A
sp
ar
t 
M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 A
ni
m
as
 2
02
0 
12
 
 
15
 (1
.4
) 
 
7.
9 
(0
.7
) 
32
 
 00
:0
0h
 -
08
:0
0h
 
(d
ay
3)
 
3.
9-
10
 
7  Se
lf-
se
le
ct
ed
 
Fu
ll 
bo
lu
s 
Tw
o 
20
 
m
in
ut
e 
w
al
ks
 
ou
ts
id
e;
 tw
o 
m
od
er
at
e-
in
te
ns
ity
 
se
ss
io
ns
 o
n 
a 
st
at
io
na
ry
 
bi
cy
cl
e 
C
L 
84
(7
8-
88
) v
s. 
O
L 
49
(2
6-
79
), 
p 
= 
0.
02
. 
C
L 
4.
5 
(2
.2
–7
.0
) v
s. 
O
L 
3.
8 
(0
.0
-9
.4
), 
p=
0.
85
. 
D
au
be
r 
et
 a
l 
 
20
13
 
 
(1
58
) 
N
=1
0 
IP
 
 C
L.
 v
s. 
O
L 
in
 
ch
ild
re
n 
ag
ed
 <
7 
ye
ar
s. 
 
 In
su
lin
 A
sp
ar
t 
  
PD
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 A
ni
m
as
 O
ne
To
uc
h 
Pi
ng
 
 
10
 
 
5.
1 
(1
.4
) 
 2.
1 
(1
.1
) 
8.
1 
(0
.7
) 
10
ho
ur
s  
 22
:0
0h
 –
 
08
:0
0h
 
 
6.
1-
11
.1
 
2 
N
o 
bo
lu
s 
N
/A
 
In
 h
ou
rs
: 
C
L 
5.
3 
h 
vs
. O
L 
3.
2 
h,
 p
=0
.1
2 
In
 h
ou
rs
: 
C
L 
0.
17
 h
 (0
.1
0)
 v
s. 
O
L 
0.
21
(0
.1
5)
, p
= 
0.
86
 
! !
59!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
K
ov
at
ch
ev
 
et
 a
l  
20
13
 
 
(1
59
) 
N
=2
0 
O
P 
C
L.
 v
s. 
O
L 
us
in
g 
w
ea
ra
bl
e 
A
P 
 In
su
lin
-s
ub
je
ct
’s
 
ow
n 
M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 In
su
le
t O
m
ni
po
d 
20
 
21
-6
5 
ye
ar
s 
 D
ur
at
io
n 
no
t 
av
ai
la
bl
e 
H
bA
1c
 n
ot
 
av
ai
la
bl
e 
 In
cl
us
io
n 
cr
ite
ria
: 
H
bA
1c
 
ra
ng
e 
6-
9%
 
24
 
 07
:0
0h
-
07
:0
0h
(d
ay
 
2)
 
 
3.
9-
10
 
4  V
ar
ia
bl
e 
co
nt
en
t 
Fu
ll 
bo
lu
s 
V
ar
ia
bl
e 
(tr
ea
dm
ill
, 
bi
ke
, w
al
k,
 
no
ne
) 
D
ay
 0
7:
00
-2
3:
00
: 
C
L 
68
 
 O
ve
rn
ig
ht
 2
3:
00
-
07
:0
0:
 
C
L 
72
 v
s. 
O
L 
80
  
D
ay
 0
7:
00
-2
3:
00
: 
C
L 
1.
72
 
O
ve
rn
ig
ht
 2
3:
00
-
07
:0
0:
 
C
L 
0.
69
 v
s. 
O
L 
1.
6 
H
ai
da
r 
et
 a
l 
 
20
13
 
 
(1
60
) 
N
=1
5 
IP
 
B
H
C
L 
vs
. O
L 
 In
su
lin
 A
sp
ar
t 
G
lu
ca
go
n 
Fu
zz
y 
lo
gi
c 
 M
ed
tro
ni
c 
So
fS
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
15
 
47
.1
 (1
2.
3)
 
 26
.5
 (1
4.
8)
 
7.
9 
(0
.7
) 
15
ho
ur
s 
 16
:0
0h
-
07
:0
0h
 
 
 
Fu
ll 
or
 P
ar
tia
l 
B
ol
us
: F
uz
zy
 
lo
gi
c 
de
te
rm
in
ed
 
w
he
th
er
 to
 
gi
ve
 7
0-
10
0%
 
of
 u
su
al
 b
ol
us
 
30
m
in
 
B
ik
e 
60
%
 o
f p
ea
k 
O
2 
up
ta
ke
 
C
L 
70
.7
(4
6.
1-
88
.4
) 
vs
. O
L 
57
.3
 (2
5.
2-
71
.8
), 
p=
0.
00
3.
 
C
L 
0.
0(
0.
0-
3.
0)
 v
s. 
O
L 
10
.2
(0
.0
-1
3.
0)
, 
p 
= 
0.
01
. 
Sc
hm
id
t  
et
 a
l  
20
13
 
 
(1
61
) 
N
=6
 
IP
 
C
L 
vs
. O
L 
w
ith
 
C
L 
ev
al
ua
te
d 
in
 
tw
o 
si
tu
at
io
ns
 1
. 
Eu
gl
yc
ae
m
ic
 st
ar
t 
(C
L-
Eu
) a
nd
 2
. 
H
yp
er
gl
yc
ae
m
ic
 
(C
L-
H
yp
er
) s
ta
rt.
   
 In
su
lin
 A
ps
ar
t 
M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
16
.2
 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
     
6    
45
 (4
3-
49
) 
7.
2 
(0
.4
) 
9h
ou
rs
 
 22
:0
0h
-
07
:0
0h
 
3.
9-
10
 
0 
N
/A
 
N
/A
 
O
L 
89
.5
 v
s. 
C
L-
Eu
 
77
.6
 v
s. 
C
L-
H
yp
er
 
65
.8
 
N
ot
 c
le
ar
 fr
om
 
pa
pe
r 
T
ur
ks
oy
 
et
 a
l  
20
13
 
 
(1
62
) 
N
=3
 
IP
 
A
ss
es
sm
en
t o
f C
L 
in
co
rp
or
at
in
g 
pr
ed
ic
tio
ns
 2
° t
o 
ph
ys
io
lo
gi
ca
l 
si
gn
al
s a
nd
 p
la
sm
a 
in
su
lin
 p
re
di
ct
io
ns
 
(I
O
B
). 
In
su
lin
: s
ub
je
ct
’s
 
ow
n 
 
M
PC
 
 M
ed
tro
ni
c 
M
M
T-
70
12
 
 Su
bj
ec
t’s
 o
w
n 
pu
m
p 
3 
A
ge
 +
 d
ur
at
io
n:
 
N
ot
 a
va
ila
bl
e 
H
bA
1c
 n
ot
 
av
ai
la
bl
e 
32
ho
ur
s 
 O
nl
y 
ov
er
ni
gh
t 
pe
rio
d 
in
cl
ud
ed
 in
 
an
al
ys
is
 
 
3.
9-
10
 
5 
+s
na
ck
s 
M
ea
ls
 n
ot
 
in
cl
ud
ed
 in
 
an
al
ys
is
 
- 
Tr
ea
dm
ill
 
~2
0m
in
 
In
te
ns
ity
:  
85
 ±
 8
.3
%
 o
f 
ag
e-
pr
ed
ic
te
d 
he
ar
t r
at
e 
O
ve
rn
ig
ht
 
C
L 
 9
7.
6 
O
ve
rn
ig
ht
 
C
L 
0.
0 
! !
60!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
N
im
ri
 e
t a
l 
 
20
14
 
 
(1
21
) 
N
=1
5 
O
P 
C
L 
vs
. O
L 
in
 
ch
ild
re
n 
an
d 
ad
ol
es
ce
nt
s i
n 
fr
ee
-li
vi
ng
 
co
nd
iti
on
s. 
 
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
Fu
zz
y 
lo
gi
c 
 M
ed
tro
ni
c 
En
lit
e 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
 
15
 
 
19
 (1
0.
4)
 
9.
9 
(8
.2
) 
7.
5 
(0
.5
)  
58
 (5
.9
) 
8h
ou
rs
 x
 1
 
w
ee
k 
 23
:0
0-
07
:0
0h
 
<3
.9
 
0 
N
/A
 
N
/A
 
N
ot
 a
na
ly
se
d 
C
L 
3.
8 
(0
.0
-1
1.
6)
 
vs
. O
L 
48
.7
 (0
.6
,-
67
.9
), 
p<
0.
01
. 
Ph
ill
ip
 e
t a
l 
 
20
13
 
 
(1
22
) 
N
=5
6 
O
P 
C
L 
vs
. O
L 
in
 
co
nt
ro
lli
ng
 g
lu
co
se
 
ov
er
ni
gh
t i
n 
ch
ild
re
n 
an
d 
ad
ol
es
ce
nt
s a
ge
d 
10
 to
 1
8 
ye
ar
s o
ld
 
at
 d
ia
be
te
s c
am
p 
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
Fu
zz
y 
lo
gi
c 
 M
ed
tro
ni
c 
En
lit
e 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
 
56
  
 
13
.8
 (1
.8
) 
 7.
0 
(3
.5
) 
8.
0 
(0
.7
) 
 63
.6
 (7
.6
) 
8h
ou
rs
 x
 2
 
   
 
23
:0
0h
-
07
:0
0h
 
3.
9-
7.
8 
0 
N
/A
 
N
/A
 
In
 h
ou
rs
 
C
L 
4.
4 
ho
ur
s (
2.
8 
-
6.
7)
 v
s. 
O
L 
2.
8 
(1
.5
- 4
.4
), 
p<
0.
05
. 
Ep
is
od
es
 o
f 
hy
po
gl
yc
ae
m
ia
 
(<
3.
5m
m
ol
/l)
:  
C
L 
7 
vs
 O
L 
22
, p
= 
0.
00
3.
 
Sh
er
r 
et
 a
l 
 
20
13
 
 
(1
63
) 
N
=1
2 
IP
 
C
L 
vs
. O
L 
in
 
ad
ul
ts
 a
nd
 
ad
ol
es
ce
nt
s  
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
PI
D
 w
/in
su
lin
 
fe
ed
ba
ck
 
 M
ed
tro
ni
c 
So
fS
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
71
5 
  
 
12
 
 A
do
le
sc
en
ts
 
an
d 
ad
ul
ts
 
16
.8
 (3
.6
) 
 5.
7 
6 
3.
7 
7.
4 
(0
.6
) 
75
 (1
7)
 
8 
ho
ur
s x
 2
 
Se
de
nt
ar
y 
(1
st
) 
22
:0
0h
-
06
:0
0h
 
Ex
er
ci
se
 
(2
nd
) 
22
:0
0h
-
06
:0
0h
 
3.
9-
10
 
Pa
rti
al
 B
ol
us
: 
sm
al
l m
an
ua
l 
pr
im
in
g 
bo
lu
s 
0.
05
 U
/k
g 
3  09
:0
0h
:9
3 
g 
13
:0
0h
: 
93
g 
17
:0
0h
: 
96
g 
B
ris
k 
tre
ad
m
ill
 
w
al
ki
ng
 
65
-7
0%
 m
ax
 
he
ar
t r
at
e 
Se
de
nt
ar
y 
C
L 
98
 v
s O
L 
87
, 
p<
0.
00
01
 
 Ex
er
ci
se
 
C
L 
91
 v
s O
L 
72
,  
p<
0.
00
01
 
 
Se
de
nt
ar
y 
C
L 
1.
5 
vs
 O
L 
4,
 
p<
0.
00
01
 
   Ex
er
ci
se
 
C
L 
5 
vs
 O
L 
11
,  
p<
0.
00
01
 
 
N
im
ri
 e
t a
l 
 
20
13
 
 
(1
20
) 
 
N
=1
2 
IP
 
C
L 
vs
. O
L 
 
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
Fu
zz
y 
lo
gi
c 
 M
ed
tro
ni
c 
So
fS
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
12
 
  
23
.8
 (1
5.
6)
 
 13
.5
 (1
1.
9)
 
8.
1 
(0
.8
) 
8 
hr
s 
 23
:0
0 
– 
07
:0
0r
 
 3.
5-
 7
.8
 
1 
(b
ut
 n
ot
 
in
cl
ud
ed
 in
 C
L 
an
al
ys
is
 ti
m
e)
 
19
:0
0:
 4
5-
55
g 
Fu
ll 
bo
lu
s 
N
/A
 
C
L 
76
 (5
4 
– 
85
) v
s. 
O
L 
29
 (1
1–
44
), 
p=
0.
02
 
C
L 
0.
0 
vs
 O
L 
0.
0,
 
p=
 0
.1
8 
     
! !
61!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
 /m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
M
au
se
th
  
et
 a
l  
20
13
 
 
(1
64
) 
N
=7
 
IP
 
A
im
 to
 e
va
lu
at
e 
sa
fe
ty
 o
f f
uz
zy
 
lo
gi
c 
co
nt
ro
lle
r  
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
Fu
zz
y 
lo
gi
c 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 In
su
le
t O
m
ni
Po
d 
7 
23
.6
 ( 
ra
ng
e1
8-
35
) 
 8.
7 
(r
an
ge
 2
-1
2)
 
7.
7(
ra
ng
e 
6.
4–
8.
6)
 
24
 h
ou
rs
 
 20
:0
0h
-
20
:0
0h
 
(D
ay
 2
) 
3.
9-
10
 
2  08
:0
0h
: 3
0g
 
 14
:0
0h
: 6
0g
 
  
N
o 
bo
lu
s 
N
/A
 
C
L 
65
 
C
L 
0.
1 
R
us
se
ll 
et
 a
l 
 
20
12
 
 
(8
8)
 
N
=6
 
IP
 
 A
im
 to
 a
ss
es
s 
sa
fe
ty
 a
nd
 e
ff
ic
ac
y 
of
 B
H
C
L 
 
 In
su
lin
 L
is
pr
o 
G
lu
ca
go
n 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 In
su
le
t O
m
ni
Po
d 
6 
52
 (1
4)
 
 32
 (1
4)
 
7.
4 
(0
.7
) 
48
hr
s  
 18
:0
0h
-
18
:0
0h
 (d
ay
 
3)
 
3.
9-
10
 
6 18
:0
0h
 
07
:3
0h
 
12
:3
0h
 
18
:0
0h
 
07
:3
0h
 
12
:3
0h
 
V
ar
ia
bl
e 
g 
Pa
rti
al
 B
ol
us
: 
pa
rti
al
 p
rim
in
g 
bo
lu
s o
f 0
.0
35
 
iU
/k
g;
 c
ha
ng
ed
 
to
 0
.0
5 
iU
/k
g 
St
at
io
na
ry
 
bi
ke
 ~
30
m
in
  
In
te
ns
ity
: 
H
ea
rt 
ra
te
 
12
0-
14
0b
pm
 
C
L 
69
 (1
2)
 
C
L 
0.
6(
0.
8)
 
R
ui
z 
et
 a
l 
 
20
12
 
 
(1
65
) 
N
=4
 
IP
 
C
L 
vs
. C
L 
w
ith
 
in
su
lin
 fe
ed
ba
ck
 
(C
L-
IF
B
) 
 In
su
lin
 
 
PI
D
 
 M
ed
tro
ni
c 
G
ua
rd
ia
n 
C
G
S 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
71
5 
4 
A
ge
 a
nd
 d
ur
at
io
n 
no
t a
va
ila
bl
e 
H
bA
1c
 n
ot
 
av
ai
la
bl
e.
 
  In
cl
us
io
n 
cr
ite
ria
: 
<9
%
. 
24
 h
ou
rs
 
 08
:0
0h
-
08
:0
0h
 
  
3.
9-
10
 
3 08
:0
0h
 
13
:0
0h
 
18
:0
0h
 
 V
ar
ia
bl
e 
g 
N
o 
bo
lu
s 
N
/A
 
C
L 
vs
 C
L-
IF
B
 
 N
ot
 c
le
ar
 fr
om
 
pa
pe
r (
ta
bl
e 
di
st
or
te
d)
 
C
L 
vs
 C
L-
IF
B
 
W
ei
nz
im
er
 
et
 a
l  
20
12
 
 
(1
66
) 
N
=8
 
IP
 
 A
ss
es
s i
f p
re
-
pr
an
di
al
 
pr
am
lin
tid
e 
w
ou
ld
 
im
pr
ov
e 
po
st
pr
an
di
al
 
gl
yc
ae
m
ia
 
 In
su
lin
 
Pr
am
lin
tid
e 
 
PI
D
 
 M
ed
tro
ni
c 
So
fS
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
71
5 
8 
A
ge
 ra
ng
e:
 1
5-
28
 
7.
5 
(0
.7
) 
24
 
 08
:0
0h
-
08
:0
0h
(d
ay
 
2)
 
3.
9-
10
 
6  08
:0
0h
 
13
:0
0h
 
18
:0
0h
 
08
:0
0h
 
13
:0
0h
 
18
:0
0h
 
N
o 
m
ea
l b
ol
us
 N
/A
 
      
C
L 
71
 v
s C
L-
P 
75
 
 O
ve
rn
ig
ht
 2
3:
00
-
07
:0
0 
C
L 
94
 v
s. 
C
L-
P 
96
 C
L 
94
1.
0 
vs
. C
L-
P 
2.
0 
 O
ve
rn
ig
ht
 2
3:
00
-
07
:0
0 
C
L 
1.
0 
vs
. C
L-
P 
3.
0 
! !
62!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
E
lle
ri
 e
t a
l 
 
20
12
 
 
(1
67
) 
N
=8
 
IP
 
 Ev
al
ua
te
 C
L 
in
 
ad
ol
es
ce
nt
s 
st
ar
tin
g 
tw
o 
se
pa
ra
te
 ti
m
e 
po
in
ts
 (f
ol
lo
w
in
g 
m
ea
l o
r a
t n
ig
ht
)  
 In
su
lin
 A
sp
ar
t 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 C
om
bi
ne
d 
C
on
tro
lle
r 
 A
bb
ot
t A
vi
at
or
 2
 
 N
B
 A
m
bu
la
to
ry
 
po
rta
bl
e 
pr
ot
ot
yp
e 
us
ed
 
8   
14
.3
 (1
.7
) 
 7.
9 
(2
.8
) 
8.
2 
(1
.3
) 
66
 (9
) 
 
11
 h
ou
rs
 
 21
:0
0-
08
:0
0h
 
3.
9-
8.
0 
N
o 
C
L 
m
ea
ls
 
in
cl
ud
ed
 in
 
an
al
ys
is
 
 
Fu
ll 
bo
lu
s 
N
/A
 
C
L-
m
ea
l 8
2 
(5
9-
98
) v
s. 
C
L-
ni
gh
t 6
4 
(4
8-
70
), 
p=
0.
03
6.
 
C
L-
m
ea
l 0
 (0
.0
-7
.0
) 
vs
. C
L-
ni
gh
t 0
 (0
-
8.
0)
, p
=1
.0
. 
V
an
 B
on
 
et
 a
l  
20
12
 
 
(1
68
) 
N
=1
0 
IP
 
 B
H
C
L 
fe
as
ib
ili
ty
 
as
se
ss
m
en
t b
y 
ch
al
le
ng
in
g 
w
ith
 
tw
o 
m
ea
ls
 a
nd
 3
0 
m
in
ut
es
 o
f 
ex
er
ci
se
 
 In
su
lin
 A
sp
ar
t 
PD
 
 
 M
ed
tro
ni
c 
C
G
M
S 
Sy
st
em
 G
ol
d 
 D
is
et
ro
ni
c 
D
-T
ro
n+
 
 
10
 
55
.4
 (4
4-
70
) 
 34
.6
 (1
8-
56
) 
  
8.
0 
(r
an
ge
 
6.
7-
9.
6)
 
8h
ou
rs
 
 
2  B
F:
 4
0g
 
L:
 6
0g
 
N
o 
bo
lu
s 
30
m
in
 
Tr
ea
dm
ill
 
75
%
 o
f m
ax
 
he
ar
t r
at
e 
re
se
rv
e 
C
L 
62
. 3
 
 Ta
bl
e 
in
 p
ap
er
 
di
st
or
te
d 
C
L 
5.
3 
Pa
tt
e 
et
 a
l 
 
20
12
 
 
(1
69
) 
N
=2
3 
IP
 
C
L 
vs
. O
L 
 In
su
lin
: n
ot
 
sp
ec
ifi
ed
 
Em
pi
ric
al
 A
lg
or
ith
m
 
de
si
gn
ed
 b
y 
R
oc
he
 
D
ia
gn
os
tic
s 
 R
oc
he
 D
ia
gn
os
tic
s 
SC
G
M
1;
 M
ed
tro
ni
c 
C
G
M
S 
 R
oc
he
 A
cc
uc
he
k 
D
-
Tr
on
 
23
 
40
.2
 (8
.7
) 
 20
.6
 (1
0.
5)
 
7.
0 
(1
.0
) 
6 
ho
ur
s 
 00
:0
0h
-
06
:0
0h
 
3.
3-
8.
3 
4 
Fu
ll 
bo
lu
s 
N
/A
 
C
L 
92
.2
 v
s. 
O
L 
82
.4
 
C
L 
1.
9 
vs
. O
L 
9.
2 
N
im
ri
 e
t a
l 
 
20
12
 
 
(1
19
) 
N
=6
 
IP
 
C
L 
vs
. C
L 
fo
llo
w
in
g 
ex
er
ci
se
 
(C
LE
)  
In
su
lin
 A
sp
ar
t 
Fu
zz
y 
lo
gi
c 
 M
ed
tro
ni
c 
So
fS
en
so
r 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
V
eo
 
 
6   
20
.6
 (4
.7
) 
 9.
6(
2.
6)
 
7.
8 
(0
.8
) 
8 
ho
ur
s 
 23
:0
0-
07
:0
0 
  
3.
5-
7.
8 
1 (N
B
 n
ot
 
in
cl
ud
ed
 in
 C
L 
an
al
ys
is
) 
19
:0
0:
 4
5-
50
g 
Fu
ll 
bo
lu
s 
40
m
in
 o
n 
tre
ad
m
ill
 w
ith
 
in
cr
ea
si
ng
 
re
si
st
an
ce
 
un
til
 
H
R
=1
40
bp
m
 
C
L 
92
(9
) v
s. 
C
LE
 
73
 (1
6)
, p
=0
.0
3.
 
C
L 
0.
0 
vs
. C
LE
 0
.0
 
! !
63!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
B
re
to
n 
et
 a
l 
 
20
12
 
 
(1
15
) 
N
=3
8 
IP
 
 Te
st
 th
e 
sC
TR
 a
nd
 
eC
TR
 v
er
su
s 
tra
di
tio
na
l C
SI
I 
th
er
ap
y 
in
 se
pa
ra
te
 
co
ho
rts
 (S
tu
dy
 1
 
(S
1)
 a
du
lts
 a
nd
 
ad
ol
es
ce
nt
s a
nd
 
St
ud
y 
2 
(S
2)
 a
du
lts
 
on
ly
). 
 In
su
lin
 L
is
pr
o 
M
PC
 
 D
ex
co
m
 S
ev
en
; 
A
bb
ot
t N
av
ig
at
or
 
 In
su
le
t O
m
ni
po
d 
  
S1
 n
=1
5 
+1
1 
 
 S2
: n
=1
2 
 
St
ud
y 
1:
 
A
du
lts
 
41
 (1
0)
 
25
.3
 (9
.1
) 
 A
do
le
sc
en
ts
 
14
.5
 (1
.5
) 
6.
2 
(3
.8
) 
 St
ud
y 
2:
 
A
du
lts
 
38
 (1
0)
 
21
.7
 (8
.7
) 
 
St
ud
y 
1:
 
A
du
lts
 
7.
3 
(0
.9
) 
 A
do
le
sc
en
ts
 
8.
6 
(0
.8
) 
 St
ud
y 
2:
 
A
du
lts
 
7.
5 
(0
.9
) 
  
16
 h
ou
rs
 
 16
:0
0-
08
:0
0 
(D
ay
 2
) 
3.
9-
10
 
2  19
:0
0h
 
22
:0
0h
 
  
Fu
ll 
bo
lu
s 
30
m
in
 
 A
du
lts
:  
50
%
 o
f p
ea
k 
ox
yg
en
 
up
ta
ke
;  
 A
do
le
sc
en
ts
: 
O
M
N
I r
at
e 
of
 
pe
rc
ei
ve
d 
ex
er
tio
n<
3 
St
ud
y 
1 
sC
TR
 7
4.
4 
(3
.9
) v
s. 
O
L 
61
.5
 (5
.2
), 
   
p=
 
0.
01
. 
 St
ud
y 
2 
eC
TR
 9
0.
1 
(3
.4
) v
s. 
O
L 
76
.8
 (5
.0
), 
p=
 
0.
05
. 
 
C
ob
el
li 
et
 a
l 
 
20
12
 
 
(1
70
) 
N
=2
 
O
P 
Ev
al
ua
tio
n 
of
 
w
ea
ra
bl
e 
O
P 
A
P.
 
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
M
PC
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 In
su
le
t O
m
ni
po
d 
  
2 
A
ge
 ra
ng
e 
32
-5
8 
H
bA
1c
 n
ot
 
av
ai
la
bl
e 
28
 h
ou
rs
 
 07
:0
0h
 –
 
11
:0
0h
 (d
ay
 
3)
 
? 
4 
at
 fo
llo
w
in
g 
tim
es
: 
08
:0
0,
 1
2:
00
, 
20
:0
0 
an
d 
08
:0
0h
. 
 50
-7
0g
/m
ea
l 
Fu
ll 
bo
lu
s 
30
m
in
 
W
al
ki
ng
 
Lo
w
 in
te
ns
ity
 
N
ot
 a
va
ila
bl
e 
in
 
pa
pe
r 
N
ot
 a
va
ila
bl
e 
in
 
pa
pe
r 
E
l Y
ou
ss
ef
  
et
 a
l  
20
11
 
 
(1
71
) 
N
=1
4 
IP
 
Ev
al
ua
tio
n 
ad
ap
tiv
e 
PD
 
al
go
rit
hm
 v
s. 
fa
di
ng
 m
em
or
y 
PD
 
al
go
rit
hm
 in
 
de
al
in
g 
w
ith
 
in
su
lin
 re
si
st
an
ce
 
2°
 to
 o
ra
l 
hy
dr
oc
or
tis
on
e 
ad
m
in
is
tra
tio
n 
 In
su
lin
 A
sp
ar
t 
G
lu
ca
go
n 
  
PD
 
 D
ex
co
m
 S
ev
en
 P
lu
s 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
52
2/
72
2 
 &
 S
m
ith
s 
M
ed
ic
al
 M
ed
fu
si
on
 
20
01
  
 
14
 
46
 (1
1)
 
7.
2 
(0
.3
) 
33
 h
ou
rs
 
- 
5 
Pa
rti
al
 B
ol
us
: 
60
%
 
N
/A
 
- 
- 
! !
64!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
E
lle
ri
 e
t a
l 
 
20
11
 
 
(1
72
) 
N
=8
 
IP
 
 Ev
al
ua
te
 C
L 
ef
fic
ac
y 
ba
se
d 
on
 
tim
in
g 
of
 
in
iti
at
io
n:
 S
tu
dy
 1
 
(S
1)
 C
L 
st
ar
t a
t 
18
:0
0 
an
d 
St
ud
y 
2 
(S
2)
 C
L 
st
ar
t a
t 
21
:0
0 
in
 c
hi
ld
re
n.
 
 In
su
lin
 A
sp
ar
t 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 Sm
ith
's 
M
ed
ic
al
 
D
el
te
c 
C
oz
m
o 
8  
9.
4 
(2
.7
) 
 3.
9 
 (2
.5
) 
7.
9 
(0
.9
) 
11
 h
ou
rs
 
 21
:0
0-
08
:0
0h
 
3.
9-
8.
0 
1  21
:0
0h
: 2
1g
 
Fu
ll 
bo
lu
s 
N
/A
 
C
L-
ea
rly
 4
2 
(1
8-
64
) v
s C
L-
la
te
  5
8 
(3
2-
79
), 
p=
0.
16
. 
C
L-
ea
rly
  0
 (0
-1
1)
  
vs
 C
L-
la
te
  8
 (0
-
17
), 
p=
0.
5.
 
M
ur
ph
y 
et
 a
l 
 
20
11
 
 
(1
18
) 
N
=1
0 
IP
 
 Ev
al
ua
te
 C
L 
du
rin
g 
ea
rly
 a
nd
 
la
te
 g
es
ta
tio
n 
in
 
pr
eg
na
nt
 w
om
en
 
w
ith
 T
1D
M
 
 In
su
lin
 A
sp
ar
t 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 Sm
ith
's 
M
ed
ic
al
 
D
el
te
c 
C
oz
m
o 
10
 
31
.1
 (2
8.
7–
 3
1.
7)
 
 19
 (1
3.
5–
24
) 
6.
9 
(6
.2
–8
.0
) 2
2 
ho
ur
s 
 14
:0
0h
-
12
:0
0h
 
3.
5-
7.
8 
2  18
:0
0h
: 8
0g
 
 07
:0
0h
: 
60
g 
Fu
ll 
bo
lu
s 
N
/A
 
O
ve
rn
ig
ht
 2
3:
00
-
07
:0
0 
C
L-
ea
rly
 8
4 
(5
0–
10
0)
 
C
L-
la
te
 1
00
 (9
4–
10
0)
, p
=0
.0
9.
 
 
O
ve
rn
ig
ht
 2
3:
00
-
07
:0
0h
 
C
L-
ea
rly
 0
 (0
–3
) 
C
L-
la
te
 0
 (0
-0
), 
p=
0.
18
. 
H
ov
or
ka
  
et
 a
l  
20
11
 
 
(1
13
) 
N
=2
4 
IP
 
 C
L 
vs
. O
L 
 In
su
lin
 A
sp
ar
t 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 Sm
ith
's 
M
ed
ic
al
 
D
el
te
c 
C
oz
m
o 
 
24
 
37
.5
 (9
.1
) 
 20
.6
 (9
.7
) 
7.
8 
(0
.6
) 
Ea
tin
g 
in
: 
11
 h
ou
rs
 
21
:0
0-
08
:0
0 
Ea
tin
g 
ou
t: 
14
 h
ou
rs
 
(2
2:
00
-
12
:0
0)
 
3.
9-
8.
0 
 Ea
t i
n:
 
19
:0
0h
: 6
0g
 
 Ea
t o
ut
: 
22
:0
0h
: 1
00
g 
w
/a
lc
oh
ol
 
Fu
ll 
bo
lu
s 
N
/A
 
Ea
tin
g 
in
 
C
L 
80
 (6
0 
94
) v
s. 
O
L 
51
 (3
9 
- 7
5)
, p
= 
0.
00
2.
 
 Ea
tin
g 
ou
t 
C
L 
70
 (6
0 
-8
6)
 v
s 
O
L 
47
 (2
8-
66
), 
 
p=
0.
01
. 
Ea
tin
g 
in
 
C
L 
1 
(0
-9
) v
s. 
O
L 
3 
(0
 - 
25
), 
p=
0.
19
. 
 Ea
tin
g 
ou
t 
C
L 
0(
0-
4)
 v
s. 
O
L 
14
 (0
-2
6)
, p
= 
0.
21
. 
 
M
ur
ph
y 
et
 a
l 
 
20
11
 
 
(1
17
) 
 
N
=1
2 
IP
 
C
L 
vs
. O
L 
in
 
pr
eg
na
nc
y.
  
 In
su
lin
 
M
PC
 
A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 Sm
ith
's 
M
ed
ic
al
 
D
el
te
c 
C
oz
m
o 
12
 
32
.9
 (3
0.
4–
36
.7
) 
 17
.6
 (8
.0
–2
7.
3)
 
6.
4 
(6
.1
–
6.
6)
. 
24
 h
ou
rs
 
3.
5-
7.
8 
2 
Fu
ll 
bo
lu
s 
3x
 2
0 
m
in
 
w
al
ki
ng
 
 2 
x 
50
m
in
 
Tr
re
ad
m
ill
  
B
ris
k 
w
al
ki
ng
 C
L 
81
 (5
9–
87
) v
s. 
O
L 
81
 (5
4–
90
), 
   
p=
0.
75
. 
C
L 
6.
9 
(1
.3
–1
2)
 v
s. 
O
L 
7.
5 
(3
.6
–1
8)
, 
p=
0.
48
. 
! !
65!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
St
ei
l e
t a
l 
 
20
11
 
 
(5
1)
 
N
=8
 
IP
 
 Ev
al
ua
te
 a
bi
lit
y 
of
 
in
su
lin
 fe
ed
ba
ck
 to
 
im
pr
ov
e 
th
e 
br
ea
kf
as
t-m
ea
l 
pr
of
ile
 
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 A
ni
m
as
 2
02
0 
8 
44
 (2
2–
60
) 
7.
1 
(6
.5
–8
.5
) 3
0h
ou
rs
 
 06
:0
0 
-
12
:0
0(
da
y 
2)
 
- 
4  07
:0
0h
:4
4.
5g
 
12
:0
0h
:6
2.
5g
 
18
:0
0h
:5
9.
5g
 
07
:0
0h
: 4
5g
 
 
Pa
rti
al
 B
ol
us
: 
2U
 g
iv
en
 a
t 
st
ar
t o
f m
ea
l 
N
/A
 
-  Po
st
-p
ra
nd
ia
l 
ou
tc
om
es
 a
nl
ay
se
d 
- 
E
l K
ha
tib
  
et
 a
l  
20
10
 
 
(1
23
) 
N
=1
1 
IP
 
 B
H
C
L 
Fe
as
ib
ili
ty
 
st
ud
y 
 
 In
su
lin
 L
is
pr
o 
G
lu
ca
go
n(
El
i 
Li
lly
) 
PI
D
 w
/IF
 
 M
ed
tro
ni
c 
G
ua
rd
ia
n 
R
T-
C
G
M
 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
71
5 
11
 
40
 (1
6)
 
 23
 (1
3)
 
 
7.
3 
(0
.8
) 
24
 h
ou
rs
 
 06
:0
0-
06
:0
0h
 
3.
9-
10
 
3  18
:0
0h
 
07
:0
0h
 
12
:0
0h
 
N
o 
bo
lu
s 
N
/A
 
C
L 
62
 
C
L 
<1
  
R
en
ar
d 
et
 a
l 
20
10
 
 
(1
11
) 
N
=8
 
IP
 
 A
ss
es
s C
L 
in
tra
-
pe
rit
on
ea
l i
ns
ul
in
 
in
fu
si
on
 fr
om
 a
n 
im
pl
an
te
d 
pu
m
p 
dr
iv
en
 b
y 
a 
SC
 
gl
uc
os
e 
se
ns
or
 v
ia
 
a 
pr
op
or
tio
na
l-
in
te
gr
al
-d
er
iv
at
iv
e 
(P
ID
) a
lg
or
ith
m
 
 In
su
lin
 U
-4
00
 
    
M
PC
 
 Sm
ith
's 
M
ed
ic
al
 
D
el
te
c 
C
oz
m
o 
8 
59
.8
 (8
.7
) 
 31
.7
 (1
5.
1)
 
6.
8 
(1
.0
) 
48
ho
ur
s 
4.
4 
-6
.6
 
6  08
:0
0h
:4
0g
 
13
:0
0h
:7
0g
 
19
:0
0h
:7
0g
 
08
:0
0h
:4
0g
 
13
:0
0h
:7
0g
 
19
:0
0h
:7
0g
 
Pa
rti
al
 b
ol
us
: 
m
an
ua
lly
 
pr
og
ra
m
m
ed
 
in
su
lin
 b
ol
us
 
(3
0%
 o
f u
su
al
) 
15
 m
in
ut
es
 
be
fo
re
 m
ea
ls
 
N
/A
 
C
L 
 3
9.
1 
(4
.5
) v
s. 
O
L 
27
.7
 (6
.2
), 
p=
0.
05
. 
C
L 
9.
9 
(2
.7
) v
s. 
O
L 
15
.3
 (4
.6
), 
p=
0.
4.
 
! !
66!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
H
ov
or
ka
 
et
 a
l  
20
10
 
 
(1
12
) 
N
=1
7 
IP
 
C
L 
ev
al
ua
te
d 
in
 
ad
ol
es
ce
nt
s i
n 
3 
se
pa
ra
te
 st
ud
ie
s:
  
A
PC
A
M
 0
1:
  
C
L 
vs
 O
L 
A
PC
A
M
02
: 
C
L 
ra
pi
d 
vs
 sl
ow
 
m
ea
l 
A
PC
A
M
03
:  
C
L 
vs
 O
L 
ex
er
ci
se
 M
PC
 
 M
ed
tro
ni
c 
R
T 
C
G
M
 
  or
  
 A
bo
ot
t F
re
es
ty
le
 
N
av
ig
at
or
  
17
 
 01
: 
n=
12
 
 02
: 
n=
6 
 03
: 
n=
9 
13
. 5
 (3
.6
) 
 6.
4 
(4
.0
) 
8.
5 
(1
.8
) 
12
 h
ou
rs
 
 20
:0
0-
08
:0
0h
 
3.
9-
8.
0 
N
on
e 
in
cl
ud
ed
 
in
 C
L 
pe
rio
d 
N
/A
 
45
 m
in
ut
es
 
tre
ad
m
ill
 
 55
%
 o
f 
V
o2
m
ax
 
A
PC
A
M
01
 
C
L 
52
 (4
3–
83
) v
s. 
O
L 
39
 (1
5–
51
), 
p=
0.
06
. 
 A
PC
A
M
02
 
C
L 
ra
pi
d 
53
 (4
8–
57
) v
s. 
C
L 
sl
ow
 
55
(3
7–
64
), 
p=
0·
97
. 
 A
PC
A
M
03
 
C
L 
78
 (6
0-
92
) v
s 
O
L 
43
 (2
5-
65
), 
p=
0.
02
4 
A
PC
A
M
01
 
C
L 
1 
(0
–7
) v
s. 
O
L 
2 
(0
–4
1)
, p
=0
·1
3.
 
 A
PC
A
M
02
 
C
L 
ra
pi
d 
0 
(0
–4
) v
s. 
C
L 
sl
ow
0 
(0
–0
), 
p=
0·
16
. 
 A
PC
A
M
03
 
C
L 
10
 (2
–1
5)
 v
s. 
O
L 
6(
0–
44
), 
p=
0·
27
. 
A
tla
s e
t a
l 
 
20
10
 
 
(6
1)
 
N
=9
 
IP
 
Ev
al
ua
te
 n
ov
el
 
M
D
-L
og
ic
 A
P 
Sy
st
em
 d
ur
in
g 
fa
st
in
g 
st
ud
y 
(S
1)
 
an
d 
ov
er
 2
4 
ho
ur
s 
(S
2)
 
 In
su
lin
 A
sp
ar
t 
Fu
zz
y 
lo
gi
c 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
; D
ex
co
m
 
ST
S 
Se
ve
n 
 In
su
le
t O
m
ni
Po
d;
 
M
ed
tro
ni
c 
Pa
ra
di
gm
 
72
2 
S1
:  
7  S2
: 
2 
23
.9
 (3
.4
) 
 10
 (4
) 
6.
6 
(0
.7
) 
St
ud
y 
1:
 
8 
ho
ur
s 
fa
st
in
g 
 St
ud
y 
2:
 
24
 h
ou
rs
 
3.
9-
10
 
St
ud
y 
2:
 
 3 19
:3
0 
08
:0
0 
13
:0
0 
 17
.5
-7
0g
 
Fu
ll 
bo
lu
s 
N
/A
 
St
ud
y 
2:
 
C
L 
73
 v
s. 
O
L 
(3
-
da
y 
ho
m
e)
 7
0.
5.
 
St
ud
y 
2:
 C
L 
0 
vs
. 
O
L 
(3
-d
ay
 h
om
e)
 
15
.3
. 
K
ov
at
ch
ev
  
et
 a
l  
20
10
 
 
(1
14
) 
N
=2
0 
IP
 
C
L 
vs
. O
L 
 In
su
lin
 L
is
pr
o 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 In
su
le
t O
m
ni
Po
d 
 
20
 
41
.1
 (1
0.
4)
 
 18
.6
 (5
.6
) 
7.
25
 (0
.9
) 
 
10
.5
ho
ur
s 
 21
:3
0h
 -
08
:0
0h
 
3.
9-
7.
8 
1  
N
o 
bo
lu
s 
N
/A
 
C
L 
78
 v
s. 
O
L 
64
, 
p=
0.
03
. 
C
L 
2.
0 
vs
. O
L 
8.
44
, 
p<
0.
05
. 
C
as
tle
 e
t a
l 
 
20
10
 
 
(8
6)
 
N
=1
3 
IP
 
C
L 
vs
. O
L 
 In
su
lin
-A
sp
ar
t 
G
lu
ca
go
n 
(N
ov
o)
 
PD
 
D
ex
co
m
 S
ev
en
 P
lu
s;
 
M
ed
tro
ni
c 
G
ua
rd
ia
n 
 
A
ni
m
as
 IR
 1
00
0 
fo
r 
in
su
lin
; M
ed
fu
si
on
 
20
01
 fo
r g
lu
ca
go
n 
13
 
36
.7
 (3
.7
) 
 14
.1
 (3
.1
) 
7.
6 
(0
.3
) 
9-
 2
8 
ho
ur
s 
- 
4   
Pa
rti
al
 B
ol
us
: 
In
iti
al
ly
 
53
.3
%
, 
ad
ju
st
ed
 to
 
75
%
 
N
/A
 
- 
M
in
ut
es
 o
f 
hy
po
gl
yc
ae
m
ia
 p
er
 
da
y:
 
C
L 
15
 (6
) v
s. 
O
L 
40
 (1
0)
 m
in
/ d
ay
, 
p=
0.
04
. 
 
! !
67!
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
V
an
 B
on
 
et
 a
l  
20
10
 
 
(1
73
) 
N
=5
 
IP
 
 C
L 
vs
. O
L.
  
 In
su
lin
 
G
lu
ca
go
n 
PD
 
 M
en
ar
in
i D
ia
gn
os
tic
s 
G
lu
co
D
ay
 S
 
 D
is
et
ro
ni
c 
D
-T
ro
n+
 
5 
50
.8
 (r
an
ge
 3
8-
60
) 
 30
.3
 (1
4–
45
) 
8.
7 
(r
an
ge
 
7.
0-
12
.2
) 
5 
ho
ur
s 
3.
9-
10
 
1  40
g 
N
o 
bo
lu
s 
N
/A
 
C
L 
60
 v
s. 
O
L 
31
, 
p=
0.
08
. 
C
L 
11
 v
s. 
O
L 
19
, 
p=
1.
0.
 
B
ru
tt
om
es
so
 
et
 a
l  
20
09
 
 
(1
74
) 
N
=6
 
IP
 
 C
L 
vs
. O
L 
 In
su
lin
 L
is
pr
o 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 In
su
le
t O
m
ni
Po
d 
6 
41
.7
 (1
2.
3)
 
 20
.7
 (1
3.
8)
 
7.
4 
(0
.4
) 
14
 h
ou
rs
 
 22
:3
0h
 -
12
:3
0h
 
- 
1  07
:0
0h
: 5
0g
  
N
o 
bo
lu
s 
N
/A
 
-  In
di
vi
du
al
 g
ra
ph
s, 
bu
t n
o 
ra
w
 d
at
a 
gi
ve
n 
- 
C
la
rk
e 
et
 a
l 
 20
09
 
 (1
75
) 
N
=8
 
IP
 
 C
L.
 v
s. 
O
L 
 In
su
lin
 L
is
pr
o 
M
PC
 
 A
bb
ot
t F
re
eS
ty
le
 
N
av
ig
at
or
 
 In
su
le
t O
m
ni
Po
d 
8 
37
.1
 (9
.9
) 
 16
.1
 (9
.2
) 
7.
0 
(1
.1
) 
14
.5
 
 21
:3
0h
-
12
:0
0h
 
3.
9-
10
 
1  07
:0
0h
: 5
0g
  
N
o 
bo
lu
s 
 
C
L 
96
.9
 v
s. 
O
L 
81
.7
, p
=0
.0
5.
 
Ep
is
od
es
 
hy
po
gl
yc
ae
m
ia
: 
C
L 
0.
13
 v
s. 
O
L 
1.
63
, p
=0
.0
07
. 
W
ei
nz
im
er
 
et
 a
l 
20
08
 
 
(5
5)
 
 IP
 
N
=1
7 
IP
 
 A
im
ed
 to
 e
va
lu
at
e 
fu
ll 
C
L 
an
d 
hy
br
id
 
C
L 
(H
y-
C
L)
 
ve
rs
us
 O
L 
in
 
ch
ild
re
n.
  
 In
su
lin
-n
ot
 
sp
ec
ifi
ed
 
PI
D
 
 M
ed
tro
ni
c 
se
ns
or
 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
71
5 
Fu
ll 
C
L:
 
n=
8 
 H
y-
C
L:
 
n=
9 
 
15
.9
 (1
.6
) 
   
7.
1 
(0
.8
) 
34
 h
ou
rs
 
 7:
00
h 
-
17
:0
0h
 (d
ay
  
2)
 
3.
9-
10
 
5  08
:0
0h
 
12
:0
0h
 
17
:0
0h
 
08
:0
0h
 
12
:0
0h
 
N
o 
bo
lu
s o
r 
 Pa
rti
al
 B
ol
us
: 
25
-5
0%
 
N
/A
 
C
om
bi
ne
d 
C
L 
85
 
vs
 O
L 
(3
-d
ay
 
ho
m
e)
 5
8,
 p
<0
.0
02
 
 N
o 
di
ff
er
en
ce
 
be
tw
ee
n 
fu
ll 
C
L 
an
d 
H
yb
rid
 C
L 
C
om
bi
ne
d 
C
L 
3.
0 
vs
 O
L 
(3
-d
ay
 h
om
e)
 
9.
0,
 p
<0
.0
02
 
R
en
ar
d 
et
 a
l 
 
20
06
 
 
(1
10
) 
N
=4
 
IP
 
C
L 
fe
as
ib
ili
ty
 
as
se
ss
m
en
t w
ith
 
in
tra
-p
er
ito
ne
al
 
in
su
lin
 p
um
p 
 In
su
lin
 U
-4
00
 
PI
D
 
 M
ed
tro
ni
c 
IV
 lo
ng
-
te
rm
 g
lu
co
se
 se
ns
or
 
 M
ed
tro
ni
c 
Im
pl
an
ta
bl
e 
se
ns
or
 
4 
60
.5
 (1
.0
) 
 38
.5
 (1
0.
2)
 
H
bA
1c
 n
ot
 
av
ai
la
bl
e 
48
ho
ur
s 
4.
4-
6.
7 
6  13
:0
0h
:8
0g
 
19
:0
0h
:8
0g
 
08
:0
0h
:4
0g
 
13
:0
0h
:8
0g
 
19
:0
0h
:8
0g
 
08
:0
0h
:4
0g
 
N
o 
bo
lu
s 
 N
/A
 
C
L 
22
.5
 (1
.8
) 
C
L 
5.
2 
(2
.0
) 
! !
68!
 
T
ab
le
 2
. S
um
m
ar
y 
of
 a
ll 
cl
os
ed
-lo
op
 c
lin
ic
al
 tr
ia
ls
 b
et
w
ee
n 
th
e 
ye
ar
s 2
00
4 
to
 2
01
5 
 
Fo
ot
no
te
s:
 *
 A
ll 
co
nt
in
uo
us
 d
at
a 
ar
e 
ex
pr
es
se
d 
as
 e
ith
 m
ea
n 
(S
D
) o
r m
ed
ia
n 
(I
Q
R
). 
1 
H
yp
og
ly
ca
em
ia
 is
 d
ef
in
ed
 a
s t
he
 lo
w
er
 th
re
sh
ol
d 
of
 g
lu
co
se
 in
 th
e 
ta
rg
et
 g
lu
co
se
 ra
ng
e
A
ut
ho
r 
Y
ea
r 
St
ud
y 
D
es
ig
n 
Pa
rt
ic
ip
an
t C
ha
ra
ct
er
is
tic
s 
M
et
ho
do
lo
gy
 
R
es
ul
ts
* 
Se
tt
in
g 
D
es
ig
n 
H
or
m
on
e(
s)
 
ev
al
ua
te
d 
C
on
tr
ol
 A
lg
or
ith
m
 
 
Se
ns
or
 M
A
R
D
 
 
Pu
m
p 
n 
M
ea
n 
(S
D
) A
ge
 
M
ea
n 
(S
D
) 
D
M
 d
ur
at
io
n 
 
(y
ea
rs
) 
M
ea
n 
(S
D
) 
H
ba
1c
 
%
 
m
m
ol
/m
ol
 
 
H
ou
rs
 o
f 
C
L
 
in
cl
ud
ed
 in
 
fin
al
 
an
al
ys
is
 
T
ar
ge
t 
gl
uc
os
e 
ra
ng
e 
(m
m
ol
/l)
 
N
o 
of
 C
L
 
m
ea
ls
 
 
C
H
O
 C
on
te
nt
 
(g
) 
M
ea
l b
ol
us
 
de
ta
ils
 
E
xe
rc
is
e 
(T
im
e,
 ty
pe
, 
in
te
ns
ity
) 
%
 T
im
e 
in
 ta
rg
et
 
 
%
 T
im
e 
in
 
hy
po
gl
yc
ae
m
ia
1  
 
St
ei
l e
t a
l 
 
20
06
 
 
(1
09
) 
N
=1
0 
IP
 
C
L 
vs
. O
L 
 
 In
su
lin
 L
is
pr
o 
PI
D
 
 M
ed
tro
ni
c 
se
ns
or
 
 M
ed
tro
ni
c 
Pa
ra
di
gm
 
51
1 
10
 
43
.4
 (1
1.
4)
 
 18
.2
 (1
3.
5)
 
7.
2 
(0
.8
) 
28
 h
ou
rs
 
 07
:0
0h
-
11
:0
0h
 
(D
ay
 2
) 
3.
9-
10
 
5 08
:0
0h
: 5
5g
 
13
:0
0h
: 8
8g
 
18
:0
0h
: 7
0g
 
22
:0
0h
: 4
5g
 
08
:0
0h
: 5
5g
 
N
o 
bo
lu
s 
N
/A
 
C
L 
75
 v
s. 
O
L 
(3
-
da
y 
ho
m
e)
 6
3.
 
N
um
be
r o
f 
bi
oc
he
m
ic
al
 
hy
po
gl
yc
ae
m
ic
 
ep
is
od
es
 p
er
 2
4 
ho
ur
s:
 C
L 
13
 v
s. 
O
L 
13
. 
Sc
ha
lle
r 
et
 a
l 
 
20
04
 
 
(1
76
) 
N
=6
 
IP
 
In
tra
ve
no
us
-C
L 
(C
L-
IV
) v
s. 
su
bc
ut
an
eo
us
 C
L 
(C
L-
SC
) 
 In
su
lin
 L
is
pr
o 
M
PC
 
 V
en
ou
s g
lu
co
se
 u
se
d 
 D
is
et
ro
ni
c 
D
-T
ro
n 
(s
ub
cu
ta
ne
ou
s s
en
so
r)
 6
   
A
ge
 n
ot
 a
va
ila
bl
e 
 15
.5
 (7
–3
4)
 
8.
5 
(6
.8
–9
.7
) 8
 h
ou
rs
 
 11
:3
0h
 –
 
19
:3
0h
 
3.
3-
7.
5 
0 
N
/A
 
N
/A
 
N
o 
si
gn
ifi
ca
nt
 
di
ff
er
en
ce
 b
et
w
ee
n 
C
L-
IV
 a
nd
 C
L-
SC
 
ro
ut
e 
N
o 
si
gn
ifi
ca
nt
 
di
ff
er
en
ce
 b
et
w
ee
n 
C
L-
IV
 a
nd
 C
L-
SC
 
ro
ut
e 
   
H
ov
or
ka
 
et
 a
l  
20
04
 
 
(5
6)
 
N
=3
7 
IP
 
Ev
al
ua
te
 fe
as
ib
ili
ty
 
of
 p
ra
nd
ia
l b
ol
us
 
ge
ne
ra
te
d 
by
 M
PC
 
ov
er
 fi
ve
 d
iff
er
en
t 
tim
e 
pe
rio
ds
 
(S
tu
di
es
 1
-5
:  
S1
-5
) 
 In
su
lin
 L
is
pr
o 
M
PC
 
 IV
 g
lu
co
se
 (S
.C
 
si
m
ul
at
ed
 b
y 
us
in
g 
30
m
in
 d
el
ay
) 
 D
is
et
ro
ni
c 
D
-T
ro
n 
S1
: 
n=
6 
 S2
: 
n=
11
 
 S3
: 
n=
5 
 S4
: 
n=
9 
 S5
: 
n=
6 
A
ge
 a
nd
 D
M
 
du
ra
tio
n 
no
t 
av
ai
la
bl
e 
H
bA
1c
 n
ot
 
av
ai
la
bl
e 
St
ud
y 
1:
 1
4 
ho
ur
s  
St
ud
y 
2:
 
26
.5
 h
ou
rs
  
St
ud
y 
3:
 2
4 
ho
ur
s  
St
ud
y 
4:
 8
 
ho
ur
s  
St
ud
y 
5:
 8
 
ho
ur
s  
- 
St
ud
y 
1:
 1
 
08
:0
0h
: 4
0g
 
 St
ud
y 
2:
 3
 x
 
60
g 
 St
ud
y 
3:
 4
 
14
:0
0h
: 6
0g
 
19
:0
0h
: 4
8g
 
07
:0
0h
: 6
0g
 
11
:0
0h
: 6
0g
 
 St
ud
ie
s 4
 a
nd
 
5:
 0
 
Fu
ll 
bl
ou
s 
N
/A
 
- 
- 
!! 69!
1.7 Hypotheses, Aims & Objectives and Study design 
1.7.1 Hypotheses !
Bio-inspired Artificial Pancreas  
• The Bio-inspired Artificial Pancreas (closed-loop) is safe during fasting 
conditions 
• The Bio-inspired Artificial Pancreas is safe during overnight and post-prandial 
conditions 
• The Bio-inspired Artificial Pancreas provides increased time in target and 
reduces hypoglycaemia compared to open-loop (standard pump therapy) 
• The BiAP algorithm is safe in the absence of meal announcement 
• The bi-hormonal Bio-inspired Artificial Pancreas is safe during fasting 
conditions 
 
Glycaemic variability and QoL 
• Increased glycaemic variability is associated with decreased quality of life in 
type 1 diabetes 
 
1.7.2 Aims and objectives !
Bio-inspired Artificial Pancreas  
• To assess safety and feasibility of the BiAP over 6 hours of fasting in adults 
with T1DM 
• To evaluate safety and feasibility of the BiAP overnight and after breakfast in 
adults with T1DM 
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• To compare the efficacy of the BiAP with open-loop (standard pump therapy) 
in an 24-hour randomised controlled trial in a clinically controlled 
environment 
• To evaluate safety of the BiAP algorithm without meal announcement 
• To evaluate safety and feasibility of the BiAP with the addition of glucagon in 
a bi-hormonal configuration during fasting conditions 
 
Glycaemic variability and QoL 
• To evaluate whether glycaemic variability has an impact on QoL in T1DM  
 
1.7.3 Study design !
The study was designed to aim for clinical validation of the closed loop insulin 
delivery device in path of incremental challenges to the algorithm and hardware, 
starting with a short daytime fasting basal study in advisory mode (proposed insulin 
dose by algorithm to be approved by clinician), progressing to and overnight study 
and finally longer meal studies in automatic closed loop mode (automatic delivery of 
the insulin dose without approval by the clinician) as follows: 
  
1. A non-randomised single arm open-label study to evaluate the BiAP in during 
6 hours of fasting  
2. A non-randomised single arm open-label study to evaluate the BiAP during 
the night and after breakfast 
3. A randomised controlled open-label study evaluating the BiAP over 24 hours 
with three meal challenges and without meal announcement 
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1.7.4 Regulatory approvals !
The following approvals were obtained: 
R&D at Imperial College Healthcare NHS Trust (Ref no JROSM0279) 
Sponsor (Ref no CRO1710) 
NRES London Committee–Westminster (REC Ref no 11/LO/0833) 
MHRA (Ref no CI/20100/0023) 
The study has been registered at ClinicalTrials.gov with identification number:  
NCT01534013 
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2 Chapter 2: A 6-hour fasting closed-loop study 
2.1 Introduction and aim 
The Bio-inspired Artificial Pancreas (BiAP) consists of a subcutaneous glucose 
sensor (Enlite, Medtronic), the novel bio-inspired glucose controller and a 
subcutaneous insulin pump (Accu-Chek Combo Spirit, Roche). The bio-inspired 
control algorithm is implemented on a complementary metal–oxide–semiconductor 
(CMOS) microchip within a handheld device which is small, uses low power, and 
allows communication between the three components of the complete system. 
Medical device usability and acceptability are significant factors for the design of any 
artificial pancreas (AP) system. The implementation of the algorithm within a silicon 
microchip makes it potentially suitable for integration with current insulin pumps and 
continuous glucose monitoring (CGM) devices.  
Following safety and efficacy validation of the bio-inspired control algorithm in silico 
(65), using the Padova UVa type 1 diabetes (T1DM) simulator, the next step was 
commencement of the clinical studies.  
 
 The aim of the first stage of the clinical assessment of the bio-inspired artificial 
pancreas system was to evaluate the safety and feasibility in adults with T1DM during 
fasting conditions over six hours in a clinically controlled environment.  The generic 
details of the bio-inspired algorithm has been discussed in the main introduction 
(Chapter 1) under section 1.4, but the specifications used in this first phase of the 
clinical study has been outlined under 2.2 methods.  
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Hypothesis:  
• The Bio-inspired Artificial Pancreas (closed-loop) is safe during fasting 
conditions 
 
2.2 Methods 
2.2.1 Participants and study design !
This was a non-randomised single arm open-label study. 
Participants with T1DM were recruited from the diabetes clinics at Imperial College 
Healthcare NHS Trust in London, UK.  
Inclusion criteria were age 18 –75 years, duration of diabetes >1 year, fasting C-
peptide < 200 pmol/l, treatment with continuous subcutaneous insulin infusion for > 6 
months and HbA1c < 8.5% (69 mmol/mol).  
Exclusion criteria were recurrent severe hypoglycaemia, pregnancy or planning 
pregnancy, breastfeeding, enrolment in other clinical studies, active malignancy or 
under investigation for malignancy.  
Study withdrawal criteria were as follows: 
1. Loss of capacity to give informed consent 
2. Cessation of CSII as usual care for type 1 diabetes 
3. Recurrent severe hypoglycaemia 
4. Terminal illness 
Withdrawal would be immediate and subjects would be followed up in the 
appropriate outpatient diabetes clinic within 4 weeks of withdrawal. 
Participant information sheets were given to potential subjects, and after a minimum 
of 48 hours and allowing questions to be asked, informed consent was taken and 
screening performed. 
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2.2.2 Screening !
Potential participants attended the clinical research facility in the morning for the 
screening visit in a fasting state. Details of their diabetes background and other 
clinical history were collected and a clinical examination of the cardiovascular- and 
respiratory systems and feet for signs of peripheral neuropathy performed. A 
proforma was used for collecting and documenting the information. The following 
investigations were done:  an electrocardiography (ECG), blood samples for c-
peptide, glucose, HbA1c, lipids and creatinine, urine for albumin:creatinine ratio 
(UACR) and a urine pregnancy test in female subjects of childbearing age to rule out 
pregnancy. Participants were also asked to fill out two validated questionnaires, the 
Diabetes Quality of Life (DQOL) and Diabetes Treatment Satisfaction Questionnaire 
(DTSQ). A continuous glucose monitor (retrospective/ blinded, iPro2, Medtronic, 
Alameda, CA) was placed in the anterior abdominal wall, according to manufacturer’s 
instructions. Participants were instructed to keep a food diary for five days and avoid 
strenuous exercise during the CGM period. 
Participants then attended the clinical research facility after five days i.e day 6 after 
sensor insertion. The CGM was removed and the data uploaded to the Medtronic 
CareLink Pro software, the calibration data (at least two capillary blood glucose 
values per day) was entered and the results reviewed with the subject. If necessary, 
adjustments were made to optimise the participants’ basal rates, insulin to 
carbohydrate ratio (ICR) and insulin sensitivity factor (ISF). 
 
2.2.3 6-hour closed-loop study protocol !
The subjects attended the NIHR/Wellcome Trust Imperial Clinical Research Facility 
at 08:00h in a fasting state (fasted from midnight). The capillary blood glucose was 
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then measured on arrival, and if deemed necessary by the attending physician, the 
subject’s basal rate was adjusted between 08:00h to 10:00h.!A subcutaneous glucose 
sensor (Enlite, Medtronic, Northridge (CA), USA) was inserted in the abdomen and 
connected to the handheld unit containing the control algorithm, which in turn was 
connected to a laptop with a graphical user interface implemented in Matlab 
(Mathworks, Natick (MA) USA), allowing the study team to approve each 
recommended insulin dose. The control algorithm was tuned proportionally to the 
subject’s ISF (the reduction in glucose concentration by 1 unit of insulin) aiming for a 
target glucose of 5.5mmol/L.  
The subject’s own insulin pump was replaced with the study pump (Accu-Chek Spirit 
Combo pump, Roche, Basel, Switzerland) and their usual basal insulin rates 
continued subcutaneously until closed-loop insulin delivery was commenced. Rapid-
acting insulin aspart (Novorapid, Novo Nordisk, Bagsværd, Denmark) was used 
throughout the study. The sensor signal was transmitted to the handheld unit by cable 
and communication between the handheld unit and the laptop was achieved via USB. 
The insulin infusion instruction was transmitted to the pump by the Roche Bluetooth 
communication protocol. Following sensor calibration to venous glucose at the start 
of closed-loop control, the control algorithm recommended an insulin dose (micro 
boluses) according to the interstitial glucose level measured by the subcutaneous 
sensor every five minutes. Every 15 minutes throughout the study a venous blood 
sample was taken and analysed for glucose using the YSI 2300 (Yellow Springs 
Instrument, Yellow Springs, OH, USA). The sensor and blood glucose was blinded to 
the subject, but unblinded to the study team.  Subjects were allowed to drink water 
throughout the study. Hypoglycaemia, defined as venous BG <3.9mmol/l, was 
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confirmed by an additional venous blood plasma glucose sample and treated 
according to Imperial College Hospitals NHS Trust Guidelines.  
After completion of 6 hours of closed-loop, the subject’s own CSII pump was 
reconnected and started as per the subject’s usual insulin regime. Once running, the 
study pump was disconnected and the subcutaneous glucose sensor and intravenous 
cannula removed. The subject was then allowed to eat and drink freely and discharged 
after ensuring that glucose concentrations were stable. The 6-hour closed-loop study 
protocol is summarised in Figure 6. 
 
 
Figure 6.  Summary of the 6-hour fasting closed-loop study protocol 
 
2.2.4 Materials used and sample analysis !
Continuous glucose monitoring 
The glucose sensor used for CGM was the Enlite sensor, a CE marked device 
manufactured by Medtronic, which has a lifespan of 6 days. The sensor was inserted 
using an insertion device (serter). The Enlite  sensor is intended for use with the Mini-
link transmitter which sends glucose data in real-time to the MiniMed  pumps and the 
Guardian REAL-Time monitor allowing real-time CGM.  
! At  08:00:  
•  Attend clinical research facility fasting 
•  Insert one Enlite sensor 
•  Connect bio-inspired closed-loop system 
to subject 
•  Run basal insulin at normal rate 
! At 10:00: 
•  Start closed-loop control 
! At 16:00 
•  End of closed-loop study 
Fasting  
closed-loop study  
(6 hours) 
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The Enlite sensor is also compatible with the retrospective blinded Professional CGM 
system (iPro 2) used for the screening CGM. The iPro 2 system uses a recorder rather 
than a transmitter and the data is uploaded via a USB connection using the Carelink 
iPro software which is web based. Once the raw CGM data (i.e the current) is 
uploaded the iPro 2 system requires entry of at least two CBG measurements per day 
for retrospective calibration prior to generating reports.  
 
For the purpose of the closed-loop study the Enlite sensor sent glucose data to the 
BiAP handheld unit via a wire. The wire used was part of the previous generation 
Medtronic real-time CGM system (Medtronic CGMS Gold). 
 
The BiAP controller, handheld unit and the laptop GUI 
The bio-inspired control algorithm has been described in detail in the introduction 
chapter under Section 1.4 with a schematic overview of the controller used in the 
fasting closed-loop study (Figure 5). The input to the controller included forecasted 
sensor glucose and 70% of the participant’s basal rate was delivered independent of 
the beta-cell model. The beta-cell model itself was activated as soon as the closed-
loop was commenced with no prior knowledge of insulin-on-board (IOB). The 
algorithm’s target glucose was 5.5mmol/L.  
 
The personalised tunable gain is based on the individual subject’s pre-experimental 
correction factor (CF).  Using existing parameters from a cohort of virtual subjects 
(n=30) in the UVA T1D simulator we were able to demonstrate that the CF correlated 
well with the optimal gain for each individual in that cohort (R2=0.999, p<0.01). In 
particular, the following nonlinear correlation between the two parameters was found: 
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K=0.751/CF, where CF is in mmol/L per unit of insulin.!The CF range for the study 
population in the bio-inspired artificial pancreas study was 1 unit insulin to 1.0 - 
4.0mmol/L, which is translated into a gain range of 0.2 - 0.75 (arbitrary units). 
 
Hypoglycaemia safety features included a 50% suspension of insulin delivery if 
forecast glucose fell below 5mmol/L or complete suspension if below 4mmol/L. 
Insulin delivery was re-commenced as soon as the glucose was above the 
aforementioned thresholds. The maximum time of complete insulin suspension was 
90 minutes after which 50% of insulin delivery was recommenced. If glucose 
remained below 4mmol/L after 30 minutes of restarting insulin delivery then insulin 
would be suspended again for a maximum of 90 minutes.  
 
The BiAP handheld unit prototype version 1.1 used in the 6-hour study is illustrated 
in Figure 7. Clinical supervision was enabled through the laptop GUI implemented in 
Matlab (Mathworks, Natick (MA) USA) which displayed the sensor glucose, 
reference blood glucose (entered manually every 15 minutes), the deviation of sensor 
glucose from blood glucose (i.e. the MARD) and the calculated insulin dose which 
was approved by the attending physician (myself) every 5 minutes before sending the 
dose delivery command to the pump via Bluetooth. Figure 8 displays the various 
features of the laptop GUI. Alarms were also incorporated into the Matlab GUI to 
notify the study team at times when the MARD was >30%, occurrence of pump 
communication failure leading to disruption in insulin delivery, or if sensor glucose 
values were not received from the BiAP handheld unit. 
The sensor glucose, blood glucose and insulin doses were automatically saved in 
Matlab and exported and saved in an Excel database as anonymized data after 
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completion of each 6-hour study. In addition, a manual record of the sensor glucose, 
blood glucose, insulin delivered, re-calibrations, and any technical or clinical faults 
requiring intervention was kept as back-up for each 6-hour study.  
 
 
Figure 7. Illustration of the integrated Bio-inspired artificial pancreas: 
The Medtronic Enlite glucose sensor is connected to the BiAP unit, which holds the control algorithm. 
The BiAP unit (prototype version1.1) sends data to the graphical user interface (GUI) running on the 
laptop. The Roche Accu-Chek Combo Spirit insulin pump is controlled remotely from the GUI. 
 
 
Sensor 
BiAP unit 
Insulin 
pump 
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Figure 8. Screenshot of the graphical user interface used during the 6-hour closed-loop study. The 
glucose graphs displays the blood reference glucose (green dots) and the sensor glucose (blue stars). 
 
Continuous subcutaneous insulin infusion 
The study insulin pump used was the Accu-Chek Combo Insulin Pump, a CE marked 
device manufactured by Roche. The Accu-Chek pump size is 82.5 x 56 x 21 mm and 
weighs approximately 110g with battery, filled cartridge and infusion set. The insulin 
pump was set up as per user instructions by the manufacturer (http://images.accu-
chek.com/demos/combo/demo_mmol/index.html). The Accu-Chek pump is able to 
deliver a minimum microbolus of 0.1unit, hence in the event that the algorithm 
recommend a dose lower than 0.1 unit the algorithm added up the microboluses until 
it reached > 0.1unit before the pump delivered the dose.  
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Roche supplied a license to use the communications protocol for research purposes. 
The Accu-Chek pump also has capability for direct communication (using infrared) 
from the pump motor allowing verification that the pump is doing what the software 
commands. This ensures safe communication between the control algorithm and the 
pump and provides a fail-safe to ensure that the pump motor is responding 
appropriately to the control algorithm.  
 
The pump cartridge was filled with 1-1.5 ml (100-150 units) of insulin. Rapid-acting 
insulin aspart (trade name = Novorapid), manufactured by Novo Nordisk, Bagsværd, 
Denmark, was used throughout the study. Details of the pharmacodynamics and 
pharmacokinetics of insulin aspart has been summarised in the main introduction 
under section 1.5.1. 
 
Venous blood sampling and analysis 
Venous blood samples were collected via the intravenous cannula every 15 minutes 
throughout the 6-hour study. After each sampling 10ml of 0.9% saline was flushed 
through the intravenous cannula. Prior to each sampling 2ml of blood was drawn and 
discarded to ensure fluid in the dead space did not dilute the actual blood sample. 
Whole blood samples were analysed for glucose immediately using the YSI 2300 
analyser. The remaining blood was distributed into a non-clotting (red top) blood tube 
and put on ice. Blood samples were centrifuged within 30 minutes of collection at 
4000 revolutions per minute (RPM) for 10 minutes with the temperature set to < 4⁰C. 
The serum was then extracted and aliquoted into cryotubes before immediately being 
stored in a -20°C freezer. After completion of the 6-hour study the samples were 
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transferred to an -80°C freezer and stored for future analysis. The serum samples were 
later analysed for insulin concentrations.  
 
Glucose analysis: 
Whole blood samples were analysed for glucose concentration using the YSI 2300 
STAT Plus Glucose & Lactate analyser.  25 microliters of blood was aspirated from 
the collection tube. The YSI STAT 2300 uses a steady state measurement 
methodology, where membrane based glucose oxidase catalyses the oxidation of 
glucose to gluconic acid and hydrogen peroxide. The difference between the sample 
generated plateau current and the initial baseline current is proportional to the glucose 
concentration. The precision for glucose is  ±2% or 0.2mmol/l (whichever is greater). 
 
Insulin analysis: 
Serum insulin concentrations were analysed using a immunoassay (ARCHITECT 
i2000 immunoassay, Abbott Laboratories). The assay uses a chemiluminescent 
immunoreaction carried out on the ARCHITECT i2000 immunoassay analyser (Abbott 
Laboratories). It does not show cross-reactivity with pro-insulin. The reaction is single-
step with anti-insulin binds onto insulin and is then added to a reaction mixture, creating 
the chemiluminescent reaction which is measured as relative light units (RLUs) by the 
ACHITECT i optical system. As there is a direct relationship between RLUs and amount 
of insulin in mU/L, this is then converted into mU/L. The reportable range for this assay 
is 1.0 µU/mL to 300 µU/mL. The ARCHITECT insulin assay has a sensitivity (the 
minimum concentration this assay can detect) of ≤ 1.0 µU/ml. The cross-reactivity of 
the assay is ≤ 0.1% with pro-insulin and ≤ 0.001 % with both C-peptide and Glucagon 
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Primary and secondary objectives 
The primary outcome was percentage time spent in glucose target range of 3.9 – 
10.0mmol/L. Secondary outcomes were percentage time in euglycaemia (3.9 –
7.8mmol/L), hypoglycaemia (<3.9mmol/L) and hyperglycaemia (>10.0mmol/L). 
Other secondary outcomes were mean glucose, insulin dose (units/hour) and 
glycaemic variability measures of low blood glucose index (LBGI, reference range 
0.0 – 6.9) and high blood glucose index (HBGI, 0.0 – 7.7).  
 
2.2.5 Statistical analysis !
All outcomes were measured using sensor glucose as well as blood glucose. The 
glucose data from the first two hours of the study has been excluded from the primary 
data analysis, but all data points over the entire 6–hour study have also been reported. 
All outcomes are reported as mean (SD) or median (interquartile range (IQR)), unless 
stated otherwise. Sensor accuracy was evaluated by calculating the median absolute 
relative difference (MARD). Data were analysed using Stata/SE version 13.1.   
 
2.3 Results 
In total 23 potential participants were recruited and screened, out of which three were 
excluded (two participants had HbA1c of <69mmol/mol (<8.5%) and one participant 
was undergoing investigations for gastric problems). 20 adult subjects with T1DM 
were included and participated in the 6–hour fasting closed-loop study. Their baseline 
characteristics are summarized in Table 3. 
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Characteristic Mean ± SD 
Age 44 ± 10 years 
Gender 55% male       45% female 
Duration of diabetes 22 ± 12 years 
Duration of insulin pump therapy 3.4 ± 4 years 
HbA1c 7.4 ± 0.7 % 
Body mass index (BMI) 25 ± 4 kg/m2 
C-peptide 20% had detectable c-peptide:  
73.5 ± 15.3 pmol/l 
Insulin antibody (Ref range 0-5 mU/L) 4.6 (2.7) 
Total cholesterol (mmol/L) 4.5± 0.8 
HDL (mmol/L) 1.7 ± 0.3 
Chol:HDL ratio 2.6 ± 0.5 
Creatinine (umol/L) 73.5 ± 10.8 
Urine ACR (mg/mmol (creat)) 0.7 ± 0.6 
 
Table 3. Baseline characteristics (n=20) of the participants in the 6-hour fasting closed-loop study 
  
The glycaemic outcome measures from the fasting 6–hour closed–loop study are 
summarised in Table 4. Glycaemic outcomes for each participant can be found in 
Appendix 2. The glucose data from the first two hours of the study has been excluded 
from the primary data analysis, as the controller is unable to influence the glucose 
concentration over this initial time period. Additionally all data points over the 6–hour 
study are reported, to illustrate that the controller is able to bring the glucose down to 
target safely irrespective of the initial conditions.  
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Outcome measure 
 
Results 
(n=20) 
Time 12:00–16:00 
(Total 4 hours) 
Sensor glucose 
Median (IQR) 
 
Blood glucose 
Median (IQR) 
% time in target range  
3.9 – 10.0mmol/L 
98.0 (90.8 – 100.0) 
 
100.0 (84.7 – 100.0) 
 
% time in euglycaemia  
3.9 – 7.8mmol/L 
96.4 (63.7 – 100.0)) 
 
100.0 (75.0 – 100.0) 
% time in hypoglycaemia 
<3.9mmol/L 
0.0 (0.0 – 0.0) 
 
0.0 (0.0 – 0.0) 
% time in  hyperglycaemia 
>10.0mmol/L 
0.0 (0.0 – 0.0) 
 
0.0 (0.0 – 0.0) 
 
 Mean (SD) 
 
Mean (SD) 
Glucose (mmol/L) 5.7 (1.8) 
 
5.8 (1.5) 
Low blood glucose index 
(0.0 – 6.9) 
3.2 (4.1) 
 
2.4 (2.0) 
 
High blood glucose index 
(0.0 – 7.7) 
1.4 (3.5) 
 
1.1  (2.2) 
 
Time 10:00–16:00 
(Total 6 hours) 
Sensor glucose 
Median (IQR) 
Blood glucose 
Median (IQR) 
% time in target range  
3.9 – 10.0mmol/L 
89.0 (69.1 – 98.7) 
 
86.5 (78.4 – 100.0) 
 
% time in euglycaemia  
3.9 – 7.8mmol/L 
69.9 (49.8 – 91.1) 
 
72.0 (53.6 – 89.0) 
% time in hypoglycaemia 
<3.9mmol/L 
0.0 (0.0 – 5.8) 
 
0.0 (0.0 – 1.0) 
% time in  hyperglycaemia 
>10.0mmol/L 
0.8 (0.0 – 17.8) 
 
0.0 (0.0 – 17.2) 
 
 Mean (SD) 
 
Mean (SD) 
Glucose (mmol/L) 6.6 (1.9) 
 
6.7 (1.6) 
Low blood glucose index 
(0.0 – 6.9) 
3.0 (3.6) 
 
2.4 (1.9) 
 
High blood glucose index 
(0.0 – 7.7) 
3.9 (4.5) 
 
3.6  (3.2) 
 !
Table 4: Glycaemic outcome measures from the 6–hour fasting closed–loop study  
 
Reassuringly no time was spent in severe hyperglycaemia (>15mmol/L) nor severe 
hypoglycaemia (<2.8 mmol/L). The mean (SD) sensor glucose from the fasting study 
was 5.7 (1.8) mmol/L with a 95% confidence interval (CI) of 4.9-6.5mmol/L. The 
target glucose of 5.5mmol/L lies within this CI and we are therefore confident that the 
mean glucose achieved did not differ significantly from the target. Figure 9 displays 
the median sensor and blood glucose concentration with interquartile ranges (IQR) 
throughout the 6–hour study. The glycaemic outcome measures based on sensor 
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glucose were equivalent to the blood glucose measurements, suggesting good sensor 
accuracy.  
 
 
 
Figure 9: Median glucose trend and insulin delivered for all 20 subjects during the 6–hour fasting 
closed–loop study (top graph) and corresponding insulin concentrations (bottom graph). 
Red dotted line = median blood (YSI) glucose (±  IQR); blue dotted line = median sensor glucose (±  
IQR); orange bars = mean insulin dose delivered; black dashed lines = upper/lower glucose target 
thresholds; green dotted line = median insulin concentration (±  IQR). 
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Recalibrations and sensor accuracy 
The median absolute relative difference (MARD) between the venous blood glucose 
and the sensor glucose was 9.5 (IQR 4.9 – 18.0) % for all subjects. The sensor was 
re–calibrated on 6 occasions overall during a total of 120 hours of closed–loop control 
(0.3 re–calibrations / 6–hour study).  
 
Interruptions to insulin delivery and technical faults 
We experienced one sensor failure at 3 hours into one of the closed-loop studies, 
where a replacement sensor was inserted and connected to the BiAP handheld unit for 
completion of the study. This resulted in disruption to insulin delivery for 40 minutes.  
The controller’s insulin dose recommendations were rejected on eight occasions 
overall, representing 0.6% of all recommended doses. The rejected insulin dose 
recommendations were a result of intermittent artefactual glucose spikes reported by 
the sensor in two subjects.  
On one study occasion it was noted by the study team that the safety mechanism had 
not been activated when the predicted sensor glucose was below 5mmol/L. As a result 
0.35units of excess insulin had been delivered in the preceding 80 minutes, but did 
not result in hypoglycaemia.  
 
During the 6-hours of the study the low glucose suspend feature (either 50% reduction 
or complete suspension in insulin delivery) came into play on 10 occasions in total for 
all 20 subjects (2.0 times/24-hour day). 
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2.4 Discussion 
The results from the first phase of the study demonstrate the feasibility and safety of 
the bio–inspired artificial pancreas and its ability to achieve glycaemic control in 
adults with T1DM. This is the first time the bio–inspired control algorithm has been 
evaluated in human subjects with T1DM and confirms the conclusions from in silico 
studies with virtual subjects in a simulated environment. This is a feasibility study and 
at this stage it is limited by the absence of a control group. The primary outcome of 
the fasting study, 98.0 % of time spent in target range (3.9 – 10.0mmol/L), and 96.4% 
in a tighter target (3.9-7.8mmol/L), is comparable to other closed–loop fasting 
studies(109, 122, 176).   The inclusion of the glucose data from first two hours of the 
study in the sub-analysis, showing 89% within the target range, demonstrated that the 
controller was able to safely bring down the glucose to target irrespective of the blood 
glucose at initialization of the controller and in a scenario where the controller does 
not know the insulin on board. We advised subjects to avoid exercise for 24-hours 
prior to the study, so the higher initial fasting blood glucose on arrival may in part be 
a result of reduced activity the evening before the study. Hypoglycaemia (glucose less 
than 3.9mmol/L) occurred in only one subject and there were no episodes of severe 
hypoglycaemia. To solve the issue of artefactual sensor spikes leading to 
inappropriate insulin infusion rates, saturation thresholds for glucose rate of change 
were introduced into the control algorithm, avoiding excess insulin infusion.  
The overall results from the 6–hour fasting study confirmed the safety of the BiAP 
system allowing further assessment over a longer period of time and following a meal 
challenge. 
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3 Chapter 3: A 13-hour overnight and post-
breakfast closed-loop study 
3.1 Introduction and aim 
The overall results from the 6–hour fasting study confirmed the safety of the Bio-
inspired Artificial Pancreas (BiAP) system allowing further assessment of the closed-
loop over a longer time period- including the night when hypoglycaemia is of 
increased concern and following a breakfast meal which is often the most difficult 
meal to control post-prandially due to increased insulin resistance on waking. Based 
on what was learnt from the fasting 6-hour study adaptations were made to the BiAP 
system for the second phase of the study i.e. the overnight and post-prandial study and 
these are outlined under the methods section 3.2 below.  In view of potential sensor 
failure it was decided to insert a second sensor for back-up at the beginning of the 
study visit to eliminate the disruption in closed-loop delivery associated with a new 
sensor insertion.  
 
Hypothesis: 
• The Bio-inspired Artificial Pancreas is safe during overnight and post-prandial 
conditions 
 
3.2 Methods  
3.2.1 Participants and study design !
This is a non-randomised single arm open-label study. The same cohort that took part 
in the 6-hour study participated in the 13-hour study. 3 of the 20 participants from the 
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original cohort were unable to commit to the study schedule and were therefore 
excluded. 
 
3.2.2 13-hour closed-loop study protocol !
Subjects attended the NIHR/Wellcome Trust Imperial Clinical Research Facility non–
fasting at 18:00h. The capillary blood glucose was measured on arrival to the research 
unit and the subject’s basal rate at that point was adjusted if deemed necessary by the 
attending physician from 18:00h to 22:00h.!Two subcutaneous glucose sensor (Enlite, 
Medtronic) were inserted in the abdomen. The first sensor was used as the primary 
sensor and the other inserted in case of failure of the primary sensor. The second 
sensor was connected to a Guardian real-time transmitter. The sensor and blood 
glucose was blinded to the subject, but unblinded to the study team.  They then 
consumed a meal of their choice and were advised to take their normal insulin bolus 
prior to meal consumption. The closed-loop insulin delivery system was set up and 
connected as outlined for the 6–hour fasting study except that communication 
between the handheld unit and the laptop was achieved via Bluetooth radio, allowing 
subjects to be mobile. A slightly higher target glucose of 6.5mmol/L was used for 
increased safety during the overnight period. Following sensor calibration to venous 
glucose at the start of closed–loop control at 22:00h, the control algorithm 
recommended an insulin dose according to the interstitial glucose level measured by 
the subcutaneous sensor every five minutes. Every 15–30 minutes throughout the 
study (full schedule of blood sampling given below) a venous blood sample was taken 
and analysed for glucose using the YSI 2300 glucose analyser. Subjects were only 
allowed to drink water overnight. At 06:00h the next day a standard breakfast 
containing 40 grams of carbohydrates was provided. The meal was announced to the 
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algorithm and a 70% bolus dose of insulin, calculated using the subject’s insulin to 
carbohydrate ratio was delivered.  Hypoglycaemia, defined as venous BG <3.9, was 
confirmed by an additional venous blood plasma glucose sample and treated 
according to Imperial College Hospitals NHS Trust Guidelines. The closed-loop study 
ended five hours after the meal, at 11:00h. After completion of 13 hours of closed 
loop, the subject’s own CSII pump was reconnected and started as per the subject’s 
usual insulin regime. Once running, the study pump was disconnected and the 
subcutaneous glucose sensor and intravenous cannula removed. The subject was then 
allowed to eat and drink freely and discharged after ensuring that glucose 
concentrations were stable. The study protocol is summarised in Figure 10.  
 
 
           Figure 10.  Summary of the 13-hour overnight and post-breakfast closed-loop study protocol 
 
3.2.3 Materials used and sample analysis !
Continuous glucose monitoring 
The glucose sensor used for CGM was the Enlite  sensor by Medtronic as described in 
detail in Chapter 2 section 2.2. 
 
! At  18:00:  
•  Attend clinical research facility  
•  Meal of own choice with normal meal bolus 
•  Insert two Enlite sensors 
! At 20:00:  
•  Connect bio-inspired closed-loop system to subject 
•  Run basal insulin at normal rate 
! At 22:00: 
•  Closed-loop start 
! At 06:00 
•  Standard 40g breakfast with 70% pre-meal bolus 
! At 11:00 
•  End of closed-loop study 
Overnight and 
meal challenge 
closed-loop study  
(13 hours) 
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The BiAP controller, handheld unit and the laptop GUI 
The reader is referred to Chapter 1 Section 1.4 for details about the BiAP algorithm 
and Chapter 2 Section 2.2 for details about the set up of the BiAP system and the 
hypoglycaemia prevention strategy for the clinical trial. The same prototype (v1.1) of 
the BiAP handheld unit was used for the 13-hour study.  
The following changes were implemented prior to 13-hour study: 
• To avoid insulin stacking at the beginning of the trial the controller was not 
fully activated (only the basal insulin delivery and safety mechanism were 
initiated) until the drop in glucose was less than a predefined threshold of 
0.3mmol/L per 15 minutes. 
• To prevent inappropriate insulin infusion rates secondary to artefactual sensor 
spikes, saturation thresholds for glucose rate of change were introduced into 
the control algorithm. 
• The target glucose for the algorithm was increased from 5.5mmol/L to  
6.5mmol/L for added safety.  
• A meal announcement strategy was employed aiming for 70% of the meal 
bolus to be delivered just before eating. The algorithm calculated the meal 
bolus based on the participants pre-existing ICR and the carbohydrate content 
of the meal.  
• The LGS algorithm was programmed in such a way that it would not affect the 
meal bolus. 
• The communication between the handheld unit and the laptop was achieved 
via Bluetooth radio rather than via wire as in the 6-hour study 
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Continuous subcutaneous insulin infusion 
The Roche Accu-Chek Combo Insulin Pump was used as the study pump and has 
been described in detail in Chapter 2 section 2.2. 
 
Venous blood sampling and analysis 
Venous blood samples were collected via the intravenous cannula every 15 to 30 
minutes throughout the 13-hour study and analysed immediately for glucose 
concentration using the YSI 2300 analyser. The sampling schedule was as follows: 
Time period : Sampling interval  
22:00h – 00:00h (not included in final analysis) :  Every 15 minutes   
00:00h – 06:00h (overnight period) :    Every 30 minutes  
06:00h – 11:00h (post-prandial period):   Every 15 minutes  
The rest of the venous blood sampling process was the same as described in Chapter 2 
section 2.2. The serum samples were later analysed for insulin concentrations using a 
chemilluminescent immunoassay (ARCHITECT i2000 immunoassay, Abbott 
Laboratories). 
 
3.3  Results 
17 participants completed the study and were included in the analysis. The 
participants demographics were as follows: 65% male, mean ± SD (range) age 44 ± 
10 years, BMI 25.5 ± 4.8,  HbA1c 7.4 ± 0.7%. Time since diagnosed with T1D was 
20 ± 11 years and time spent using the CSII pump was 3.8 ± 4.2 years.  
Table 5 summarises the glycaemic outcome measures from the combined overnight 
and post–prandial closed-loop study, and the glycaemic outcome measures from the 
night period only. The data generated from the first two hours of closed–loop control 
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was excluded from the analysis to account for the insulin bolus taken with the evening 
meal at 18:00h, making the assumption that the average insulin action time is up to 6 
hours. Glycaemic outcomes for each participant can be found in Appendix 3. 
 
Outcome measure Results 
(n=17) 
Time 00:00 – 11:00 
(11 hours in total) 
Sensor glucose 
Median (IQR) 
Blood glucose 
Median (IQR) 
 
% time in target range  
3.9 –10.0mmol/L 
70.7 (63.9 – 77.4) 
 
67.6 (59.5 – 70.3) 
 
% time in euglycaemia  
3.9 – 7.8mmol/L 
42.9 (18.8 – 51.9) 
 
37.8 (29.7 – 51.4) 
% time in hypoglycaemia 
<3.9mmol/L 
0.0 (0.0 – 2.3) 
 
0.0 (0.0 – 0.0) 
% time in  hyperglycaemia 
>10.0mmol/L 
26.3 (20.3 – 26.3) 
 
 32.4 (29.7 – 40.5) 
 
 
 
Mean (SD) Mean (SD) 
Glucose (mmol/L) 8.3 (1.2) 
 
9.0 (1.4) 
Low blood glucose index 
 
3.0 (5.1) 
 
 1.2 (1.9) 
 
High blood glucose index 
 
 8.3 (3.3) 
 
8.3  (3.4) 
 
Time 00:00 – 06:00  
(6 hours in total) 
Sensor glucose 
Median (IQR) 
 
Blood glucose 
Median (IQR) 
% time in target range  
3.9 –10.0mmol/L 
93.2 (71.6 – 97.3) 
 
100 (81.3 – 100)  
 
% time in euglycaemia  
3.9 – 7.8mmol/L 
67.6 (32.4 – 82.4) 
 
58.8 (35.3 – 94.1)  
 
% time in hypoglycaemia 
<3.9mmol/L 
0.0 (0.0 – 4.1) 
 
0·0 (0·0 – 0·0) 
% time in  hyperglycaemia 
>10.0mmol/L 
0.0 (0.0 – 14.9) 
 
0.0 (0.0 – 11.8)  
 
 
 
Mean (SD) 
 
Mean (SD) 
Glucose (mmol/L) 6.7 (1.9) 
 
7.4 (2.0)  
 
Low blood glucose index 
 
3.0 (5.1) 
 
1.2 (1.9)  
 
High blood glucose index 
 
3.2 (2.8) 3.4 (3.9)  
 
 
Table 5: Glycaemic outcome measures from the overnight and post–prandial closed–loop study 
(00:00h -11:00h) and from the overnight period only (00:00h – 06:00h). 
 
The median sensor and blood glucose with IQRs throughout the whole 13–hour study 
period is displayed in Figure 11. The mean glucose remains within the target from 
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closed-loop start at 22:00h until breakfast at 06:00h and the mean post–prandial peak 
glucose reaches 12.0mmol/L before returning to target. The sensor glucose 95% 
confidence interval for the overnight study was 5.8-7.6 mmol/L with a mean (SD) of 
6.7 (1.9) mmol/L. The achieved mean glucose overnight did not differ significantly 
from the target glucose of 6.5 mmol/L as the target value lies within the CI.  
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Figure 11: Median glucose trend and insulin delivered for all 17 subjects during the 13–hour 
overnight and post–prandial closed–loop study (top graph) and corresponding insulin 
concentrations (bottom graph) 
Red dotted line = median blood (YSI) glucose (±  IQR); blue dotted line = median sensor glucose (±  
IQR); orange bars = mean insulin dose delivered; black dashed lines = upper/lower glucose target 
thresholds; green dotted line = median insulin concentration (±  IQR) A standard breakfast meal 
containing 40 grams of carbohydrates was provided at 06:00h and announced to the algorithm. 
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Recalibrations and sensor accuracy 
The MARD between the venous blood glucose and the sensor glucose was 11.8 (5.4 – 
20.9) % for all subjects. The sensor was re-calibrated on 21 occasions overall during a 
total of 221 hours of closed-loop control (1.6 re–calibrations / 13–hour study).  
 
Interruptions to insulin delivery and technical faults 
There was a sensor failure in one of the 13-hour studies where the BiAP handheld unit 
had to be connected to the back-up sensor resulting in 15min of interruption to insulin 
delivery. Interestingly the sensor failure occurred in the same participant who 
experienced sensor failure in the 6-hour fasting study.  
In the final hour of another 13-hour study the BiAP handheld unit was reading very 
high currents and switching to the back-up sensor did not resolve the issue. As a result 
insulin delivery was interrupted for during the last 50 minutes of the study.  
  
The controller’s insulin dose recommendations were adhered to at all times. The low 
glucose suspend feature was activated on 12 occasions overall (1.3 times/24-hour 
day). 
 
3.4  Discussion 
The overall results from the 6–hour fasting study outlined in the previous chapter 
confirmed the safety of the BiAP system and allowed further assessment over a longer 
period of time and following a meal during which the overall time in target range was 
acceptable at 71%. There is scope to further optimise the glucose controller to allow 
more aggressive glucose lowering when concentrations are above the hyperglycaemic 
threshold, particularly post–prandially. We observed that the insulin feedback term 
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was exerting a significant influence after a meal bolus and aimed to address this in the 
next stage of the study. With the current glucose sensing technology and insulin 
analogues available, providing the facility to announce meals, in order to minimize 
prandial hyperglycemia and delayed post-prandial hypoglycaemia, seems to be the 
best approach. However, proving safety of any artificial pancreas algorithm in the 
absence of meal announcement is important and this will also be assessed in the next 
stage of the BiAP study.   
Differences in study protocol preclude comparisons with other non–fasting closed–
loop studies but the inclusion of a longer post-prandial period would have allowed a 
further reduction of the post–prandial glucose to be demonstrated. As a result of the 
post–prandial glucose surge the mean HBGI was elevated at 8.3. The median peak 
post–prandial sensor glucose was however reasonable at 12.0mmol/L and target mean 
glucose was achieved during overnight control. Reassuringly, the LBGI was low at 
3.0 suggesting minimal risk of hypoglycaemia, although not completely eliminated. 
The addition of glucagon in a bi–hormonal closed–loop system has the potential to 
reduce the incidence hypoglycaemia further (86, 123, 160). 
It has been reported that glucose sensors are least accurate on the first day of 
operation(177). A MARD of 9.5% and 11.8% as seen in the 6-hour fasting and 13-
hour overnight/post–prandial study respectively suggest acceptable sensor accuracy, 
although the MARD may be biased by the number of re–calibrations in any 
assessment of a closed-loop system.  
Having proven safety of BiAP during fasting condition, overnight and following a 
meal challenge it would be important to assess whether the BiAP is able to improve 
glycaemic control in terms of percentage spent in target and reduction in 
hypoglycaemia compared to open-loop (standard pump therapy). 
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4 Chapter 4: A 24-hour randomised controlled 
crossover closed-loop study 
4.1 Introduction and aim 
After demonstrating proof of concept, feasibility and safety of the BiAP system 
during fasting, overnight and post-breakfast conditions, with encouraging results, a 
randomised controlled study comparing the BiAP system (closed-loop) with standard 
insulin pump therapy (open-loop) over 24 hours was commenced.  
At present capillary blood glucose is measured in type 1 diabetes self-management. 
Measurement of capillary blood ketone bodies (3-hydroxybutyrate) is encouraged at 
times of hyperglycaemia to guide management, prevent diabetic ketoacidosis and 
assess the need for hospital admission. Rising glucose values in the context of falling 
ketone concentrations suggest a post-meal state while rising glucose with rising 
ketones suggests insulin deficiency. In an AP system these scenarios require different 
action from the controller. In this study we measured 3-hydroxybutyrate to assess its 
potential value in an AP system and additionally measured lactate and non-esterified 
fatty acids (NEFA) to establish patterns of these analytes in closed-loop and open-
loop therapy. Changes in lactate, and 3-hydroxybutyrate concentrations were 
investigated for the first time during closed-loop control. 
 
Proving safety of any AP algorithm in the absence of meal announcement is important 
and we therefore evaluated BiAP system with partial and no meal announcement as a 
sub-study at the end.  
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Hypothesis: 
• The Bio-inspired Artificial Pancreas achieves increased time in target and 
reduces hypoglycaemia compared to open-loop (standard pump herapy) 
• The BiAP algorithm is safe in the absence of meal announcement 
 
4.2 Methods  
4.2.1 Participants and study design !
This is a prospective randomised controlled open-label crossover study. Regulatory 
approvals by the regional ethics committee and by the MHRA were obtained. Adult 
participants with T1DM were recruited from the diabetes clinics at Imperial College 
Healthcare NHS Trust. Inclusion criteria were age 18–75 years, duration of diabetes 
>1 year, fasting c-peptide <0.2nmol/l, treatment with CSII for >6 months and HbA1c 
<8.5% (69mmol/mol). Exclusion criteria were recurrent severe hypoglycaemia, 
pregnancy or planning pregnancy, breastfeeding, enrolment in other clinical studies, 
active malignancy or being under investigation for malignancy. Informed written 
consent was obtained. Participants were screened as outlined in Chapter 2 section 2.2.  
 
Randomisation  
Participants were randomly assigned the order of the closed-loop and open-loop study 
visit using computer-generated allocation numbers, by the study investigators. A one-
week minimum washout period occurred between visits. Participants were blinded to 
the sensor and blood glucose. In the event of hypoglycaemia requiring carbohydrate 
(CHO) rescue participants were informed of their venous glucose.  
After completion of both the closed-loop and open-loop visit all participants were 
invited to attend an additional visit to participate in a sub-study without randomisation 
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to evaluate the safety of the BiAP algorithm without and with partial meal 
announcement.  
 
4.2.2 Closed-loop visit !
Two subcutaneous glucose sensors (Enlite, Medtronic) were inserted in the abdomen 
the day before the study. The first sensor was designated as the primary sensor for the 
closed-loop system and the second sensor as reserve in case of primary sensor failure. 
Participants attended the Clinical Research Facility at 16:00h on the day of the study. 
Capillary blood glucose was measured on arrival and the participant’s basal insulin 
infusion rate was adjusted if required. The handheld BiAP unit was connected to one 
of the sensors. The participant’s own insulin pump was replaced with the study pump 
(Accu-Chek Spirit Combo pump, Roche) and basal insulin infusion continued until 
closed-loop insulin delivery was commenced. Rapid-acting insulin aspart (Novorapid, 
Novo Nordisk) was used throughout. The sensor signal was transmitted to the 
handheld unit by cable and communication between the handheld unit and the laptop 
with a graphical user interface was achieved via Bluetooth. The insulin infusion 
instruction was transmitted to the pump by Bluetooth communication protocol. 
Following sensor calibration to venous glucose at the start of closed-loop control, the 
control algorithm recommended an insulin dose and insulin was automatically 
delivered. Every 30 minutes a venous blood sample was analysed for glucose and 
lactate using a YSI 2300 bedside analyser . Three standardised meals were provided: 
dinner containing 80g of carbohydrate at 19:00h, breakfast (40g) at 07:00h and lunch 
(50g) at 12:00h. Participants pre-selected their meal choices from a limited hospital 
canteen menu prior to the study. All the meals were announced to the algorithm based 
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on the participant’s insulin: carbohydrate ratio. Participants were allowed to drink 
water throughout the study visit.  
 
4.2.3 Open-loop visit !
This visit followed as for the closed-loop visit except the participant used their own 
insulin pump pre-set with their normal basal rates. One of the sensors was connected 
to the BiAP handheld unit for continuous glucose monitoring. Sampling and meals 
were the same as during the closed-loop visit. Participants were asked to measure 
their capillary blood glucose pre-meal, calculate the meal insulin bolus and administer 
it. Participants were permitted to do additional capillary testing between meals and 
administer correction boluses if desired. Figure 12 gives an outline of the time frames 
for the various interventions throughout the closed-loop and open-loop study visits. 
 
 
Figure 12. Outline of the time frames for the various interventions throughout the closed-loop and 
open-loop study visits. 
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4.2.4 Closed-loop without and with partial meal announcement visit !
This visit followed as for the closed-loop visit, with the exception of the meal 
announcement strategy. The dinner was not announced to the controller, 100% of the 
breakfast carbohydrate was announced and lunch was partially announced (50% of 
carbohydrate content announced).  
 
4.2.5 Materials used and sample analysis !
Continuous glucose monitoring 
The Enlite sensor by Medtronic has been described in detail in Chapter 2 section 2.2. 
 
The BiAP control algorithm, handheld unit and the laptop GUI 
The reader is referred to Chapter 1 Section 1.4 for an overview of the BiAP algorithm 
and to Sections 2.2 and 3.2 in Chapter 2 and 3 respectively for details of the BiAP 
system set up for the clinical trials.  
 
Further changes implemented prior to commencing the 24-hour study were as 
follows: 
• As mentioned before the algorithm is initialised with a personalized gain 
based on the participant’s pre-existing correction factor. For the 24-hour study 
the gain was dynamic and automatically adapted according to the sensor 
glucose taking into account glucose thresholds and rate of change in both 
directions. 
• For safety, the algorithm did not allow the gain to change in the post-prandial 
period (set to 3 hours). 
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• The insulin-feedback term which is important to prevent insulin stacking was 
also changed to be more dynamic i.e. enables to re-set at times of prolonged 
hyperglycaemia.  
• In the previous 13-hour closed-loop study we employed a meal announcement 
strategy of 70% of the carbohydrate announced to the controller. To improve 
post-prandial hyperglycaemia 100% meal announcement was used in this 
study.  
• The insulin dose proposed by the algorithm was automatically sent to the 
pump without first being approved by the study team. The trial was still 
supervised by observing changes in sensor glucose on the GUI.  
• Access to view the GUI via password protected application (VNC) was set up 
enabling the study team to remotely monitor trial progress. Of note, for safety 
the study team were not able to physically change anything on the GUI 
remotely. 
• Existing alarms which were already incorporated into the Matlab GUI to 
notify the study team, at times when MARD was >30%, pump communication 
failure, sensor failure, were synchronised with the clinician’s study phone 
alerting the clinician to any issues with the closed-loop insulin delivery system 
even when not in the same room as the participant.  
• An updated prototype of the BiAP handheld unit (version 1.2) was used in this 
phase of the study (see Figure 13). 
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Figure 13: The Bio-inspired controller implemented in a microchip integrated into the portable hand-
held unit prototype version 1.2 which interfaces the components of the 
 Bio-inspired Artificial Pancreas system 
 
Continuous subcutaneous insulin infusion 
The Accu-Chek Combo Insulin Pump (study pump) has been described in detail in 
Chapter 2 section 2.2. 
 
Venous blood sampling and analysis 
Venous blood samples were collected via the intravenous cannula every 30 minutes 
throughout the 24-hour study and analysed immediately for blood glucose and lactate 
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concentrations using the YSI 2300 analyser. The rest of the venous blood sampling 
process was the same as described in Chapter 2 section 2.2.  
Serum samples were stored at -80°C and later analysed for insulin, NEFAs and 
ketones (3-hydroxybutyrate). Serum insulin concentrations were analysed using a 
chemilluminescent immunoassay (ARCHITECT i2000 immunoassay, Abbott 
Laboratories) (see Chapter 2 Section 2.2.3 for details of assay used). Serum 3-
hydroxybutyrate and NEFAs were analysed using an automated analyser (COBAS 
Mira S, Roche Diagnostics).  
 
Lactate analysis: 
Whole blood samples were analysed for glucose concentration using the YSI 2300 
STAT  Glucose & Lactate analyser.  The YSI 2300 uses a membrane-bound enzyme 
(immobilized L-lactate oxidase) electrode methodology for measuring lactate. The 
precision for Lactate is ±2% or 0.1 mmol/L (whichever is greater) 
 
3-hydroxybutyrate analysis: 
Ketones are analysed using the RANDOX RANBUT kit. It measures D-3- 
Hydroxybutrate, which is the major ketone in the blood and the most stable of all 
ketones in the blood. When ketone levels increase, D-3-Hydroxybutrate is the main 
ketone body that increases, making it a more sensitive marker of ketones. The assay 
uses a kinetic enzymatic reaction to measure the change in absorbance.  
The reaction is as follows:  
D-3-hydroxybutyrate + NAD+ --- 3-hydroxybutyrate dehydrogenase ! acetoacetate + 
H+ + NADH 
Baseline measurement is made after 60 seconds at 37°C and absorption change is 
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measured after a further 60 and 120 seconds.  Sample concentration is proportional to 
mean absorbance change per minute compared with a calibration standard. 
This method is accepted between the concentrations of 0.100 to 5.75 mmol/L. 
Samples with higher concentrations are diluted and reassayed by the COBAS. The 
sensitivity level is 0.100 mmol/L. Intraassay CV% <4%, interassay CV% <5.26% 
!
 
NEFA analysis: 
The NEFA assay consists of the RANDOX NEFA kit, stored in a 4°C fridge and used 
within 5 days after reconstitution. It uses a colorimetric end point reaction (enzymatic 
colorimetric assay) to convert NEFAs into a purple complex . The chemical reaction 
is as follows:  
NEFA + ATP + coenzyme A --- Acetyl CoA Synthetase ! acylCoA + AMP + PPi  
AcylCoA + O2 – Acetyl CoA Oxidase ! 2,3 trans-enoyl CoA + H2O2 
H2O2 +TOOS +4-AAP   --Peroxidase!  Purple adduct +4 H20 
TOOS = N-ethyl-N-(2hydroxy-3-sulphopropyl) 3-methylaniline 
4-AAP = 4-aminoantipyrine 
The method is linear up to 2.24 mmol/L. Samples with higher concentrations are 
diluted and reassayed by the COBAS. The sensitivity level is 0.072 mmol/L.  CV% is 
<5% (inter and intra assay) 
 
Primary and secondary outcomes 
The primary outcome was percentage time spent in glucose target range (3.9–
10.0mmol/L). Secondary outcomes were percentage time in euglycaemia (3.9–
7.8mmol/L), hypoglycaemia (<3.9mmol/L) and hyperglycaemia (>10.0mmol/L), 
mean sensor glucose, insulin dose delivered and glycaemic risk measures of low 
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blood glucose index (LBGI) and high blood glucose index (HBGI). We calculated all 
glycaemic outcomes for the whole time period and the overnight period. Other 
secondary outcomes included inter-correlations between metabolic analytes during 
closed-loop and open-loop control. 
 
4.2.6 Statistical analysis !
The glycaemic outcomes presented are calculated using the sensor glucose. The 
equivalent glycaemic outcomes using blood glucose have also been analysed and are 
presented for comparison. The study start time was 17:00, but we encountered up to 
45 minutes delay in starting in some participants due to hypoglycaemia on arrival, late 
arrival, and technical issues. The first hour of the study has therefore been excluded 
from the data analysis.  
LBGI and HBGI were calculated using the EasyGV version 9.0 software. Normally 
distributed data were compared using the paired t-test and non-normally distributed 
data with the Wilcoxon matched-pairs signed-rank test. All outcomes are reported as 
mean (SD) or median (IQR), unless stated otherwise. p-values below 0.05 were 
considered statistically significant. Sensor accuracy was evaluated by calculating the 
median absolute relative difference (MARD). Data were analysed using Stata/SE 
version 13.1. 
 
4.3 Results 
Fourteen participants were screened and included in the 24-hour randomised 
controlled crossover study of which two participants were unable to complete both 
study visits (recurrent venous cannula failures in one participant and illness unrelated 
to diabetes in another) and were excluded from the analysis (Figure 14). Table 6 
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outlines the baseline characteristics for the twelve participants included. Eight of 
these participants agreed to participate in the closed-loop visit without and with 
partial meal announcement.  
 
 
 
Figure 14. Flowchart of participants going through each study visit (excluding the no meal 
announcement visit) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomised*
to*CL*(n=8)!
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OL*(n=6)!
Crossover*to*
CL*(n=6)!
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Characteristic Results (mean (SD)) 
Age (years) 45 (10) 
Sex Male 42%     Female 58% 
BMI (kg/m2) 25 (4) 
Duration of diabetes (years) 22 (12) 
Duration of insulin pump therapy (years) 3.4 (4) 
Insulin requirements (units/kg) 0.5 (0.1) 
HbA1c     (%) 
(mmol/L) 
7.4(0.7) 
58 (8) 
C-peptide (pmol/L) Detectable in 3 participants (range 62-69pmol/L) 
Total cholesterol (mmol/L) 4.7 (0.7) 
HDL (mmol/L) 1.9 (0.3) 
Chol:HDL ratio 2.6 (0.5) 
Creatinine (umol/L) 71 (10) 
Urine ACR (mg/mmol (creat)) 0.7 (0.6) 
 
Table 6: Demographics and baseline characteristics (n=12) 
 
Outcomes from the 24-hour study comparing closed-loop with open-loop (18:00h -
18:00h) 
There was no significant difference in time spent in glucose target (3.9-10mmol/L) 
between closed-loop and open-loop, 71% vs. 66.9% respectively (p=0.9). The median 
sensor glucose and insulin delivered during closed-loop and open-loop for all 12 
participants throughout the 24-hour study is displayed in Figure 15. More insulin was 
delivered over 24 hours of open-loop compared to closed-loop (38.0 (5.7) vs. 32.2 
(6.4) units, p<0.01), however no difference was observed over night (5.2 (1.6) vs. 5.2 
(2.2), p=0.9). Similarly the mean rate of basal insulin delivery (defined as insulin 
delivered per hour excluding the meal boluses) was higher over 24 hours of open-loop 
(0·9 (0·2) units/hour vs.. 0·7 (0·3) units/hour, p=0·01) and again no difference was 
found over night (0.7 (0.2) units/hour vs. 0.7 (0.3) units/hour, p=0.9). Circulating 
insulin concentrations were higher in the open-loop group compared to closed-loop 
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(26.57 (12.5) mU/l vs. 23.08 (10.17) mU/l, p=0.05). The median (IQR) meal boluses 
given during closed-loop and open-loop were 8.0 (7.1-8.1) units vs. 8.0 (7.6-8.8) units 
at 19:00h, 4.0 (3.6-4.2) units vs. 3.8 (3.4-4.3) units at 07:00h and 5.0 (4.5-5.1) units 
vs. 5.0 (4.7-6.3) units at 12:00h. 
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(A) 
 
 
(B) 
 
Figure 15: Median (IQR) sensor glucose (A) and median (IQR) insulin (excluding the meal boluses) 
(B) delivered for all 12 subjects during the 24–hour closed–loop (green line) and open-loop (blue line) 
study. Standardized meals (black squares) were provided at 19:00h (80grams CHO), 07:00h (40grams 
CHO) and at 12:00h (50grams CHO). Triangles denote episodes of rescue CHO (10-15g CHO) for 
hypoglycaemia. 
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Glycaemic outcome measures based on sensor glucose and venous blood glucose 
from the full 24-hour study are outlined in Table 7. Details of glycaemic outcomes for 
individual participants can be found in Appendix 4. Although open-loop achieved a 
lower mean glucose compared to closed-loop (8.4 (1.1) versus 6.4 (0.8) mmol/L, 
p<0.01), this was at the expense of significantly increased % time spent in  
hypoglycaemia (<3.9mmol/L) with open-loop (17.9% vs. 3.0%, p<0.01). The 
difference in % time spent in hypoglycaemia for each individual participant over 24-
hours and overnight is illustrated in Figure 16. With <3.5 mmol/L or <3.3mmol/L as 
cut-off points for hypoglycaemia, the significant reduction in hypoglycaemia with 
closed-loop remains. Hypoglycaemia at <2.8mmol/L was completely eliminated with 
closed loop whereas a small proportion (1.7%) of time was spent at <2.8mmol/L with 
open-loop. The risk of hypoglycaemia, as measured by LBGI was much lower in the 
closed-loop group (3.0 (0.9-4.9) vs. 5.9 (3.8-10.8), p=0.01).  Rescue carbohydrates for 
hypoglycaemia (defined as symptomatic blood glucose <3.9mmol/L or asymptomatic 
blood glucose <3.5mmol/L) were required on 28 occasions overall (2.3 (2.5) 
times/24h) during open-loop compared to three occasions (0.3 (0.5) times/24h) during 
closed-loop. In addition to the meal boluses, 13 correction boluses were taken during 
open-loop (1.1(1.0) correction bolus/24h). The correction bolus doses ranged from 
0.05 units to 3.4 units. An increase in time spent in hyperglycaemia (>10mmol/L) was 
seen with closed-loop (10% vs. 28.9%, p=0.01), mostly attributed to the post-prandial 
glucose excursions seen, particularly following the evening meal.  
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Time 18:00 -18:00 (next day)  
(total 24 hours) 
Glycaemic outcome 
measure 
Closed-loop 
(n=12) 
Sensor glucose 
Open-loop 
(n=12) 
Sensor glucose 
p 
 
Closed-loop  
(n=12) 
Blood glucose 
Open-loop 
(n=12) 
Blood glucose 
p 
 
% time in target range 
3.9 – 10.0mmol/L 
71 (61.0 -73.8) 66.9 (55.4 – 
82.5) 
0.9 68.4 (50.6 – 74.5) 76.5 (70.2 - 
79.4) 
0.05 
% time in euglycaemia 
3.9 – 7.8mmol/L 
41.9 (27.0 – 
59.5) 
60.4 (40.2- 
65.5) 
0.1 40.8 (25.8 - 51.0) 60.2 (46.9 - 
73.5) 
0.02 
% time in severe 
hypoglycaemia <2.8 
mmol/L 
0.0 (0.0 – 0.0) 1.7 (0.0 – 10.2) 0.02 0.0 (0.0 - 0.0) 0.0 (0.0 - 1.0) 0.08 
% time in hypoglycaemia   
< 3.3mmol/L 
0.0 (0.0-1.9) 4.4 (0.0-14.8) 0.02 0.0 (0.0 - 0.0) 2.0 (1.0 - 2.1) 0.01 
% time in hypoglycaemia   
< 3.5mmol/L 
0.0(0.0-4.0) 6.6(1.7-18.1) 0.01 0.0 (0.0 - 0.1) 4.0 (1.0 - 6.1) 0.01 
% time in hypoglycaemia   
< 3.9mmol/L 
3.0 (0.0 – 7.0) 17.9 (8.4 – 33.8) <0.01 0.0 (0.0 - 2.1) 12.2 (3.1 - 18.4) 0.01 
% time in hyperglycaemia 
>10mmol/L 
28.9 (23.6 - 
36.8) 
10.1 (7.7 – 15.1) 0.01 31.6 (23.5 – 49.4) 12.5 (6.2 – 17.3) 0.01 
% time in  
hyperglycaemia 
>15mmol/L 
1.4 (0.0 – 5.0) 0.0 (0.0 – 1.2) 0.3 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 0.95 
Glucose (mmol/L) 
 
8.4 (1.1) 6.4 (0.8) <0.01 8.8 (1.2) 6.6 (0.9) <0.01 
Low blood glucose index 
(0.0 – 6.9) 
3.0 (0.9 – 4.9) 5.7 (3.8- 10.8) 0.01 1.4 (0.4 – 2.6) 4.4 (3.0 – 5.8) <0.01 
High blood glucose index 
(0.0 – 7.7) 
6.9 (6.1 – 9.4) 5.0  (3.2 – 9.2) 0.27 7.3 (5.5 – 11.4) 4.8 (3.3 – 6.8) 0.01 
No of CHO rescue in total 
 
3 28 <0.01 3 27 0.01 
Time 00:00 -07:00 
(total 7 hours overnight) 
% time in target range 
3.9 – 10.0mmol/L 
82.7 (69.0 – 
100) 
79.2 (29.0- 
85.7) 
0.1 75.0 (52.8 – 
100.0) 
78.6 ( 60.2 – 
100) 
0.84 
% time in euglycaemia 
3.9 – 7.8mmol/L 
59.5 (47.0 – 
90.2) 
66.7 (29.0 – 
78.3) 
0.4 46.4 (28.6 – 98.2) 78.6 ( 54.7 – 
100.0) 
0.07 
% time in severe 
hypoglycaemia <2.8 
mmol/L 
0.0 (0.0 – 0.0) 0.0 (0.0 – 4.5) 0.08 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 0.32 
% time in hypoglycaemia   
< 3.3mmol/L 
0.0 (0.0-0.0) 0.0 (0.0-19.6) 0.03 0.0 (0.0 – 0.0) 0.0 (0.0 – 7.1) 0.05 
% time in hypoglycaemia   
< 3.5mmol/L 
0.0 (0.0-0.0) 4.2 (0.3-31.0) <0.01 0.0 (0.0 – 0.0) 3.6 (0.0 – 7.6) 0.02 
% time in hypoglycaemia   
< 3.9mmol/L 
0.0 (0.0 - 0.0) 20.8 (14.3 – 
71.0) 
<0.01 0.0 (0.0 – 0.0) 21.4 (0.0 – 39.8) 0.01 
% time in hyperglycaemia 
>10mmol/L 
6.5  (0.0 – 31.0) 0.0 (0.0 – 0.0) 0.01 25.0 (0.0 – 48.2) 0.0 (0.0 – 0.0) 0.01 
% time in  
hyperglycaemia 
>15mmol/L 
0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 0.3 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) - 
Glucose (mmol/L) 
 
7.5 (1.3) 4.8 (1.5) <0.01 8.1 (1.9) 5.0 (0.9) <0.01 
Low blood glucose index 
(0.0 – 6.9) 
0.8 (0.1 – 1.8) 5.8 (4.2- 9.4) <0.01 0.1 (0.0 – 1.7) 5.2 (1.9 – 7.0) <0.01 
High blood glucose index 
(0.0 – 7.7) 
2.8 (1.0- 6.9) 0.1 (0.0-2.0) 0.01 5.1 (0.5 – 9.2) 0.1 (0.0 – 1.0) <0.01 
 
Table 7: Glycaemic outcome measures of closed–loop versus open-loop based on sensor glucose and 
venous blood  glucose (n=12). Outcomes are expressed as median (IQR) unless stated otherwise. 
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(A)  
 
 
(B) 
 
Figure 16: Percentage time in hypoglycaemia (<3.9mmol/L) throughout the 24-hour study (A) and 
overnight (B) for each individual participant. 
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Venous glucose, insulin, lactate, NEFA and 3-hydroxybutyrate concentrations 
An overview of the median (IQR) of blood glucose concentration, insulin 
concentration, lactate concentration, NEFA concentration and 3-hydroxybutyrate 
concentration throughout the 24-hour study is displayed in the  Figure 17.  
There was no significant difference between mean concentration of lactate (0.60 
(0.09) mmol/L vs. 0.62 (0.12) mmol/L and NEFA (0.30 (0.11) mmol/L vs. 0.28 (0.1) 
mmol/L) between closed-loop and open-loop. The mean concentration of 3-
hydroxybutyrate was higher with closed-loop (0.14 (0.07) mmol/L vs. 0.09 (0.06) 
mmol/L, p=0.03).  
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(D) 
 
 
 
 
(E) 
 
 
Figure 17. Median (IQR) blood glucose (A) insulin concentration (B), lactate (C), 3-hydroxybutyrate 
(D) and NEFA (E) for all 12 subjects during the 24–hour closed–loop (green line) and  
open-loop (blue line) study. 
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There were significant inter-correlations between glucose, lactate, 3-hydroxybutyrate, 
NEFA and insulin levels for both open- and closed-loop studies (Table 8). The 
strongest positive correlations were between 3-hydroxybutyrate and NEFA (r = 0.7, p 
<0.01), but there were no consistent differences in strengths of association between 
open- and closed-loop. NEFA and 3-hydroxybutyrate were suppressed post-meals.  
 
 
Open-loop Sensor 
glucose 
Blood 
glucose 
Lactate 3-hydroxybutyrate NEFA 
Blood glucose 0.8154 
<0.01 
    
Lactate 0.3294 
<0.01 
0.3605 
<0.01 
   
3-
hydroxybutyrate 
-0.0774 
0.09     
-0.0436 
 0.3     
-0.1768 
<0.01 
  
NEFA -0.1815 
<0.01 
-0.1423 
  <0.01 
-0.2736 
<0.01 
0.7815 
<0.01 
 
Insulin 0.2630 
<0.01 
0.1371 
<0.01 
0.2617 
<0.01 
-0.3108 
<0.01 
-0.3597 
<0.01 
Closed-loop Sensor 
glucose 
Blood 
glucose 
Lactate 3-hydroxybutyrate NEFA 
Blood glucose 0.8469 
<0.01 
    
Lactate 0.3306 
<0.01 
0.2984 
<0.01 
   
3-
hydroxybutyrate 
-0.1608 
<0.01 
-0.1049 
 0.02 
-0.2778 
<0.01 
  
NEFA -0.2403 
<0.01 
-0.2006 
<0.01 
-0.3379 
<0.01 
0.7729 
<0.01 
 
Insulin 0.1657 
<0.01 
0.2681 
<0.01 
0.3067 
<0.01 
-0.2644 
<0.01 
-0.2990 
<0.01 
 
Table 8: Correlations (r)  (with p-values underneath) between sensor glucose, blood glucose, lactate, 3-
hydroxybutyrate, NEFA and insulin concentrations during the 24-hour study with open-loop  and 
closed-loop. 
 
Outcomes from the overnight time period comparing closed-loop with open-loop 
(00:00h - 07:00h) 
The percentage time in target (3.9-10mmol/L) overnight did not significantly differ 
between closed-loop and open-loop (82.7% vs. 79.2% respectively, p=0.1). However 
there was a significant reduction in hypoglycaemia (<3.9mmol/L) with closed-loop 
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(20.8% vs. 0.0%, p<0.01). There was a small increase in percentage time spent in 
hyperglycaemia with closed-loop compared to open-loop, but severe hyperglycaemia 
was not observed in either group. Mean glucose with open-loop (4.8mmol/L) is 
significantly lower than with closed-loop (7.5mmol/L), in accord with the increased 
time spent in hypoglycaemia during open-loop. Glycaemic outcome measures from 
the overnight study period are outlined in the latter section of Table 7. 
 
Sensor accuracy 
The sensor was calibrated at the beginning of each study and was recalibrated if the 
discrepancy between sensor glucose and blood glucose was >30% over one hour or as 
determined by the supervising physician. 0.8 re-calibrations/24h were required during 
closed-loop and 1.0 recalibration/24h during open-loop. Overall 0.9 recalibrations/24h 
were carried out, consistent with the manufacturer’s guidance. The MARD between 
the venous blood glucose and the sensor glucose was 11.0% (7.0 – 26.0) and 15.0% 
(5.0 – 20.0) during closed-loop and open–loop respectively with an overall MARD of 
12.6% (5.7 – 23.6).  
 
Insulin delivery interruptions and missing data points 
During the 24-hour randomised controlled crossover study closed-loop insulin 
delivery was interrupted on three occasions overall (0.25 times per 24-hour closed-
loop visit) after study start due to technical fault with the BiAP handheld device. Each 
interruption lasted for 20 minutes and was resolved by resetting the BiAP. We 
experienced one sensor failure during closed-loop, where the study was completed 
using the second sensor without any interruptions to the insulin delivery. There were 
no interruptions to open-loop insulin delivery. During open-loop we experienced one 
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sensor failure and two technical faults with BiAP unit resulting in some gaps in the 
continuous monitoring of interstitial glucose. 
Overall 0.9% of the closed-loop sensor glucose data and 3.7% of open-loop sensor 
glucose data were missing from the study period as a result of the above mentioned 
technical faults. 
 
Closed-loop without and with partial meal announcement 
The median (IQR) sensor glucose during closed-loop without and with partial meal 
announcement, closed-loop (with meal announcement) and open-loop for the eight 
participants who completed all three 24-hour study visits is displayed in the Figure 
18. The percentage time in target was higher when all meals were announced during 
closed-loop compared to no or partial meal announcement (65.7% (53.6-80.5) vs. 
45.5% (38.2-68.3), p=0.12), but this was not statistically significant. The time spent in 
hypoglycaemia (<3.9mmol/L) was lower with closed-loop without meal 
announcement compared to closed-loop (0.4% (0.0 -1.3) vs. 5.8% (0.8-8.0), p=0.03). 
The mean glucose was 9.8mmol/L (1.3) with closed-loop without and with partial 
meal announcement compared to 8.4 (1.3) closed-loop with meal announcement 
(p=0.06). Additional glycaemic outcomes based on sensor glucose comparing closed-
loop without and with partial meal announcement and closed-loop with meal 
announcement are summarised in Table 9. 
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Figure 18. Median (IQR) sensor glucose for eight participants during the 24–hour closed-loop without 
meal announcement (red line), closed–loop (green line) and open-loop (blue line) study. Standardized 
meals were provided at 19:00 (80grams CHO), 07:00 (40grams CHO) and at 12:00 (50grams CHO). 
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Time 18:00 -18:00 (next day)  
(total 24 hours) 
Glycaemic outcome measure Closed-loop  
(n=8) 
Sensor glucose 
Closed-loop NMA 
(n=8) 
Sensor glucose 
p-value 
 
% time in target range 
3.9 – 10.0mmol/L 
65.7 (53.6 -80.5) 45.5 (38.2 – 68.3) 0.12 
% time in euglycaemia 
3.9 – 7.8mmol/L 
40.9 (27.0 – 61.4) 24.5 (18.6 – 37.7) 0.11 
% time in severe hypoglycaemia 
<2.8 mmol/L 
0.0 (0.0 - 0.0) 0.0 (0.0 – 0.0) 0.93 
% time in hypoglycaemia   
< 3.3mmol/L 
0.5 (0.0-3.6) 0.0 (0.0-0.3) 0.38 
% time in hypoglycaemia   
< 3.5mmol/L 
1.7(0.0-4.6) 0.0 (0.0 – 0.6) 0.11 
% time in hypoglycaemia   
< 3.9mmol/L 
5.8 (0.8 – 8.0) 0.4 (0.0 – 1.3) 0.03 
% time in hyperglycaemia 
>10mmol/L 
30.4 (15.0 – 41.5) 51.7 (31.1 – 61.5) 0.07 
% time in  hyperglycaemia 
>15mmol/L 
1.4 (0.0 – 6.1) 4.4 (0.0 – 12.0) 0.73 
Glucose (mmol/L) 
 
8.4 (1.3) 9.8 (1.3) 0.06 
Time 00:00 -07:00 
(total 7 hours overnight) 
% time in target range 
3.9 – 10.0mmol/L 
82.7 (69.0 – 100) 58.5 (32.4 – 96.4) 0.21 
% time in euglycaemia 
3.9 – 7.8mmol/L 
60.7 (42.0 – 98.8) 24.7 (2.4 – 72.3) 0.12 
% time in severe hypoglycaemia 
<2.8 mmol/L 
0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) NS 
% time in hypoglycaemia  < 
3.3mmol/L 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.93 
% time in hypoglycaemia  < 
3.5mmol/L 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.93 
% time in hypoglycaemia  < 
3.9mmol/L 
0.0 (0.0 – 7.1) 0.0 (0.0-0.0) 0.46 
% time in hyperglycaemia 
>10mmol/L 
6.5  (0.0 – 31.0) 40.2 (3.6 – 67.6) 0.21 
% time in  hyperglycaemia 
>15mmol/L 
0.0 (0.0 – 0.0) 0.0 (0.0 – 2.7) 0.68 
Glucose (mmol/L) 
 
7.4(1.6) 9.5 (2.5) 0.1 
Table 9: Glycaemic outcome measures of closed–loop versus closed-loop without meal announcement 
using sensor glucose (n=8) 
 
4.4  Discussion 
The results from this study demonstrate that the BiAP system significantly reduces 
hypoglycaemia compared to standard insulin pump therapy. This reduction in 
hypoglycaemia was most prominent overnight when hypoglycaemia poses the highest 
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risk, as hypoglycaemic awareness is reduced while sleeping (178). An increased time 
in hyperglycaemia (>10mmol/L) was observed with closed-loop compared to open-
loop and one could argue that the reduction in hypoglycaemia seen was at the expense 
of hyperglycaemia resulting from less insulin delivered during closed-loop. However, 
insulin delivered overnight did not differ between the groups.  
Data from the initial hours of closed-loop control demonstrate that the algorithm was 
able to safely control the glucose without knowledge of insulin on board, an important 
safety consideration, while the prolonged post-prandial hyperglycaemia seen after the 
evening meal is explained by some participants starting the study with lower glucose 
and minimal insulin being delivered over the first hours of the study. This resulted in 
low circulating insulin concentrations (to prevent imminent hypoglycaemia) prior to 
challenging the controller with a meal.  
This is the first time ketone bodies and lactate have been investigated in a closed-loop 
study. Previous measurement of NEFA showed, similarly to our study, suppression 
after meals (109). Although, the mean concentrations of lactate and NEFAs did not 
differ between open-loop and closed-loop the relationships between the analytes may 
prove useful in future as an additional input to AP systems. Circulating 3-
hydroxybutyrate was higher with closed-loop compared to open-loop. However this 
difference is unlikely to be clinically significant at such low concentration levels.  
At present, technology to measure analytes beyond interstitial glucose in the home 
setting is unavailable. Manual input of capillary blood glucose values is currently 
used for sensor calibration at least twice daily though newer sensors are capable of 
calibration free operation (179). Multi-array micro-needle sensors capable of multiple 
analyte sensing are in development (180) but the benefits of intermediary metabolites 
as an input to the closed-loop algorithm needs further investigation.  
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Continuous glucose monitoring technology senses glucose in interstitial fluid where 
glucose changes lag behind blood by around five to seven minutes (181) while rapid 
acting insulin analogues delivered subcutaneously do not exert their peak effect for 60 
minutes(182). These delays pose a challenge to AP systems around mealtimes and a 
meal announcement strategy, with meals announced to the controller, minimizes 
initial prandial hyperglycemia and delayed post-prandial hypoglycaemia. Without 
meal announcement a higher and longer hyperglycaemic excursion post-evening meal 
was observed compared to a meal announcement strategy. Reassuringly no delayed 
hypoglycaemic episodes occurred after the unannounced meal. As expected, 
improved glycaemic outcomes are achieved with meal announcement, an approach 
also adopted by other closed-loop groups (126, 129). However, we have shown that 
the BiAP remains safe in the event that a meal is unannounced or the carbohydrate 
content is underestimated.  
A major advantage of the BiAP system is the implementation of the bio-inspired 
algorithm in a microchip within a miniaturised low power device. With power 
consumption of under 2mW guaranteeing two days use, the BiAP system also has the 
potential to overcome the limited battery life issue seen with other platforms such as 
smartphones. The bio–inspired approach replicating the biphasic nature of insulin 
secretion by the beta cell may have additional advantages when used with 
intraperitoneal insulin or novel ultra-rapid insulins. This study is limited by the small 
sample size , relatively short duration and that it took place in a controlled clinical 
environment. Participants were not randomised for the sub-study evaluating the safety 
of the BiAP algorithm without and with partial meal announcement, and the bias of 
participant selection is a limitation of this part of the study. The blinding of the sensor 
glucose to participants during open-loop may be considered a limitation of the study 
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since the state of the art in current care is sensor augmented pump therapy. However, 
sensor augmented pump therapy has not yet been widely adopted by people with type 
1 diabetes in the UK as continuous glucose monitoring currently requires self-
funding. Work in progress includes assessing the BiAP system with glucagon, during 
exercise and mixed meals, followed by longer duration home studies, including 
hybrid studies of overnight closed-loop and daytime open-loop control. 
We conclude that the Bio-inspired Artificial Pancreas system is safe and reduces 
hypoglycaemia compared to standard pump therapy in a clinically controlled 
environment. The reduction in hypoglycaemia was at the expense of an increase in 
time spent in hyperglycaemia, which could be counteracted by using a less 
conservative approach in tuning the algorithm.  ! !
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5 Chapter 5: Feasibility of a Bi-hormonal Bio-
inspired Artificial Pancreas During Fasting 
Conditions: Preliminary Results 
5.1 Introduction and aim 
Evaluation of the Bio-inspired Artificial Pancreas (BiAP) using insulin alone has 
demonstrated safety and its ability to reduce hypoglycaemia when compared to open-
loop (Chapter 4 Section 1.3). The bio-inspired closed-loop system has not previously 
been tested with glucagon. Addition of glucagon allows the closed-loop system to 
safely set a lower glucose target with glucagon delivery in situations of impending 
hypoglycaemia. One of the main limitations of using glucagon in a bi-hormonal 
closed-loop system is that currently available glucagon preparations are only licensed 
for immediate use after reconstitution due to its instability in solution. However, 
studies have shown that glucagon retains its biological activity up to several days 
when stored in solution at various temperatures (92, 93). In the work presented in this 
chapter the aim was to assess the bio-inspired closed-loop system in a bi-hormonal 
configuration during basal fasting conditions to demonstrate safety and proof of 
concept. The bi-hormonal BiAP controller employed, in addition to the existing 
component for insulin delivery, a separate algorithm using proportional derivative 
(PD) control for glucagon delivery. In silico testing of the bi-hormonal BiAP 
controller has been done in a simulation environment that takes into account the effect 
of glucagon on glucose concentration in addition to insulin-glucose dynamics (183). 
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Hypothesis: 
• The bi-hormonal Bio-inspired Artificial Pancreas is safe during fasting 
conditions 
 
5.2 Methods 
5.2.1 Participants and study design !
This was a non-randomised single arm open-label study. 
Participants with T1DM were recruited from the diabetes clinics at Imperial College 
Healthcare NHS Trust in London, UK.  
Inclusion criteria were age >18 years, duration of diabetes >1 year, random C-peptide 
< 200 pmol/l, treatment with continuous subcutaneous insulin infusion for > 6 months 
and HbA1c < 10% (86 mmol/mol).  
Exclusion criteria were recurrent severe hypoglycaemia, pregnancy or planning 
pregnancy, breastfeeding, enrolment in other clinical studies, active malignancy, 
under investigation for malignancy, known allergy to lactose or glucagon. 
Study withdrawal criteria were as follows: 
5. Loss of capacity to give informed consent 
6. Cessation of CSII as usual care for type 1 diabetes 
7. Recurrent severe hypoglycaemia 
8. Terminal illness 
Withdrawal would be immediate and subjects would be followed up in the 
appropriate out-patient diabetes clinic within 4 weeks of withdrawal. 
Participant information sheets were given to potential subjects, and after a minimum 
of 48 hours and allowing questions to be asked, informed consent was taken and 
screening performed. 
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5.2.2 Screening !
Potential participants attended the clinical research facility non-fasting for the 
screening visit. Details of their diabetes background and other clinical history was 
collected and a clinical examination of the cardiovascular- and respiratory systems 
and feet for signs of peripheral neuropathy performed. The following investigations 
were done:  an electrocardiography (ECG), blood samples for random c-peptide, 
glucose, HbA1c, lipids and creatinine , urine for albumin:creatinine ratio and urine 
pregnancy test in female subjects of childbearing age to rule out pregnancy. 
Participants were also asked to fill out three validated questionnaires, the Problem 
Areas in Diabetes (PAID), DQOL and DTSQ questionnaires. A continuous glucose 
monitor (CGM retrospective/ blinded, iPro2, Medtronic) was placed in the anterior 
abdominal wall, according to manufacturer’s instructions. Participants were instructed 
to keep a food diary for CGM period of 5 days. 
Participants then attended the clinical research facility after five days i.e day 6 after 
sensor insertion. The CGM was removed and the data uploaded to Medtronic 
CareLink Pro software, the calibration data (at least two capillary blood glucose 
values per day) was entered and the results reviewed with subject. If necessary, 
adjustments were made to optimise the participants’ basal rates, ICR and ISF. 
 
5.2.3 6-hour bi-hormonal closed-loop study protocol !
The Subjects attended the NIHR/Wellcome Trust Imperial Clinical Research Facility 
at 08:00h fasting. Two subcutaneous glucose sensors (Enlite, Medtronic) were 
inserted in the abdomen the day before the study. The capillary blood glucose was 
measured on arrival to the research unit and the subject’s basal rate at that point was 
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adjusted if deemed necessary by the attending physician from 08:00h to 09:00h.!The 
primary glucose sensor was connected to the BiAP handheld unit. 
The subject’s own insulin pump was discontinued and replaced with two study pumps 
(Accu-Chek Spirit Combo pump, Roche). One pump was filled with insulin aspart 
(Novorapid, Novo Nordisk) and the second pump with glucagon (GlucaGen, Novo 
Nordisk). The pumps were clearly labelled.  The subject’s normal basal rates were 
continued via the insulin pump until study start. 
The sensor signal was transmitted to the handheld unit by cable and communication 
between the handheld unit and the laptop was achieved wirelessly via Bluetooth. The 
insulin and glucagon infusion instructions were transmitted to the pump by the Roche 
Bluetooth communication protocol. Following sensor calibration to venous glucose at 
the start of closed-loop control, the control algorithm recommended an 
insulin/glucagon dose according to the interstitial glucose level measured by the 
subcutaneous sensor every five minutes. Every 15 minutes throughout the study a 
venous blood sample was taken and analysed for glucose using the YSI 2300 glucose 
analyser. The sensor glucose was unblinded to the subject and the study team.  
Subjects were allowed to drink water throughout the study. The hypoglycaemia 
threshold for treating with rescue carbohydrate was lowered to 3.0mmol/L for this 
study or <3.9mmol if symptomatic. Hypoglycaemia was confirmed by an additional 
venous blood plasma glucose sample and treated according to Imperial College 
Hospitals NHS Trust Guidelines.  
After completion of 6 hours of closed loop, the subject’s own CSII pump was 
reconnected and started as per the subject’s usual insulin regime. Once running, the 
study pumps were disconnected and the subcutaneous glucose sensors and 
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intravenous cannula removed. The subject was then allowed to eat and drink freely 
and discharged after ensuring that glucose concentrations were stable. 
 
5.2.4 Materials used and sample analysis !
Continuous glucose monitoring 
The Enlite glucose sensor by Medtronic has been described in detail in Chapter 2 
Section 2.2. 
 
The BiAP control algorithm, handheld unit and the laptop GUI 
The reader is referred to Chapter 1 Section 1.4 for an overview of the BiAP algorithm 
utilising insulin alone and to Chapter 4 Section 1.2 for the illustration of the BiAP 
handheld unit version (v1.2) which was used in this study too. The Roche 
communication protocol was set up to enable both the insulin and glucagon dose 
delivery commands to be sent to the two study pumps via Bluetooth. 
The following changes were implemented in the BiAP controller for the 6-hour bi-
hormonal closed-loop study: 
• 100 %, rather than 70% as previously, of the participants’ pre-existing basal 
rate was delivered independent of the beta-cell model.  
• The BiAP algorithm for insulin was tuned more aggressively (the personalised 
gain was multiplied by 2). 
• The LGS feature still included 50% insulin reduction when below a pre-set 
threshold, but complete suspension of insulin delivery was removed as safety 
constraint. 
• The glucose target for the controller was set to 5.5mmol/L.  
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• The controller employed a separate PD control algorithm for glucagon 
delivery (without glucagon feedback), which was independent of the 
algorithm based on beta-cell physiology calculating the insulin dose.  
• The PD controller was tuned based on in silico tests with the new version of 
the UVa-Padova T1DM simulator including glucagon-glucose-insulin 
dynamics. Since no a priori information is known about the 'glucagon 
sensitivity' of a subject with T1DM, a unique tuning was employed during the 
study. 
 
Continuous subcutaneous insulin infusion 
The Accu-Chek Combo Insulin Pump (study pump) has been described in detail in 
Chapter 2 section 2.2.  
 
Continuous subcutaneous glucagon infusion 
A second Accu-Chek pump was used for the glucagon infusion. The glucagon 
solution was prepared as follows: 
" GlucaGen (Novo Nordisk) was reconstituted with 1 mL of Sterile Water 
(as per manufacturer’s instructions). Using a syringe, all of the Sterile 
Water for Reconstitution was be withdrawn and injected into a vial 
(supplied with GlucaGen). The vial was then gently shaken until the 
powder was completely dissolved and the reconstituted fluid was clear and 
of water-like consistency. The reconstituted GlucaGen gave a 
concentration of 1 mg/mL glucagon. 
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" For each 6-hour closed-loop study 2ml of glucagon at a concentration of 
1mg/ml was prepared and the solution drawn into a standard Roche pump 
cartridge.  
 
Venous blood sampling and analysis 
Venous blood samples were collected via the intravenous cannula every 15 minutes 
throughout the 6-hour study. After each sampling 10ml of 0.9% saline was flushed 
through the intraveneous cannula. Prior to each sampling 2ml of blood was drawn and 
discarded, to ensure fluid in the dead space did not dilute the actual blood sample. 
Whole blood samples were analysed for glucose immediately using the YSI 2300 
analyser. The remaining blood was distributed into a red top blood tube and green top 
bottle (with Trasylol (Aprotinin, bovine pancreatic trypsin inhibitor)) before being put 
on ice. The centrifuge settings were the same as in the previous studies. The serum 
and plasma were then extracted and aliquoted into cryotubes before immediately 
being stored in a -20°C freezer. After completion of the 6-hour study the samples 
were transferred to a -80°C freezer for storage. The serum samples will later be 
analysed for insulin concentrations and the plasma samples for glucagon. 
 
Primary and secondary objectives 
The primary outcome was percentage time spent in glucose target range of 3.9 – 
10.0mmol/L. Secondary outcomes were percentage time in euglycaemia (3.9 –
7.8mmol/L), hypoglycaemia (<3.9mmol/L) and hyperglycaemia (>10.0mmol/L). 
Other secondary outcomes were mean glucose, insulin dose (units/hour).  
 
!! 134!
5.2.5 Statistical analysis !
All outcomes were measured using sensor glucose as well as blood glucose. The 
analysis includes all data points over the 6–hour study. All outcomes are reported as 
mean (SD) or median (IQR), unless stated otherwise. Sensor accuracy was evaluated 
by calculating the median MARD. Data were analysed using Stata/SE version 13.1.   
 
5.3 Results 
Six subjects participated in the study and their baseline demographics are summarised 
in Table 10 
Characteristic Mean ± SD 
Age (years) 55 (6)  
Gender 33% male      67 % female 
Duration of diabetes (years) 24 ± 17  
Duration of insulin pump therapy (years) 4.9 ± 2.5  
HbA1c (mmol/mol) 57 ± 7  
Body mass index (kg/m2) 25 ± 6  
Total cholesterol (mmol/L) 4.1 ± 1.3 
HDL (mmol/L) 1.8 ± 0.2 
Cholesterol/HDL ratio  2.7 ± 0.3 
Creatinine (umol/L) 71.8 ± 11.7 
Glucose (mmol/L) 9.0 ± 5.0 
C-peptide (pmol/L) 2 participants had detectable C-peptide  
(37 and 7 pmol/L) 
 
Table 10. Baseline characteristics (n=6) of the participants in the 6-hour fasting bi-hormonal closed-
loop study 
 
The glycaemic outcome measures, based on both sensor and venous blood glucose, 
from the fasting 6–hour bi-hormonal closed–loop study are summarised in Table 11. 
All data points over the 6–hour study were included in the analysis.  
 
!! 135!
Outcome measure 
 
Results 
(n=6) 
Time 09:00–16:00 
(Total 4 hours) 
Sensor glucose 
Median (IQR) 
 
Blood glucose 
Median (IQR) 
% time in target range  
3.9 – 10.0mmol/L 
100 (97.8-100) 100 (100-100) 
% time in euglycaemia  
3.9 – 7.8mmol/L 
92. 4 (81.9-97.2) 98 (90.0-100) 
% time in hypoglycaemia 
<3.9mmol/L 
0.0 (0.0 – 2.2) 0.0 (0.0 – 0.0) 
% time in  hyperglycaemia 
>10.0mmol/L 
0.0 (0.0-0.0) 0.0 (0.0 – 0.0) 
 Mean (SD) 
 
Mean (SD) 
Glucose (mmol/L) 5.6 (0.8) 5.7 (0.3) 
 
Table 11: Glycaemic outcome measures from the 6–hour fasting bi-hormonal closed–loop study 
 
Reassuringly no time was spent in severe hyperglycaemia (>15mmol/L) nor severe 
hypoglycaemia (<2.8 mmol/L). Figure 19 displays the median sensor and blood 
glucose concentration with IQRs throughout the 6–hour study. The mean (SD) total 
insulin and glucagon dose delivered over the 6-hour study period was 3.9 (1.4) units 
(0.6 (0.2) units/hour) and 0.23 (0.17 ) mg (0.04 (0.03) mg/hour) respectively. The 
glucagon microboluses ranged from 0.001 – 0.02 mg. Figure 20 shows an example of 
the glucose trend, insulin dose delivery and glucagon delivery throughout the 6 hours 
for one subject.  
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Figure 19: Median glucose trend for all 6 subjects during the 6–hour fasting bi-hormonal closed–loop 
study. Red dotted line = median blood (YSI) glucose (± IQR); blue dotted line = median sensor glucose 
(± IQR; black dashed lines = upper/lower glucose target thresholds. 
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Figure 20: Upper graph: Glucose trend and insulin delivered for one subject during the 6–hour fasting 
bi-hormonal closed–loop study. Lower graph: Glucagon delivered for the same subject 
Red dotted line = median blood (YSI) glucose; blue dotted line = median sensor glucose; black dashed 
lines = upper/lower glucose target thresholds; orange bars = insulin dose delivered (units) and red bars 
= glucagon dose delivered (mg) 
 
 
Recalibrations and sensor accuracy 
The sensor required re–calibration in one subject only over the 6 hour study period.  
The median absolute relative difference between the venous blood glucose and the 
sensor glucose was 8.4 (4.0-16.4) % for all subjects.  
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Interruptions to insulin/glucagon delivery and technical faults 
In one study the BiAP handheld unit was not receiving sensor glucose readings 
(between 13:00h to 14:20h) resulting in disruption to the insulin and glucagon 
delivery for 80 minutes. On a different occasion there was a fault with the Bluetooth 
communication between the BiAP handheld unit and the MATLAB GUI at the start 
of the study resulting in a 45 minute delay in study start.  
 
5.4 Discussion 
The preliminary results from the initial evaluation of the bi-hormonal BiAP system 
has demonstrated proof of concept and safety of the system during fasting conditions.  
No major conclusions can be drawn from the results derived from this study due to 
small sample size and the short study period. However, increased time spent in 
euglycaemic target (3.9-7.8) was observed with the bi-hormonal BiAP compared to 
using insulin only (92. 4 (81.9-97.2) % vs. 69.9 (49.8 – 91.1)) without an increase in 
hypoglycaemia. It should be noted that the starting glucose was higher in the closed-
loop with insulin only study (Chapter 2).  
Other groups have utilized a bi-hormonal approach for closed-loop control (86, 87, 
132). The largest bi-hormonal closed-loop study to date showed a significant 
reduction in hypoglycaemia when compared to open-loop in an outpatient setting 
(132). However, in a head-to-head comparison, another bi-hormonal closed-loop 
system had no added benefit compared with a closed-loop system using insulin alone 
(87). 
The relatively quick action time of glucagon makes it suitable for use not only in 
established hypoglycaemia, but for preventing impending hypoglycaemia. The onset 
of action of subcutaneously delivered glucagon is ~10minutes and peak action time is 
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approximately 20 minutes (123, 184). It is important to remember that glucagon 
stimulates hepatic glycogenolysis, and hence its effect may be diminished in the event 
of depleted glycogen stores.  A significant barrier to using glucagon is the 
requirement for a larger pump or two pumps, which would be a disincentive for 
people with diabetes. As mentioned, use of glucagon as a continuous infusion is 
currently limited by its instability in solution. Efforts are being made to develop a 
more stable formulation of glucagon (94, 95). For the purpose of clinical trials the 
glucagon solution is changed with a freshly reconstituted solution at least daily (132), 
which is likely to be impractical over longer time periods. The main recognized side 
effects of glucagon given at an injection dose of 1mg/ml are nausea and vomiting. 
There were no reports of nausea or vomiting after delivery of microboluses of 
glucagon in this study.  
The use of glucagon in addition to insulin may be of particular benefit to specific 
cohorts of subjects who are at increased risk of hypoglycaemia such as children, those 
with hypoglycaemia unawareness and people who do a lot of exercise.  
Proving safety has enabled the start of the next phase which includes challenging the 
BiAP system over a longer duration (24 hours) with an exercise session using bi-
hormonal closed-loop versus closed-loop using insulin alone and comparing both 
closed-loop approaches with open-loop. It remains to be seen whether a bi-hormonal 
approach has any benefit over using insulin alone with the Bio-inspired artificial 
pancreas.  
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6 Chapter 6: Glycaemic variability and its impact on 
quality of life in type 1 diabetes 
6.1 Introduction and aim 
Quality of life (QoL) is recognised as an important health outcome in diabetes and 
other long-term conditions (3). People with type 1 diabetes (T1DM) have reduced 
QoL when compared to the non-diabetic population and sustained improvements in 
QoL are a key goal of diabetes self-management(185, 186). The determinants 
associated with health-related quality of life in people with diabetes have been 
investigated and are multi-fold with lower income, increased age and body mass 
index, smoking status, and co-existing diabetes-related complications amongst the 
determining factors (187). Psychosocial factors such as depression are stronger 
predictors of poor health outcomes, including hospitalization and death, for people 
with diabetes, than other factors such as metabolic control, weight and complications 
(188).  
Optimal glycaemic control however, when not accompanied by significant 
hypoglycaemia and treatment burden, has been shown to have a positive association 
with quality of life (189). In addition to the positive effect of metabolic control, there 
is evidence that educational interventions can improve QoL in type 1 diabetes (190, 
191).   
Glycaemic variability is characterized by glucose excursions in either direction and 
can be measured as intra- or inter-day variability. Over the last decade there has been 
an increased interest in the role of glycaemic variability as a contributory factor in the 
pathogenesis of macro-and micro vascular complications in diabetes. However, the 
importance of glycaemic variability remains uncertain. In vitro and in vivo data 
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suggest that glucose fluctuations are associated with oxidative stress and endothelial 
dysfunction (192-194), but there are also studies that contradict these findings in 
people with T1DM (195, 196). Reference ranges for measures of glycemic variability 
in a non-diabetes multi-ethnic population have been described by providing baseline 
values to benchmark diabetes populations (197).  
Despite anecdotal reports that glucose fluctuations are distressing for people with 
diabetes, the impact of glycaemic variability on QoL has not been extensively 
explored. One study suggests that negative mood and impaired cognitive function one 
hour after breakfast and evening meal are significantly correlated with the rate of 
glucose rise regardless of insulin regimen in participants with type 2 diabetes (T2DM) 
(198). A further study correlating quality of life with variability showed that the 
glycaemic variability measures, 24 hour standard deviation (SD) and continuous 
overall net glycemic action (CONGA), were significantly associated with health-
related quality of life in 23 women with T2DM (199).  
In T1DM, there is less literature on the association between glycaemic variability and 
QoL. Hermanns et al investigated the effect of actual glucose levels and glycaemic 
variability on mood in 36 participants with T1DM and showed that higher glucose 
levels were associated with negative mood; however no significant association was 
found between mood ratings and glucose variability. The glucose variability measures 
(coefficient of variation and absolute change in glucose) used in that study were 
calculated using continuous glucose monitoring (CGM) data from short 60-minute 
time periods preceding each mood rating completed by the participants (200). With 
this methodology only intermittent snapshots of glycaemic variability are analysed 
which may not accurately reflect global glycaemic variability, making the lack of 
association with mood interpretable only during short periods.  
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The current study aimed to establish whether there is an association between 
increased glycaemic variability and overall QoL and whether the two measures differ 
between T1DM participants on multiple daily injections (MDI) and continuous 
subcutaneous insulin infusion (CSII). 
 
6.2 Methods 
This study forms part of and includes participants from two separate diabetes 
technology studies comprised of 1.) a closed-loop insulin delivery study in T1DM 
(outlined in chapters 2, 3 and 4 of this thesis) and 2.) a glycaemic variability study in 
T1DM (conducted by Dr Nick Oliver). Approval by the regional ethics committee 
was obtained. Adult participants with type 1 diabetes were recruited from the diabetes 
clinics at Imperial College Healthcare NHS Trust in London, UK. Inclusion criteria 
were age >18 years, duration of diabetes >1 year, treatment with MDI of insulin or 
CSII. Exclusion criteria were recurrent severe hypoglycaemia (defined as needing 3rd 
party assistance), pregnancy or planning pregnancy, breastfeeding, active malignancy 
(defined as being on treatment or palliation) or being under investigation for 
malignancy. Informed written consent was obtained from each participant and 
screening performed.  
Each participant included in the study wore a blinded retrospective continuous 
glucose monitor (Sof Sensor or Enlite sensor, Medtronic) for up to five days at home 
and was instructed to do at least two finger-prick capillary blood measurements per 
day for calibration purposes, maintain a food diary and complete the validated 
diabetes quality of life (DQOL) questionnaire (201). The Hba1c and DQOL 
questionnaire were performed at the beginning of the CGM period. During this 
period, participants were allowed to continue ‘normal activities of daily living’ and 
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were blinded to the CGM readings so that these would not affect their regular, daily 
diabetes management practices; their only awareness of fluctuations in their glucose 
levels was then that provided by routine fingerprick glucose measurements. 
In this analysis we explored the primary hypothesis that increased glycaemic 
variability would be associated with lower QoL. Secondary hypotheses were that CSII 
would be associated with less glycaemic variability and higher QoL than MDI. 
 
6.2.1 Statistical analysis !
Twelve different glycaemic variability measures (SD, CONGA, Lability Index (LI), J-
INDEX, Low Blood Glucose Index (LBGI), High Blood Glucose Index (HBGI), 
Glycaemic Risk Assessment in Diabetes Equation (GRADE), Mean Of Daily 
Differences (MODD), Mean Amplitude of Glucose Excursions (MAGE), Average 
Daily Risk Ratio (ADRR), M-value, mean absolute glucose (MAG) were calculated 
using the EasyGV version 9.0 software (Available at 
http://www.phc.ox.ac.uk/research/diabetes/software/easygv). In addition the co-
efficient of variation (CV) was calculated. The entire CGM period was included in the 
analysis. Most of the glycaemic variability indices assess intraday variability (CV, 
SD, CONGA, LI, JINDEX, LBGI, HBGI, GRADE, MAGE, M-VALUE MAG), 
whereas the others evaluate inter-day variability (MODD, ADRR). 
The standard scoring system was used for analysis of the DQOL questionnaires 
including DQOL subscales (satisfaction, impact, worry: social/vocational, worry: 
diabetes related). 
Parametric statistical tests were used throughout and log or square root transformation 
was applied to the data if necessary to normalize distributions (as indicated by the 
symbols * or † respectively in tables). A Pearson correlation analysis was performed 
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to identify any significant associations between glycaemic variability and QoL, and 
similarly between glucose measures (mean, HbA1c, percentage time in hypo-, eu- and 
hyperglycaemia). A sub-analysis was also done to evaluate any correlation between 
glycaemic variability/glucose measures and QoL in men and women as separate 
cohorts. Multiple regression analyses were then performed to minimise any effect that 
the potential confounding factors: modality of treatment, HbA1c, age, gender, 
duration of diabetes and BMI might be having on univariate associations between 
QoL and glycaemic variability/glucose measures. Unpaired t-tests were performed to 
compare QoL scores and glycaemic variability measures between subjects on MDI 
and CSII. Non-normally distributed variables are summarized as median and 
interquartile ranges, otherwise the outcome measure is presented as mean and 
standard deviation. All p-values below 0.05 were considered statistically significant. 
Data were analysed using Stata/SE version 13.1 
 
6.3 Results 
Sixty potential participants were screened, of which three did not fit the inclusion 
criteria and were therefore excluded. 57 adult participants with T1DM were included 
in the final analysis of which 20 were on MDI and 37 on CSII (of which two 
participants were on sensor-augmented pump). The participant baseline characteristics 
are outlined in Table 12.  
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Characteristic All subjects 
N=57 
MDI group 
35%, n=20 
CSII group 
65%, n=37 
P value 
Age 41 (13) 43 (17) 40 (11.2) 0.3 
Gender   women (%) 
 
49 50 
 
49 0.9‡ 
 
Duration of diabetes 
(years) 
21 (12) 21 (14) 21(11) 0.9 
HbA1c (mmol/mol) 
(%) 
63 (12) 
7.9 (1.1) 
69 (14) 
8.5 (1.3) 
60 (9) 
7.6 (0.8) 
<0.01 
BMI (kg/m2) 25.1 (4.0) 25.8 (3.3) 24.9 (4.3) 0.4 
TC/HDL ratio 2.78 (0.6) 2.9 (0.7) 2.7 (0.5) 0.1 
Glucose measures 
from CGM data 
    
Mean glucose 
(mmol/L) 
8.8 (1.9) 9.2(2.4) 8.3 (1.4) 0.01 
% time in 
hypoglycaemia  
<3.9 mmol/L  
 (median (IQR)) 
 
3.2 ( 0.5-9.6) 
 
8.2 (0.1-14.0) 
  
2.3 (0.7-7.4) 
 
0.1 
% time in  range  
3.9-10 mmol/L 
60.7 (20.8) 44.0 (17.4) 69.9 (16.4) <0.01 
% time in 
hyperglycaemia 
>10mmol/L 
 
32.7 (20.8) 
 
45.5 (21.3) 
 
25.5 (16.8) 
  
 <0.01 
 
Table 12: Participant baseline characteristics and glucose measures. The results are shown as mean 
(SD), unless otherwise stated. 
  ‡ = Chi Squared test 
 
Two (5.4%) of the CSII participants had a previous history of depression/anxiety, but 
neither was on antidepressant medication at the time of inclusion in the study. Five 
(13.5%) of the CSII participants’ weekly alcohol consumption was above the 
recommended limit (>21units/week for men, >14 units/week for women). None of the 
participants had a history of other substance abuse. Mean HbA1c was significantly 
higher in the MDI group compared to the CSII. All the other participant 
characteristics were comparable between the two subgroups. Table 12 also shows the 
mean sensor glucose and percentage time spent in glucose target range (70-
180mg/dl), hypoglycaemia (<3.9mmol/L) and hyperglycaemia (>10mmol/L) derived 
from the continuous glucose monitoring data. A mean (SD) of 3.2 (1.5) days of CGM 
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data was collected across the study population. 
Primary outcomes: No significant correlations between glucose or glycaemic 
variability measures and total DQOL scores were apparent in the overall study 
population as outlined in Table 13. The correlation analysis of glycaemic variability 
measures and DQOL sub-scale scores (satisfaction, impact, worry: social/vocational, 
worry: diabetes related) also showed no significant correlation (all p-values > 0.05). 
Multiple regression analysis, taking into account treatment modality, HbA1c, age, 
gender, duration of diabetes and BMI, confirmed the lack of association between 
glycaemic variability and QoL. Analysis of the MDI and CSII subgroups separately 
confirmed that the lack of association between glycaemic variability and quality of 
life was irrespective of treatment modality. A correlation analysis of glycaemic 
variability and QoL in men and women separately did not show any association 
between glycaemic variability and QoL in either gender group (all R2 values were 
<0.3 with corresponding p-values >0.05). 
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Glycaemic 
variability 
measures 
DQOL Total score 
All subjects (N=57) 
DQOL Total score 
MDI subjects (n=20) 
DQOL Total score 
CSII subjects (n=37) 
 R2 P value R2 P value R2 P value 
CV* 0.001 0.8 0.04 0.4 0.003 0.7 
SD† 0.003 0.7 0.059 0.3 0.003 0.7 
CONGA 0.004 0.6 0.032 0.4 0.0 0.9 
Li† 0.007 0.5 0.08 0.2 0.001 0.8 
JINDEX† 0.003 0.6 0.045 0.3 0.001 0.8 
LBGI† 0.00 0.9 0.021 0.5 0.037 0.2 
HBGI† 0.001 0.7 0.028 0.4 0.00 0.9 
GRADE* 0.005 0.5 0.001 0.9 0.007 0.6 
MODD 0.009 0.4 0.046 0.3 0.01 0.5 
MAGE 0.002 0.7 0.051 0.3 0.0 0.9 
ADRR 0.01 0.4 0.144 0.1 0.0 0.9 
M-Value* 0.000 0.9 0.001 0.9 0.00 0.9 
MAG† 0.001 0.8 0.033 0.4 0.002 0.8 
Glucose 
measures       
Mean glucose  0.004 0.6 0.036 0.4 0.0 0.9 
HbA1c* 0.01 0.4 0.12 0.1 0.011 0.5 
% time in 
hypoglycaemia 
<3.9mmol/L 
 
0.016 
 
0.3 
 
0.076 
 
0.2 
 
0.005 
 
0.6 
% time in  
range 
 3.9-10mmol/L 
 
0.006 
 
0.5 
 
0.039 
 
0.4 
 
0.0 
 
0.9 
 % time in 
hyperglycaemia 
>10mmol/L 
 
0.0 
 
0.9 
 
0.0 
 
0.8 
 
0.0 
 
0.8 
 
Table 13: Association between glycaemic variability/glucose measures and QoL 
*  = log transformation 
† = square root transformation 
 
Secondary outcomes: Glycaemic variability was significantly higher for those 
participants on MDI compared to the CSII group for all glycaemic variability 
measures measures (Table 14), Further analysis identified a significant, but weak (all 
R2 values were below 0.3) association between HbA1c and some glycaemic 
variability measures (SD, CONGA, JINDEX, HBGI, GRADE, MODD, MAGE, M-
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Value), but not for others (CV, Li, LBGI, ADRR, MAG). The dependency of the 
higher glycaemic variability in the MDI group on long-term glycemia, as expressed 
by Hba1c concentration, was explored in multivariable analyses with, successively, 
each of the 8 GV measures that correlated significantly with HbA1c as dependent 
variable. For three of the measures, SD, MODD and MAGE, MDI group positively 
and significantly predicted glycemic variability whereas HbA1c ceased to be a 
significant predictor. For three other measures, HGBI, GRADE and M-value, both 
MDI group and HbA1c were significant positive predictors. For two measures, 
CONGA, and JINDEX, group ceased to be a significant predictor but HbA1c 
remained significant. Therefore, for 6 of the 8 GV measures that related to HbA1c, 
the higher glycaemic variability in the MDI group was not accounted for by higher 
HbA1c. There was no significant difference in QoL or sub-scale QoL between the 
two treatment modality groups (Table 15). Moreover, HbA1c did not correlate with 
QoL (R2 = 0.01, p-value 0.4) in the overall study population. In the sub-analysis of 
women and men separately an association between HbA1c and QoL was apparent in 
the cohort of women on MDI (R2 = 0.55, p-value 0.01).  
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Glycaemic variability 
measures 
 
MDI 
n=20 
CSII 
n=37 P value 
CV* 39.0(33.4-46.8) 31.3(28.2-37.7) 0.03 
SD† 3.5 (3.0-4.7) 2.8 (2.1-3.5) 0.006 
CONGA 8.6 (2.3) 7.5 (1.4) 0.02 
Li† 7.2 (4.3-10.8) 4.0 (2.1-4.6) 0.002 
JINDEX† 64.4 (41.8-78.0) 41.6 (28.3-52.5) 0.006 
LBGI† 6.7 (2.6-11.3) 2.8 (1.8-5.4) 0.01 
HBGI† 14.5(10.2-20.4) 9.0 (5.1-11.5) 0.001 
GRADE* 9.8 (5.4-15.4) 5.8 (3.1-7.4) <0.001 
MODD 4.2 (0.5) 3.5 (0.9) <0.001 
MAGE 8.6 (1.9) 5.2 (1.9) <0.001 
ADRR 30.7 (8.4) 22.2 (8.3) <0.001 
M-Value* 21.3 (13.0-34.7) 8.0 (4.3-13.0) <0.001 
MAG† 3.2 (2.3-4.1) 2.0 (1.5-2.7) 0.006 
 
Table 14: Glycaemic variability with MDI compared to CSII. The results are shown as mean (SD) or 
as median (IQR) when transformation of the data has been applied for non-normally distributed 
variables. 
* = log transformation 
† = square root transformation 
  
 
QOL measure MDI (n=20) CSII (n=37) P value 
Total 69.1(11) 68.2(11.3) 0.6 
Satisfaction 70.3(14.1) 69.4(12.0) 0.6 
Impact 66.0(10.1) 67.0(10.8) 0.3 
Worry: S/V 73.1(24.8) 73.2(19.5) 0.4 
Worry: DR 66.7(17.8) 65.8(18.0) 0.5 
 
Table 15: Quality of life in participants on MDI versus CSII. Outcomes are shown as mean (SD). 
 
 
A formal power calculation was not undertaken at the outset of this work. However, 
with 57 participants, a correlation coefficient of 0.25 or more would have been 
detected as significant at p<0.05. Therefore, if glucose variability explained 6.3 
percent (0.25 squared) or more of the variation in quality of life, the study would have 
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detected that as significant. With regard to detecting differences in glucose variability 
between MDI and CSII groups, with 20 in one group and 37 in the other, a 0.9 SD 
difference in means would have been detected as significant at p<0.05 with 90 percent 
power. In post hoc evaluation of data presented in Table 3, the observed differences in 
mean for all measures of glucose variability except CONGA were greater than 0.9 
SD, indicating that the study was adequately powered for those measures. CONGA 
differed by 0.6 SD between MDI and CSII groups, which means that although the 
difference between the groups in CONGA was detected as significant, this was only 
at 59 percent power. 
 
6.4 Sub-analysis exploring the impact of insulin variability on glycaemic 
variability  !
6.4.1 Aim !
The aim of closed loop insulin delivery is to exchange the glucose variability seen 
with conventional insulin delivery modalities for dynamic, real-time insulin 
variability. Insulin variability describes fluctuations in insulin dose delivered and is 
not well described in the literature. The aim of this exploratory analysis was to assess 
the impact variable insulin infusion rates may have on GV, and in particular 
hypoglycaemia and risk of hypoglycaemia.  
Hypothesis: A higher insulin variability would cause increased glycaemic variability, 
hypoglycaemia and hypoglycaemia risk 
 
 
!! 151!
6.4.2 Method !
Participants and study design: This was a retrospective exploratory analysis. 20 adult 
subjects with T1DM from the closed-loop cohort were included in the analysis. (55% 
male, mean (SD) age 44 (10) years, duration of diabetes 22 (12) years, duration of 
CSII 3.4 (4) years, HbA1c 7.4 (0.7) %, body mass index 25 (4) kg/m2 ). We extracted 
the following data from their study folders: 5 days of blinded CGM data (Medtronic 
iPro2) from their initial screening (see chapter 2 section 2.2 for more details) , their 
daily basal rates and daily inulin boluses (from food and activity diaries).  
Statistical analysis: Insulin infusion rate variability was measured as the standard 
deviation of insulin delivery including the basal and meal boluses (insulin units/hour).  
GV measures were calculated using the EasyGV version 9.0 software. A linear 
regression analysis to evaluate the relationship between GV and insulin infusion rate 
variability was then performed.  
 
6.4.3 Results !
There were no significant associations between insulin infusion rate variability and 
GV or hypoglycaemia as outlined in Table 16. 
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Glycaemic  Variability 
Measure 
R2 p-value 
SD 0.04 0.41 
CONGA 0.03 0.49 
Li 0.06 0.32 
JINDEX 0.03 0.46 
LBGI 0.02 0.55 
HBGI 0.03 0.48 
GRADE 0.02 0.59 
MODD 0.02 0.54 
MAGE 0.01 0.73 
ADRR 0.03 0.45 
M-Value 0.04 0.41 
MAG† 0.05 0.35 
% time in hypoglycaemia 
(<3.9mmol/L) 
0.04 0.41 
Table 16. Association between Insulin variability and glycaemic variability 
 
6.4.4 Conclusion 
 
The results suggest, surprisingly, that insulin infusion rate variability has no impact 
on hypoglycaemia risk or % time spent in hypoglycaemia in adults with T1DM on 
pump therapy. Further work is needed to understand how CSII and multiple daily 
injections affect glycaemic quality. 
 
6.5  Discussion 
This study was a preliminary investigation into the relationship between glycemic 
variability and diabetes-specific quality of life in participants with relatively well-
controlled T1DM. There is conflicting evidence regarding the role of glycaemic 
variability in the pathogenesis of diabetes-related complications and limited literature 
is available on whether glycaemic variability affects quality of life in people with 
diabetes.  
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Our study results suggest that neither overall glucose, measured by mean and HbA1c, 
nor glycaemic variability impact overall or subscale quality of life in adults with Type 
1 diabetes, irrespective of whether they are on MDI or CSII. These findings contradict 
existing, albeit limited, evidence in type 2 diabetes where an association between 
glycaemic variability and QoL has been demonstrated (198, 199). The results are also 
surprising given the anecdotal reports of the impact that glucose fluctuations from low 
to high have on motivation and mood. The lack of association noted may, in part, 
reflect a selected population taking part in a diabetes technology study and may 
additionally reveal weaknesses in the DQOL scale. Our study population, especially 
those on CSII, were generally well-controlled based on HbA1c and percentage time 
within target range (3.9-10mmol/L) compared to previous studies [6] that have looked 
at associations of glycaemic control and QoL and may therefore not be completely 
representative of the general type 1 diabetes population. Of note, we also excluded 
participants with recurrent severe hypoglycemia. Recurrent severe hypoglycemia will 
be very likely to adversely affect quality of life. Inclusion of affected individuals in 
our analysis might then have biased the results in favour of positive findings and 
obscured more subtle effects associated with more representative glycemic variability. 
Ideally we would have undertaken separate analyses in people affected and unaffected 
by severe hypoglycaemia and this is important further work. DQOL was initially 
validated and used in the DCCT study but has fixed domains which may not be 
applicable to everyone tested. One of the challenges in evaluating the association 
between QoL and glycaemic variability is that QoL is a generally stable parameter 
whereas glycaemic variability is inherently more variable with intra- and inter day 
fluctuations. Thus it could be that subtle changes in mood or worries triggered by the 
glycaemic variability were not detected, since the DQOL was only completed once 
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prior to the CGM period. Measuring glycaemic variability based on several days of 
CGM data will provide an average of the glycaemic variability for that time period, 
hence a longer CGM duration provides a better assessment of long-term glycaemic 
variability. Limitations of our study include timing of the DQOL questionnaire in 
relation to the glycaemic variability assessment and the relatively short CGM 
duration. The advantage of using blinded CGM rather than real-time open CGM is 
that it allows a pure assessment of glycaemic variability without participant 
interference (extra bolus corrections) and hypo- and hyperglycaemia alarms which 
may have an independent affect on QoL. 
The HbA1c was higher in the MDI group than the CSII group, and one might expect a 
higher HbA1c to equate to higher glycaemic variability (202). Eight GV measures 
were positively correlated with HbA1c and their higher values in the MDI group 
could, therefore, have been accounted for by the higher long-term glycemia (as 
expressed by HbA1c) in that group. However, of these 8 measures, multivariable 
analysis suggested that only 2 (CONGA and JINDEX) were higher in the MDI group 
on account of the group’s higher HbA1c, the other 6 measures of glycemic variability 
being higher in the MDI group independently of HbA1c. The maximum variance in 
any GV measure accounted for by HbA1c was 25%. There was, therefore, appreciable 
variance that was not explained and we may assume that it is this residual variance 
that accounts for the differences in the multivariable analysis findings for the different 
GV measures. The most we would conclude on the basis of these observations is that 
differences in glycemic variability between the groups might, to some extent, be 
accounted for by long-term glycemia, as expressed by HbA1c, but mostly the 
difference in glycemic variability appeared independent. 
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As expected we found that glycaemic variability was higher in participants on MDI 
than in participants on CSII, but no significant difference in quality of life was 
observed between these subgroups. It has previously been shown that people with 
Type 1 diabetes treated by CSII have a better QoL compared to MDI (203) but our 
findings contrast with this despite the risk of hypoglycaemia, (measured by LBGI) 
being significantly higher in the MDI group. There is a well-established association 
between hypoglycaemia and increased anxiety and worry (204, 205), which is not 
apparent in our population. There are several factors that could have contributed to 
this, not least the potential insensitivity of the measure, the self-selecting participant 
group and the short duration of the study period. In the UK, CSII treatment has to be 
justified by clinical reasons such as recurrent hypoglycaemia and suboptimal 
glycaemic control. Therefore, it cannot be excluded that people with CSII have a 
more complicated course of diabetes and lower QoL. Similarly people with good QoL 
on MDI may opt to remain on MDI despite suboptimal glycaemic control. These 
factors may explain why no difference in quality of life was observed between the 
CSII the MDI groups. 
There remains uncertainty about the role of glycaemic variability in diabetes 
management, but improved accuracy and reliability of CGM devices has created 
opportunities to investigate this further. Several statistical measures of glycaemic 
variability exist but there is no consensus as to which is the ‘best measure’ and hence 
comparing data from published glycaemic variability studies is challenging. Although 
we refer to glycaemic variability measurements in general, it is important to 
remember that whilst some glycaemic variability metrics evaluate actual variability of 
glycaemia (SD, CONGA, LI, MAGE, MAG), others measure quality of glycaemic 
control (JINDEX, GRADE, M-Value) and glycaemic risk (HBGI, LBGI and ADRR), 
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all of which reflect glycaemic variability even if they are not a direct measure per se. 
As with glycaemic variability, there is no ‘gold standard’ for assessing QoL in 
participants with T1DM. Several tools assess either QoL or aspects of QoL such as 
psychosocial functioning but confusion exists as to the best measure for clinical 
research.  Tools such as DQOL, diabetes treatment satisfaction questionnaire (DTSQ), 
diabetes attitudes wishes and needs (DAWN) questionnaire, are available, but poor 
implementation, poor process evaluation and the use of different methods in different 
studies make comparisons difficult.  
 
Conclusions: 
While it is limited by short duration and small numbers, this is the largest study of 
glycaemic variability and QoL to date. Our post hoc exploratory analysis with one 
assessment did not reveal any associations between correlated measures of glycemic 
variability and QoL in people with T1DM. Given the anecdotal reports in clinical 
practice that the glucose fluctuations some people with diabetes experience are 
distressing this is perhaps surprising and contrasts with previous studies in type 2 
diabetes. A larger prospective study over a longer time period with repeated mixed 
measures is needed to confirm these findings. Achieving and maintaining optimal 
QoL is an important aspect of type 1 diabetes management, but whether the reduction 
of glycaemic variability is a justified intervention target remains unclear. 
 
!  
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7 Chapter 7: Summary and Discussion  
Type 1 diabetes (T1DM) remains a challenging condition to manage despite 
improvements in insulin preparations (182), provision of structured education (9), and 
the availability of insulin pumps (42), continuous glucose monitoring (CGM) systems 
and more recently sensor augmented pump therapy (25). The barriers for achieving 
optimal glucose control are multifaceted and include fear of hypoglycaemia (17), non-
compliance with treatment and needle phobia. However, even when none of these 
obstacles present an issue, achieving stable glycaemia can still be challenging due to 
the unpredictable effect on glucose of external factors encountered in daily life, such 
as exercise, illness, hormonal changes, alcohol, meal content variability, stress and 
erratic work schedules.  
There is hope that a closed-loop insulin delivery system, also referred to as an 
artificial pancreas (AP), will overcome some of the barriers that people with T1DM 
face and have to deal with. An AP consists of a glucose sensor, a control algorithm 
and an insulin pump. The main algorithms utilised in AP systems to date include 
proportional integral derivative (PID) control and model predictive control (MPC) 
derived from control engineering techniques and fuzzy logic derived from artificial 
intelligence technique. Significant efforts have been made to evaluate and optimise 
different AP systems by different groups and over 70 clinical closed-loop trials, from 
short fasting studies to longer home trials, have been done and published in the last 
decade (summarised in Table 2 in Chapter 1).  
 
The main objective of the clinical project outlined in this thesis was to evaluate proof 
of concept, safety, feasibility and efficacy of a novel closed-loop insulin delivery 
system (the Bio-inspired Artificial Pancreas (BiAP)) in adults with T1DM in a path of 
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incremental challenges. The novelty of this AP system lies in an algorithm based on a 
mathematical model of beta cell physiology, which in turn has been implemented in a 
miniature silicon microchip integrated in a small handheld device to optimise power 
consumption.  
 
The initial 6-hour study was the first in human study evaluating the BiAP. The BiAP 
achieved 98.0 % of time spent in target range (3.9 – 10.0mmol/L), and 96.4% in a 
tighter target (3.9-7.8mmol/L) with one participant developing hypoglycaemia (blood 
glucose <3.9mmol/L). After confirming the safety of the BiAP system in fasting 
conditions, a further assessment was performed overnight and following a meal 
during which the overall time in target range was acceptable at 71%. The meal 
challenge was breakfast, which is considered to be the most challenging meal of the 
day due to increased insulin resistance secondary to the circadian release of other 
hormones such as cortisol. From this 13-hour study we learnt that there was scope to 
optimise the glucose controller to allow for more aggressive glucose lowering when 
concentrations exceeded the hyperglycaemic threshold, particularly in the post–
prandial state. The algorithm and technology were optimised prior to starting the 24-
hour randomised controlled crossover study. The results from 24-hour study 
demonstrated that the BiAP system significantly reduces hypoglycaemia compared to 
standard insulin pump therapy (3.0% vs. 17.9%, p<0.01), but this was however at the 
expense of an increase in hyperglycaemia with closed-loop. This reduction in 
hypoglycaemia was most prominent overnight. No significant difference in 
percentage time in target between closed-loop and open-loop was observed.  Our 
study was limited by the small sample size and a power calculation was not done. 
However this was still considered an early feasibility study and safety was the main 
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objective. In a sub-set of the sample cohort we assessed the safety of the BiAP 
algorithm without a meal announcement and with a partial meal announcement. As 
expected, improved glycaemic outcomes were achieved with the meal announcement. 
However, importantly, the BiAP was demonstrated to remain safe in the event that a 
meal was unannounced or the carbohydrate content underestimated.  
 
Dealing with glucose excursions post meals is challenging for all algorithms, mainly 
due to the delays associated with subcutaneous glucose sensing and subcutaneous 
insulin delivery. Although unannounced meals have been tested in closed-loop trials 
and have been shown to be safe, it is generally accepted that meal announcements are 
the best strategy with the currently available technology and insulin preparations. 
Different meal announcement strategies exist, ranging from informing the algorithm 
that a meal is about to be consumed and increasing the aggressiveness of the 
controller to delivering a partial or full pre-meal bolus based on the ICR and 
carbohydrate content of the meal. Russell et al. use an adaptive method to optimise 
the controller and the meal bolus calculation over time (206).  
 
A novel decision support algorithm, developed by our group, based on case-based 
reasoning (CBR) has been implemented in a smartphone application and is referred to 
as the Advanced Bolus Calculator for Diabetes (ABC4D) (207). CBR is an artificial 
intelligence technique that solves newly encountered problems by applying the 
solutions learned from solving similar problems encountered in the past. The ABC4D 
system utilises continuous glucose monitoring (CGM) data and aims to provide 
improved flexibility and adaptability compared to existing bolus calculators. In 
collaboration with the engineering team we have completed a 6-week clinical trial 
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evaluating the ABC4D in adults with type 1 diabetes and a 6-month randomised 
controlled trial is underway. The details of the ABC4D study are beyond the scope of 
this thesis. However, the novel decision support algorithm used in ABC4D has the 
potential to be implemented in the Bio-inspired Artificial Pancreas for improving 
post-prandial glucose excursions due to its personalised adaptability.  
The other challenge associated with calculating meal boluses irrespective of whether 
insulin is delivered via multiple daily injections (MDI), continuous subcutaneous 
insulin infusion (CSII) or closed-loop, relates to the chemical complexity of the type 
carbohydrate and the other components of the meal such as fat and protein. Complex 
carbohydrates in unrefined foods are absorbed more slowly than refined disaccharides 
and monosaccharides while a high fat content may delay carbohydrate absorption 
 
Exercise poses a significant challenge for people with T1DM. Generally they are 
advised to reduce their insulin bolus by 20-30% pre- or post exercise 
(http://www.excarbs.com), and if on CSII there is the option to use a temporary 
reduced basal rate for a pre-defined time period following exercise. Managing insulin 
requirements during exercise is particularly important as exercise promotes glucose 
uptake in skeletal muscle independently of insulin and increases peripheral insulin 
sensitivity, thus increasing the risk of hypoglycaemia, both during exercise and for a 
period of several hours afterwards. It is therefore crucial that exercise is detected and 
quantified rapidly and insulin delivery adjusted according to the duration and intensity 
of activity. Activity monitors utilising algorithms, in the form of accelerometers and 
heart rate monitors, are available to quantify physical activity. Various closed-loop 
systems have been evaluated during and after exercise, but how and whether or not 
the exercise should be announced to the controller has not been clearly established.  A 
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study by Breton et al showed that heart rate can be valuable input to the control 
algorithm in the context of exercise (124).  
 
The impact of glycaemic variability on quality of life in T1DM was explored and 
outlined in Chapter 6.  It is well-established that people with T1DM have a reduced 
QoL compared to the population without diabetes (186). Glycaemic variability is 
likely to play a role in the development of microvascular complications in T1DM 
(192-194) though there are some studies that contradict these findings (195, 196). 
There is limited literature on whether glycaemic variability affects quality of life in 
T1DM.  Our study did not reveal any associations between correlated measures of 
glycemic variability and QoL in people with T1DM. The main limitation of our study 
was the short time duration of CGM monitoring that was used to measure glycaemic 
variability. Achieving and maintaining optimal QoL remains an important aspects 
T1DM management, but whether intervening to reduce glycaemic variability is a 
justified intervention target remains unclear. 
 
Developing new technology such as the artificial pancreas is complex and relies on a 
collaborative approach including engineers and clinicians. Involving the potential user 
in the development process is crucial. User acceptability and expectations when it 
comes to new technologies might differ significantly from what the developers would 
consider a successful final product. It is therefore important to understand what users 
want. An online survey completed by 266 people with T1DM or parents of children 
with T1DM assessed the views and expectations of a future AP and found that the 
main reasons for not wanting an AP were the perceived downsides such as size of the 
device and lack of effectiveness (208). Human factors play an important role in 
!! 162!
acceptance of new technology, but assessment of psychosocial outcomes have not 
been prioritized in the majority of the closed-loop clinical trials to date (209). A better 
understanding of various psychosocial aspects related to AP systems may benefit 
future users. In clinical practice we aim to provide individualised care tailored to 
patients’ needs and preferences and the same approach will apply when deciding 
whether any future AP systems would be the best option for achieving improved 
glycaemic control and a better quality of life.  
 
In conclusion, the work outlined in this thesis showed that Bio-inspired Artificial 
Pancreas is safe and is able to reduce hypoglycaemia when compared to standard 
pump therapy. A major advantage of the BiAP system is the implementation of the 
bio-inspired algorithm in a microchip within a miniaturised low power device, which 
therefore has the potential to overcome the limited battery life issue seen with other 
platforms such as smartphones. Initial fasting studies integrating the BiAP with 
glucagon in a bi-hormonal configuration confirmed its safety. This has led to ongoing 
work including the assessment of the bi-hormonal BiAP, insulin only BiAP and SAP 
during exercise within a controlled environment. Longer home trials are planned for 
2016.  
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